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ABSTRACT 
 
Novel fluorine-18 labelled luminescent rhenium tricarbonyl complexes were synthesised to test 
their utility as agents for positron emission tomography (PET) and optical hybrid imaging. The 
complexes were found to afford reasonable quantum yields and lifetimes for use as optical 
agents and were found to form in high radiochemical yield (RCY) in most cases for use as PET 
radiotracers. A novel rhenium-activated method was also serendipitously discovered in the 
process, which enabled the fluorine-18 labelling of 2,2’-bipyridine ligands in high RCYs which 
were not achievable hitherto. Such an approach was found to work for nucleophilic aromatic 
substitutions in the ortho and para positions of the pyridine moiety, though no radiolabelled 
ligand was observed from substitutions in the meta position. Notably, this method also enabled 
radiofluorination under non-azeotropically dried conditions, which is rarely reported in the 
literature. The method was also applied to the radiosynthesis of an Alzheimer’s disease imaging 
agent, [18F]CABS13. While the tracer was successfully labelled, the method did not improve 
upon the RCY reported in literature, though did allow for the radiofluorination of a previously 
unreported 8-hydroxyquinoline alternative. 
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CHAPTER ONE 
INTRODUCTION 
  
2 
 
1.1 Overview of Optical and Positron Emission Imaging 
Modalities 
 
Discernment between healthy and diseased tissue is of paramount importance in order to excise 
a disease, such as cancer. Medical practitioners thus benefit from the wealth of data which can 
be accrued from multiple imaging modalities allowing for more informed decisions to be made. 
Positron emission tomography (PET) imaging is one such beneficial imaging technique which 
provides data on the biodistribution of a radioactive tracer administered to a patient. Typically, 
the radioactive molecule is designed to mimic or interact with known biochemical pathways. 
Thus, discrepancies concerning the uptake of an administered radiotracer by organs in the 
patient body often aid in distinguishing a healthy patient from one diagnosed, for instance, with 
cancer. As with all imaging modalities, however, PET imaging has its own strengths and 
limitations. While it provides excellent external imaging of a patient via detection of deep tissue 
penetrating gamma radiation photons, the technique is disadvantaged by comparatively low 
spatial resolution (on the order of millimetres).[1] Thus, efforts have been made to couple PET 
imaging with other imaging modalities to improve upon the spatial resolution. Both computed 
tomography (CT), which processes X-ray photons detected from various angles to reconstruct 
anatomical images of comparative radiodensities, and magnetic resonance imaging (MRI) 
which maps the distribution of water and lipids in an external magnetic field via nuclear 
magnetic resonance (NMR) of hydrogen nuclei, provide an approximate five-fold 
improvement in spatial resolution when coupled with PET while still relying on external 
imaging of the patient.[2] These spatial resolutions are still far from the order of magnitude 
required to discriminate variations at the cellular level, thus recent efforts have sought to couple 
the radiotracers used in PET with luminescent molecules which allow for optical imaging of 
the tracer. Unlike PET imaging, optical imaging provides significantly greater spatial 
resolution (on the order of nanometres), and while optical imaging does suffer from shallow 
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tissue penetration, this limitation can likewise be leveraged with the deep tissue penetration 
afforded by PET imaging.[3] In practice, a PET-optical radiotracer, which provides both the 
positron emission required for PET imaging and the luminescence required for optical imaging, 
could enable low resolution external identification of a tumour followed by high resolution 
internal identification of the same tumour during surgical excision. In pursuit of this goal, this 
work sought to expand upon a common class of luminescent agents characterised by a rhenium 
metal centre by chemically bonding them with the most common radioactive isotope used in 
PET radiotracers, fluorine-18.[4] This laid the framework for the underlying hypothesis, that a 
luminescent rhenium complex could be radiolabelled with the fluorine-18 radioisotope and 
would have desirable properties for use as a PET-optical agent.  
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1.2 Fluorine-18 in Positron Emission Tomography 
 
The clinical and research practices of PET imaging rely on the availability of molecular 
structures labelled with a positron emitting radioisotope. Design of such radiotracers involves 
chemically bonding the desired radioisotope to a drug or biomolecule, therefore creating a 
radioactive marker with specific features of interaction with the biological target of interest. 
Diagnostic PET imaging conventionally necessitates the administration of such radiotracers to 
monitor the distribution of the associated radioactivity in the patient. The radiotracer 
consequently accumulates in diseased tissue and radiation emitted from the radioactive decay 
of the conjugated radioisotope enables imaging by a ring of detectors to locate the site of 
disease within the patient. The process of PET imaging is summarised in Figure 1, following 
the administration of the radiotracer to the patient. The radioisotope conjugated to the 
administered tracer, having a proton rich nucleus, undergoes positron emission decay (β+ 
decay) following the spontaneous internal conversion of a proton to a neutron (via internal 
conversion of an up quark to a down quark), as exemplified in Figure 2. This positron emission 
process can be universally represented by the nuclear decay equation (1), wherein 𝑋𝑍
𝐴  refers to 
the original radioisotope, 𝑋𝑍−1
𝐴  refers to the transmutation product with one lesser proton and 
𝑣𝑒  refers to an emitted electron neutrino accompanying the positron (β
+).  
𝑋 →  𝑋′ +  𝛽+1
0 + 𝑣𝑒𝑍−1
𝐴
𝑍
𝐴 (1) 
 
The emitted positron, being the antimatter equivalent of an electron, then travels some short 
distance governed by its excess energy, before complementing the 511 KeV rest mass energy 
of a nearby electron and ultimately annihilating with it.[5] The annihilation of both particles 
results in the formation of two 511 KeV gamma radiation photons emitted approximately 180° 
apart from the annihilation event. The two gamma radiation photons are then detected by two 
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diametrically opposed scintillator crystals within the PET detector ring. The scintillators each 
exhibit luminescence upon excitation by the ionising radiation and the emitted photons are 
absorbed by a photoelectron multiplier tube within the detector block which amplifies the 
current, such that the signals can be processed for coincidence (i.e. that the two gamma 
radiation photons from the annihilation event indeed interfered with the scintillators within the 
resolving time of the detectors across an assumed linear line of response). Confirmed 
coincidence events are then processed by imaging reconstruction software to produce a PET 
image, which ultimately depicts where in the body (e.g. which organs) the radiotracer has 
accumulated for diagnostic purposes. Figure 3 shows an exemplar diagnostic PET scan of a 
patient following intravenous administration of the fluorine-18 labelled radiotracer 
[18F]fluorodeoxyglucose ([18F]FDG). [18F]FDG is commonly used in PET diagnostic scans to 
map glucose uptake of the organs and consequently to discern diseased tissue as a function of 
upregulated glucose transporters. Despite the background accumulation of [18F]FDG by the 
brain, kidneys and heart, as well as radioactive urinary accumulation within the bladder, a 
significant metastatic tumorous mass can be noticed within the liver, having migrated from a 
primary colorectal tumour (depicted in dark red from the maximum intensity projection). It is 
worth noting that PET imaging reconstruction provides only a three-dimensional distribution 
of the radiotracer within the field of view of the PET camera and imparts no further information 
regarding the anatomy of the subject. Thus, complementary techniques such as CT or MRI are 
commonly also applied and fused to the resulting PET image in order to provide correlative 
anatomical information about radiotracer accumulation within the body. 
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Figure 1.  Following administration of a PET radiotracer to a potentially diseased patient, 
the patient then lies horizontally inside a PET scanner. The radiotracer circulates 
the blood stream and eventually accumulates at the site of the diseased tissue it 
was designed to target. Pairs of gamma photons originating from the antimatter 
annihilation of the emitted positrons from the radiotracer are detected via the 
detector rings of the PET scanner. Through subsequent coincidence processing 
and the use of image reconstruction software, a PET image is attained to visually 
confirm where the radiotracer has accumulated, thus indicating the site of the 
diseased tissue. Image released into the public domain under the Wikimedia 
Commons license agreement. 
 
Figure 2.  Positron emission from a proton rich nucleus, which occurs following the 
spontaneous interconversion of an up quark to a down quark within the proton 
which results in the conversion of a proton to a neutron within the nucleus and 
the subsequent release of a position (β+) particle to conserve the charge 
(alongside an electron neutrino to conserve the energy). The released positron 
then annihilates with its matter component electron resulting in the formation 
of two gamma radiation photons (hv) spaced approximately 180° apart. 
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Figure 3.  [18F]FDG PET diagnostic scan revealing the metastasis of a primary colorectal 
tumour (dark red maximum intensity projection) to the site of the liver against 
the background accumulation of [18F]FDG by the brain, kidneys and heart, as 
well as radioactive urinary accumulation within the bladder of a 79 kg female 
patient. Image released into the public domain under the Wikimedia Commons 
license agreement. 
 
There exist several proton-rich radioisotopes exhibiting β+ decay which can be implemented 
within the molecular design of a drug or bioconjugate to serve as a PET radiotracer. Table 1. 
provides a selective list of the commonly utilised PET radioisotopes, alongside their 
comparative half-lives, probability of β+ decay per disintegration (among other decay events 
such as electron capture (EC)) and the nuclear reactions used to produce the radioisotopes 
(whereby the absorption and subsequent emission of a deuterium (d), neutron (n), proton (p), 
helium nucleus (α) or gamma photon (γ) results in the transmutation product).[5,6] Of these 
radioisotopes fluorine-18, as generated by the 18O(p,n)18F nuclear reaction, is most commonly 
used in PET imaging due to its ideal half-life of 109.8 mins, which provides sufficient time for 
synthesis and imaging while reducing the radiation dose to the patient in comparison to longer 
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lived radioisotopes, and because the majority of its nuclear decay occurs via positron emission 
(97%).[4] Applying the spontaneous conversion of a proton to a neutron within a proton-rich 
positron emitting nucleus, exemplified in equation (1), to fluorine-18 renders equation (2) 
which affords the stable oxygen-18 decay product alongside the emission of both a positron 
and an electron neutrino. 
𝐹 →  𝑂8
18 + 𝛽+ + 𝑣𝑒+1
0
9
19       (2) 
 
Table 1.  List of PET radioisotopes in order of atomic number alongside their 
accompanying  physical half-lives, probability of β+ decay and method of 
production.[5, 6] 
PET radioisotope Half-life (t1/2) Mode of Decay (%) Methods of Production 
Carbon-11 (11C) 20.4 min β+ (100) 
10B(d,n)11C 
14N(p,α)11C 
Nitrogen-13 (13N) 10.0 min β+ (100) 
12C(d,n)13N 
16O(p, α)13N 
13C(p,n)13N 
Oxygen-15 (15O) 2.0 min β+ (100) 14N(d,n)15O 
Fluorine-18 (18F) 109.8 min β+ (97), EC (3) 
18O(p,n)18F 
20Ne(d,α)18F 
Copper-64 (64Cu) 12.7 hrs β+ (18), EC (43), β– (39) 
63Cu(n,γ)64Cu 
64Zn(n,p)64Cu 
64Ni(p,n)64Cu 
Gallium-68 (68Ga) 1.1 hrs β+ (89), EC (11) 68Ge–68Ga generator 
Iodine-124 (124I) 4.2 days β+ (23), EC (77) 124Te(p,n)124I 
 
The most common means of introducing fluorine-18 into a molecule is via nucleophilic 
substitution. However, while [18F]fluoride is prepared from oxygen-18 enriched water via 
cyclotron irradiation, aqueous solutions have typically been found to supress the 
nucleophilicity of the fluoride rendering most nucleophilic substitutions unreactive.[7] Thus, for 
most applications the [18F]fluoride requires drying which is most often achieved through the 
repeated azeotropic distillation of a water-acetonitrile mixture. To enable the solubility of the 
[18F]fluoride, phase transfer catalysts are typically used to dissolve the [18F]fluoride in 
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anhydrous organic solvents during radiofluorinations. One such example is Krypotofix 222 
(K222), used in the synthesis of [
18F]FDG, which complexes the potassium cation thus liberating 
[18F]fluoride via dissolution of the salt as shown in Figure 4. Another commonly employed 
phase transfer catalyst is 18-crown-6 ether, as a cheaper alternative for complexing the 
potassium cation. Bulky cationic quaternary ammonium salts such as tetraethylammonium 
(TEA) bicarbonate are also often used to improve the reactivity of [18F]fluoride in organic 
solvents. 
 
Figure 4. Two common examples of phase transfer catalysts used to dissolve potassium 
[18F]fluoride into organic media. Kryptofix 222 (top) and 18-crown-6 ether 
(bottom).[7] 
 
One such example of a nucleophilic substitution used in radiofluorination reactions is the 
synthesis of [18F]FDG whereby a tetraacetyl mannosyl-2-triflate precursor is reacted with 
[18F]fluoride dissolved in anhydrous acetonitrile in the presence of Kryptofix 222 and 
potassium carbonate.[7] The [18F]fluoride substitutes for a triflate leaving group and the acetate 
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protecting groups are removed via acid or base hydrolysis to afford the [18F]FDG product as 
shown in Figure 5. Electrophilic radiofluorinations can also be achieved, usually via labelled 
fluorine gas ([18F]F2) or other specialised reagents. The use of [
18F]F2 in radiosyntheses is less 
common, however, due to the high reactivity which can lead to the formation of side products 
from unselective reactions, the common use of F2 gas as a carrier for [
18F]F2 produced from 
gas or liquid phases which results in lower specific activity of the resulting fluorine-18 labelled 
tracers, and the 50% probability of incorporating fluorine-19 instead of fluorine-18 isotopes.[8-
10] For these reasons and the heightened safety risk involved,  neither [18F]F2 nor any alternative 
electrophilic radiofluorination reagents were implemented in this study.[5] 
 
Figure 5. Synthesis of [18F]FDG via nucleophilic substitution of [18F]fluoride for a triflate 
group of [mannosyl etc] aided by a Krypotofix 222 phase transfer catalyst in 
acetonitrile solution. Subsequent deprotection of acetyl groups by base 
hydrolysis affords the desired product. 
 
In the synthesis of more complex radiopharmaceuticals, a prosthetic group labelled with a 
fluorine-18 radioisotope may first be prepared, followed by mild and selective conjugation of 
the prosthetic group with the biomolecule or drug of interest. A disadvantage of using 
prosthetic groups is that they require multiple-step radiosyntheses to achieve the final PET 
tracer (i.e. the fluorine-18 radioisotope is not added in the final step of the synthesis) which can 
result in a greater loss of radioactivity due to the longer time of synthesis. One advantage, 
however, is that prosthetic groups can selectively add to positions which may inherently be 
non-selective for [18F]fluoride. Additionally, while reactions using [18F]fluoride in aqueous 
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media generally provide no yield, water soluble precursors can alternatively conjugate to a 
similarly soluble fluorine-18 labelled polar prosthetic group under aqueous conditions, thus 
widening the scope of radiotracer development. One such example of radiofluorinating via the 
use of a radiolabelled prosthetic group is provided in Figure 6a, whereupon 2-[18F]fluoroethyl 
tosylate is first prepared through nucleophilic substitution of [18F]fluoride for a tosyl group.[11] 
Conjugation of the 2-[18F]fluoroethane tosylate prosthetic group with a tyrosine precursor is 
then used to yield the neurooncological PET tracer [18F]fluoroethyl-L-tyrosine ([18F]FET). 
Another common example of a fluorine-18 labelled prosthetic group is N-succinimidyl 4-
[18F]fluorobenzoate ([18F]SFB), which is employed in the labelling of proteins and peptides, 
such as endothelin-1, neurotensin and human C-peptide.[12-16] The fluorine-18 radiolabelling of 
a model dipeptide using the [18F]SFB prosthetic group is provided in Figure 6b. 
 
Figure 6. a) Synthesis of [18F]FET via a 2-[18F]fluoroethane tosylate prosthetic group.[11] 
b) Radiolabelling of a model dipeptide using the [18F]SFB prosthetic group.[13] 
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To measure the incorporation of the fluorine-18 radioisotope into the final tracer product, a few 
terms need to first be defined. Radioactivity (A) itself is a measure of the decay rate, being the 
loss of radioisotopes (N) as a function of time (t), which obeys first-order kinetics thus yielding 
the decay rate constant (λ) as provided in equation (3).[6] 
𝐴 =
−𝑑𝑁
𝑑𝑡
= 𝜆𝑁      (3) 
 
The half-life (t1/2) of a radioisotope, being the time required for an initial quantity of 
radioactivity to decay to half the amount, is related to the decay rate constant through equation 
(4). Substituting the 109.8 min half-life of the fluorine-18 radioisotope into this equation, for 
instance, affords a decay rate constant of approximately 6.3 × 10-3 min-1. 
λ = ln(2) (𝑡1
2
)
−1
      (4)  
The calculated decay rate can then be used to decay correct starting amounts of radioactivity 
back to a single standardised point in time, as per the exponential equation (5), thus allowing 
for the calculation of the radiochemical yield (RCY). 
At = A0𝑒
𝜆𝑡       (5) 
 
The RCY of a reaction refers to the radioactivity of the product expressed as a percentage of 
the starting radioactivity. Given the relatively few methods available for selective carbon-
fluorine bond formation compared to other halogenation reactions,[17] the limiting time 
constraints in which such reactions need to be performed given the half-life of the fluorine-18 
radioisotope,[18] the general requirement for anhydrous conditions,[19] and that minute amounts 
of radioactivity can cause otherwise small concentrations of impurities to considerably impact 
reaction efficiencies,[20] RCYs as low as 2-3% RCY are not uncommon for fluorine-18 labelled 
tracers (particularly for pyridines) and can still prove sufficient for PET imaging 
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applications.[21-25] Unless the radioactivity of both the product and starting material are 
measured at the same time, for example via non-isolated radiochromatogram integrated peak 
ratios, the radioactivity of both chemicals requires decay correction before determining the 
overall RCY of the reaction. Of considerable importance also in the production of radiotracers 
is the molar activity (Am), a measure of the radioactivity per number of moles (n) as described 
by equation (6). 
𝐴𝑚 = (
−𝑑𝑁
𝑑𝑡
) 𝑛−1      (6) 
 
A greater molar activity is indicative of an efficient radiosynthetic and purification process 
which encapsulates a greater amount of the radioactivity within a given amount of product and 
is particularly important for assessing dose administration of a nuclear medicine to a patient. 
To achieve greater molar activities no-carrier-added approaches, whereby the radioisotope is 
prepared without adding stable carrier isotopes of the same element (e.g. [18F]fluoride formed 
from oxygen-18 enriched water) are generally used over carrier-added approaches where the 
carrier element has been purposely added, thus diluting the radioactivity per unit mass (e.g. 
production of electrophilic [18F]F2 where [
19F]F2 is added to extract the radiofluoride source 
from the cyclotron target).[7] 
In summary, fluorine-18 is the most widely used radioisotope in PET tracers owing to its ideal 
half-life and positron emission decay profile. The radioisotope is typically produced as no-
carrier-added [18F]fluoride via the 18O(p,n)18F nuclear reaction and azeotropically dried in the 
presence of a phase transfer catalyst to ensure greater RCYs and molar activities. 
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1.3 Optical Imaging and Rhenium Photophysics 
 
Optical imaging is a non-invasive medical technique which employs luminescent 
pharmaceuticals to identify diseased cells. Following administration to a patient, excitation of 
the tracer is achieved by exposing the tissue to electromagnetic radiation within the visible to 
near-infrared (NIR) range, which results in the intense emission of red-shifted light from the 
tracer used to identify where it has accumulated in the tissue. Figure 7 shows an example of 
optical imaging used to identify metastatic tumour nodules within the liver of a mouse model, 
performed by Kennedy, et al., following injection of a fluorescein-folate conjugate targeting 
folate receptors which are over expressed by several cancers (e.g. ovary, breast, kidney, brain 
and lung cancers).[26] The molecular structure of this fluorescein-folate tracer is shown in 
Figure 8, whereby the luminescent fluorescein is depicted in red and the folate, bioconjugated 
via an ethylene diamine linker, is depicted in green. 
 
Figure 7. Optical imaging of metastatic tumour nodules (bottom) in the liver of a mouse 
model (top) following intravenous injection of a folate-fluorescein conjugate by 
Kennedy, et al.[26] 
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Figure 8. Folate (green) conjugated to Fluorescein (red) thiocyanate linked via an 
ethylene diamine linker, used for the optical imaging of cancers overexpressing 
folate receptors. 
 
As an entire human patient cannot practically be exposed to a field of the excitation light, recent 
efforts have endeavoured to create handheld fluorescence scanners for applications in optical 
imaging during intraoperative surgeries.[27-29] In these devices a continuous-wave laser diode 
provided the excitation light beam which was converged through a convex lens and delivered 
to each individual fibre within a fibre optic array. The fibre optics provided the excitation light 
source through the handheld unit, and the emission light from detection fibre arrays was 
collected by a charge-coupled device (CCD) camera coupled with a band-pass filter. Imaging 
within smaller animal subjects can ordinarily be achieved through more simplified set-ups 
which need not rely on moving the excitation apparatus. An example of an experimental set-
up used for the optical imaging of antitumour treatments in a mouse model as implemented by 
Ntziachritsos, et al. is shown in Figure 9.[30] Here the excitation beam was both broadened 
through a beam expander and passed through an optical filter to illuminate the front of the 
animal model and concurrently passed through an optical switch, feeding the light through to 
a fibre optic array, which provided transillumination from the back of the animal imaging 
chamber. An optical filter was likewise placed in front of the CCD imaging camera to filter the 
emission wavelength, with the images digitally reconstructed thereafter. Variations of this set-
up are commonly applied for in-vivo optical imaging experiments within preclinical studies. 
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Figure 9. Example of an in vivo optical imaging experimental set-up used by 
Ntziachristos, et al.[30] An animal imaging chamber was exposed to a laser, with 
the beam either expanded for excitation at the front of the chamber or an optical 
switch enabling excitation from the back. An optical filter was placed in front 
of the CCD camera to ensure only the emission wavelength was detected. 
 
While excitation and emission within the visible region of the electromagnetic spectrum allows 
for the optical imaging of exposed surface tissue, the imaging of non-exposed deep tissue 
typically requires excitation and emission within the NIR region. This is because wavelengths 
of light within the NIR region are absorbed less by chromophores present within the tissue, 
thus allowing greater tissue penetration compared to visible light of similar flux.[31] This 
phenomenon is evident in Figure 10, plotting the molar extinction coefficients of 
oxyhaemoglobin and deoxyhaemoglobin per wavelength of light, whereupon lesser 
absorptivity is observed by both chromophores from approximately 600 nm onwards. In many 
cases excitation within the NIR region can be achieved via two photon absorption techniques, 
which concentrates the flux of NIR photons approximating half the energy of the required 
excitation frequency, such that the optical tracer can absorb two photons in a given instance of 
time to transition to an excited electronic state with minimal interference from the biological 
chromophores present within the tissue.[32] 
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Figure 10. Molar extinction coefficients of oxyhaemoglobin (HbO2) and 
deoxyhaemoglobin (Hb) as a function of increasing wavelength. The notable 
decrease in light absorption by both chromophores at wavelengths longer than 
600 nm demonstrations the transparency of biological tissue within the NIR 
region. Image released into the public domain under the Wikimedia Commons 
license agreement. 
 
Fortunately, the emission of optical agents is typically red shifted towards more biologically 
transparent shorter wavelengths compared to the excitation wavelength. This phenomenon can 
be described by a Jablonski diagram, which vertically plots the quantum states of a molecule 
as a function of energy and arranges them horizontally as per the spin multiplicity of those 
states. A detailed Jablonski diagram, depicting the photophysical processes characteristic of a 
rhenium d6 complex, is shown in Figure 11, whereupon the electronic quantum states are 
represented by thick horizontal lines with each vibrational quantum state superimposed by thin 
horizontal lines. Absorption of a photon of ample energy prompts a transition from the ground 
electronic singlet state (S0) to a vibrationally coupled excited electronic singlet state (S1). 
Thereafter the molecule will undergo vibrational relaxation (VR), liberating energy to the 
environment such that it assumes the lowest energy vibrational quantum state of the S1 
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electronic state. Three potential deexcitation pathways then arise from a molecule occupying 
the S1 electronic state. The excited molecule can either undergo internal conversion (IC) to 
transition back to the ground state (S0) vibronically coupled with a vibrational quantum state 
of equivalent energy, followed by VR to lose the absorbed energy to the environment in the 
form of heat (i.e. no radiative emission); it can undergo fluorescence, transitioning to any 
number of vibrationally coupled S1 electronic states by emitting photons equivalent to the 
difference in energy (thus accounting for the wide emission bands observed at room 
temperatures), and then undergoing VR to lose the excess vibrational energy; or, due to the 
spin-orbit coupling (SOC) exhibited by the larger nucleus of the rhenium atom which perturbs 
its spin-wavefunction, the molecule may violate the spin-selection rule (which forbids 
transitions between spin states of differing multiplicities) and undergo intersystem crossing 
(ISC) to a vibronically coupled excited electronic triplet state (T1). From the T1 electronic state 
the molecule may either undergo ISC back to the S0 electronic state and lose energy via VR or 
it may undergo phosphorescence, transitioning to vibronically coupled S0 states and emitting 
the difference in energy as photons which are even further red shifted with respect to those 
emitted via fluorescence. The orders of magnitude of time required for each of these 
photophysical processes is listed in Table 2.[33] It is evident from this table that phosphorescent 
emission occurs over significantly longer periods of time than fluorescent emission, due to the 
electronic deexcitation from triplet to singlet multiplicities. Thus, agents such as rhenium 
tricarbonyl complexes which exhibit phosphorescence have found noteworthy applications in 
time-gated emission, whereupon the emission is imaged some milliseconds after excitation of 
the tracer to allow for the background decay of autofluorescence from naturally existing 
biofluorescent molecules present within the biological tissue.[34,35] Added to this advantage is 
that such phosphorescent metal complexes with d6 electron configurations also benefit from 
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significant stokes shifts (typically > 5000 chromo) which allows the emission signal to be easily 
distinguished from the excitation signal with minimal spectral overlap.[36] 
 
Figure 11. Jablonski diagram showing the photophysical processes of absorption (blue), 
internal conversion (cyan), intersystem crossing (magenta), vibrational 
relaxation (azure), fluorescence (green) and phosphoresce (red) between the 
singlet ground (S0), singlet excited (S1) and triplet excited (T1) electronic 
quantum states. 
 
Table 2. Duration of time required for the various photophysical processes.[33] 
Transition Time Scale (s) 
Absorption 10-15 
Vibrational Relaxation (VR) 10-12 – 10-10 
Internal Conversion (IC) 10-11 – 10-9 
Intersystem Crossing (ISC) 10-10 – 10-8 
Fluorescence 10-10 – 10-7 
Phosphorescence 10-6 – 10 
 
Due to the advantages afforded from phosphorescent imaging, and aided also by their intrinsic 
resistance to photobleaching, rhenium tricarbonyl complexes have found widespread 
applications as optical agents for the imaging of cellular organelles.[37,38] Typically, such 
rhenium cell imaging agents will consist of a diimine bidentate ligand datively bonded through 
two nitrogen atoms of the respective N-heterocycles, alongside a monodentate ancillary ligand 
likewise bonded through an N-heterocycle. Modulation of either the diimine or ancillary ligand 
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can induce charge effects or alter the lipophilicity of the complex resulting in the localisation 
of the rhenium optical agents in differing cellular organelles as a function of these chemical 
properties. Exemplars of such rhenium tricarbonyl complexes used in the imaging of cellular 
organelles are provided in Figure 12.[39-42] 
 
Figure 12. Organelle localisation of some rhenium tricarbonyl imaging complexes as 
influenced by the modified molecular structure of the diimine and ancillary 
ligands.[39-42] 
 
The emission observed from rhenium complexes used as imaging agents typically arise from 
high energy ligand centred (LC) excited states, resulting from electronic transitions occurring 
within the diimine and/or ancillary ligand, and from a lower energy metal-to-ligand charge 
transfer (MLCT) excited state, whereupon the electronic transition occurs from a molecular 
orbital (MO) predominantly centred on the rhenium centre to the π* antibonding orbital of the 
ligand, thus resulting in a characteristic broad signal highly subject to solvatochromic shifts 
which can stabilise the positive and negative charge separation arising between the rhenium 
centre and ligand, respectively. Absorption to the MLCT excited electronic state, denoted as a 
dπ → π* transition, is characterised by a broad lower energy peak on UV-vis spectra, whereas 
absorption to the LC states, denoted as π → π* transitions, are characterised by higher energy, 
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sharp peaks with greater molar extinction coefficients. These transitions are depicted in Figure 
13, which provides a generalised MO diagram for octahedral complexes, such as rhenium 
tricarbonyl  diimine complexes, arising from the superpositioning of the atomic orbitals of the 
metal with the molecular orbitals of the ligand.[33] Alongside the typical absorption and 
emission bands observed to and from LC and MLCT excited states, lower energy metal centred 
(MC) as well as ligand-to-metal charge transfer (LMCT) states are also traced. 
 
Figure 13. MO diagram for an octahedral metal complex (such as rhenium tricarbonyl 
diimine complexes) showing the mixing of ligand MOs with the atomic orbitals 
of the metal centre, alongside some electronic excited states (such as LC and 
MLCT states) which arise from transitions between the MOs of the complex. 
 
Figure 14 provides a clearer illustration of the orbitals involved in the transition to the MLCT 
electronic excited state. The dπ orbital occupied in the ground state (GS) of the molecule, 
consists of electron density centred around the rhenium metal centre and the carbonyl groups, 
with little electronic density present on the ligand. Upon excitation to the MLCT excited state, 
a dπ occupied electron transitions to a π* orbital whereby the electronic density is spread over 
the N-heterocyclic ligand, thus causing a dipole to exist between the ligand and the metal. 
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Figure 14. Computational density functional theory (DFT) modelling of a tricarbonyl 
rhenium(I) complex with a 1,10-phenanthroline diimine ligand, showing the 
transition of an electron occupying a dπ orbital, centred on the rhenium and 
carbonyl ligands, to a π* antibonding orbital centred on the diimine ligand upon 
absorption of a photon. Thus, causing the molecule to transition from the GS to 
the MLCT excited state and a charged dipole to exist between the negatively 
and positively charged ligand and metal centre respectively. 
 
Any of these aforementioned transitions can be summarised in part within the simplified 
photophysical schematic represented by equation (7), whereupon a molecule (M) absorbs a 
photon (hv) as per the absorption rate constant (kabs).
[43] The excited state molecule (M*) arising 
from this transition may then either undergo deexcitation via a non-radiative decay channel 
such as IC determined by the non-radiative decay rate constant (knr), or alternatively deexcite 
via a radiative decay channel determined by the radiative decay rate constant (kr), inclusive of 
fluorescent and phosphorescent emission, to emit a red-shifted photon (hv’) of lower energy. 
𝑀 + ℎ𝑣 
𝑘𝑎𝑏𝑠
⇄
𝑘𝑛𝑟
𝑀∗  
𝑘𝑟
→ 𝑀 + ℎ𝑣′     (7) 
 
Aside from the excitation and emission wavelengths required to tune instrumentation to the 
receiving and output signals appropriate for the tracer, a particularly useful parameter of an 
optical agent is its luminescent quantum yield (ϕ). The luminescent quantum yield is a measure 
23 
 
of emission efficiency which can be defined by the ratio between the rate of photons emitted 
(hv’) and the rate of photons absorbed (hv) per given unit of time (t) as per equation (8). 
𝜙 = (
−𝑑[ℎ𝑣′]
𝑑𝑡
) (
𝑑[ℎ𝑣]
𝑑𝑡
)
−1
     (8) 
 
Similarly of value is the luminescence lifetime (τ) of an optical tracer. The luminescence 
lifetime is defined as the time required for the luminescence intensity to decay to e-1 of its 
original value and is a key indicator of how long an optical tracer can be efficiently imaged for 
following excitation. Equation (9) links the lifetime to the scheme provided in equation (7), 
showing how the concentration of molecules in the excited state ([M*]), indicative of 
luminescence intensity, exponentially decays as a function of time from its initial value ([M*]0). 
[𝑀∗] = [𝑀∗]0𝑒
−(
𝑡
𝜏
)
      (9) 
 
The radiative and non-radiative decay rate constants (kr and knr respectively), governing the 
rate of the photophysical processes described by the scheme in equation (7), are intrinsically 
linked to the quantum yield and lifetime of an optical tracer as per equations (10) & (11). 
𝑘𝑟 = 𝜙. 𝜏
−1       (10) 
𝑘𝑛𝑟 = (1 − 𝜙)𝜏
−1      (11) 
 
One final consideration in the design of optical agents is that bioconjugation of a fluorophore 
or alternative luminescent molecule can potentially inadvertently affect the photophysical 
properties of the final tracer. Likewise, the attachment of a luminescence appendage can affect 
the biological properties of the conjugate, such as its receptor binding affinity or rate of 
metabolism.[44] As such, linker groups are often employed to distance, and hence decouple, the 
fluorescent group and bioconjugate from influencing the properties of one another. Though 
these groups can too affect other chemical properties of the system, such as the solubility of 
the molecule, adding an additional layer of complexity to optical tracer design.[45, 46] 
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1.4 Fluorine-18 in PET-Optical Hybrid Imaging 
 
Among the first movements towards designing PET-optical hybrid tracers was a radioreceptor 
binding assay study performed by French, et al. in 1993.[47] Several 7α-pentyl substituted 
estradiols were synthesised in the study to assess estrogen receptor binding affinities, one of 
which was functionalised with fluorine-18 (1) for use as a breast cancer imaging PET tracer 
and another of which was functionalised with the luminescent boron-dipyrromethene 
(BODIPY) dye (2) for use as an optical agent, as depicted in Figure 15. These contributions 
laid the framework for fluorine-18 PET-optical imaging, using similar compounds with 
differing functionalisation tailored to the imaging modality of interest, though no further 
attempt was undertaken by the group to combine these functions into a single molecule which 
would behave similarly in both imaging studies. 
 
Figure 15.  7α-Pentyl substituted estradiol analogues developed by French, et al. bearing a 
fluorine-18 radioisotope (blue) for PET imaging and a BODIPY dye (red) for 
optical imaging of breast cancer.[47] 
 
It was not until 2011 that Li, et al. published the first communication detailing the fluorine-18 
labelling of a BODIPY dye as a structural motif for multimodal PET-optical imaging.[48] The 
radiolabelling reaction tolerated aqueous conditions, which is rarely reported in the field of 
radiofluorinations, and afforded the tracer (4) in 22 ± 3% RCY as show in  
Figure 16 with 925 ± 148 MBq.μmol-1 molar activity (though as carrier-added). An efficient 
quantum yield of 14.3% was also measured in chloroform, with 528 nm green light emission. 
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These photophysical properties were not characterised in water or biological media, however, 
to discern solvatochromic shifts and changes to the quantum yield in an in vivo environment. 
Despite this, biodistribution studies of the tracer marked one of the first instances of PET-
optical hybrid imaging, with the results of both imaging modalities shown in Figure 17. Further 
studies on analogues of 4 by Liu, et al. and Chansaenpak, et al. noted significant uptake of the 
tracer by the heart muscle compared to other organs and thus is currently being investigated as 
a PET-optical agent for myocardinal perfusion imaging.[49, 50] The confirmed in vivo stability 
of the fluorinated BODIPY agent by Li, et al. also inspired subsequent bioconjugations by 
other research groups. 
 
Figure 16. Fluorine-18 radiolabelling of a BODIPY dye with a c.a. RCY of 22 ± 3% under 
aqueous conditions.[48] 
 
 
Figure 17. Optical (right) and PET (left) imaging of the organs used for biodistribution 
analyses performed 4 h post-injection of the fluorine-18 labelled BODIPY agent 
(4) developed by Li, et al.[48] 
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The first experiment to bioconjugate the fluorine-18 labelled BODIPY analogue was published 
by Liu, et al. in 2013, whereby the motif was conjugated to a cyclic arginylglycylaspartic acid 
(RGD) analogue.[51] As the RGD peptide had been demonstrated to bind to integrin αvβ3 
receptor proteins in former studies and given that the αvβ3 receptor proteins are overexpressed 
in certain glioblastoma cell lines, the researchers were able to use compound 5 shown in Figure 
18 to provide PET and optical imaging of a glioblastoma xenograft mouse model (Figure 19). 
The radiotracer was afforded in 82% RCY, though with a relatively low molar activity of 703 
± 148 MBq.μmol-1 achieved through carrier-added 18F/19F isotope exchange. 
 
Figure 18. Fluorine-18 (blue) labelled BODIPY dye (red) bioconjugated to an RGD 
peptide analogue for use as a PET-Optical glioblastoma imaging agent.[51] 
 
 
Figure 19. A) PET imaging of a xenograft glioblastoma tumour depicted by the white 
arrow by Liu, et al. B) PET-optical hybrid imaging of the tumour and organs 
following 0.5 h post-injection of compound 5. 1: Heart, 2: Liver, 3: Kidneys, 4: 
Muscle, 5: Tumour.[51] 
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Later examples of fluorine-18 labelled BODIPY imaging agents encompass bioconjugation to 
a triglyceride (Figure 20) by Paulus, et al. in 2017 for imaging brown adipose tissue, which 
was formed in 76% RCY and low 220 MBq.μmol-1 molar activity with no photophysical 
characterisation;[52] bioconjugation to a caspase inhibitor (Figure 21), an enzyme family 
responsible for the regulation of cellular apoptosis, achieved in 11 ± 6% RCY and considerably 
high molar activity (≥ 166 GBq.μmol-1) with a quantum yield of 12.0 ± 0.5% by Ortmeyer, et 
al. in 2017;[53] and a recent PET-optical prosthetic group developed in 2019 by Kim, et al. for 
the design of neuroimaging agents,[54] whereupon the researchers reported RCYs in the range 
of 35 – 50% and molar activities in the vicinity of 0.8 – 1.0 GBq.μmol-1. 
 
 
Figure 20.  Triglyceride molecule functionalised with a radiofluorinated BODIPY dye by 
Paulus, et al. for the PET-optical imaging of brown adipose tissue.52 
 
 
Figure 21. Caspase-inhibitor functionalised with a fluorine-18 labelled BODIPY dye by 
Ortmeyer, et al.[53] 
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Figure 22. PET-optical methyl ester prosthetic group for the development of neuroimaging 
agents synthesised by Kim, et al.[54] 
 
An alternative PET-optical strategy trialled by Ting, et al. in 2010 also relied on a boron-
fluorine-18 bond via a trifluoroborate group, though instead implemented the radioisotope 
alongside a conjugated heptamethine cyanine (Cy7) dye responsible for the 772 nm NIR 
emission maximum of the tracer in water.[55] The molecule was bioconjugated to the 
macromolecular polysaccharide tilmanocept (also marketed as Lymphoseek), consisting of 
repeating units of diethylenetriaminepentaacetic acid (DTPA) and mannose bonded to a 
dextran backbone (shown in Figure 23), which was initially designed to complex to 
technicium-99m for the single photon emission computed tomography (SPECT) imaging of 
sentinel lymph nodes.[56] The researchers were able to achieve a single step aqueous 
radiofluorination of the precursor, akin to the protocol used by Li, et al. for BODIPY 
radiolabelling, though no RCYs were reported.[48, 55] The quantum yield of the tracer was 
calculated as 2.7% in water which, while not as high as those attained by BODIPY analogues 
in organic solvents, is better representative of the expected fluorescence output in a biological 
environment and allows for deep-tissue imaging within the NIR window. Discernible PET-
optical imaging of the lymph nodes was achieved in animal models, leading to the conclusion 
that single-injections of tracer 9 may improve sentinel node biopsy over alternative protocols 
implementing multiple-injection analyses of [99mTc]Lymphoseek for nuclear imaging and 
chemically dissimilar isosulfan blue dyes for subsequent optical imaging.[57] 
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Figure 23. DTPA-mannosyl-dextran (Lymphoseek) conjugated to a Cy7 dye (red) for NIR 
optical imaging and a trifluoroborate group hosting the fluorine-18 radioisotope 
(blue) for PET imaging, developed by Ting, et al. for the PET-optical mapping 
of sentinel lymph nodes.[55] 
 
Aiming to develop PET-optical tracers of monoclonal antibodies, Rogriguez, et al. utilised a 
similar Cy7 dye as introduced by Ting, et al. also incorporating a fluorine-18 boron trap.[58] 
The 2016 study focussed on coupling two monoclonal antibodies, one being an anti-epithelial 
cell adhesion molecule (EpCAM) antibody used to label prostate tumours (10a) and the other 
being an anti-epidermal growth factor receptor (EGFR) antibody for labelling lung 
adenocarcinoma tumours (10b). The general structure for both monoclonal antibody-coupled 
PET-optical tracers is depicted in Figure 24. Significantly greater molar activities were attained 
for the EpCAM targeting prostate tumour tracer (10a) than for the EGFR targeting lung 
adenocarcinoma tumour tracer (10b), affording 592 GBq.μmol-1 and 181 MBq.μmol-1 
respectively. 
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Figure 24. PET-optical tracer designed by Rogriguez, et al. incorporating a Cy7 dye (red), 
boron-bonded fluorine-18 radioisotope (blue) and conjugated to a monoclonal 
antibody (orange) targeting EpCAM (10a) and EGFR (10b).[58] 
 
Al-Karmi, et al. also sought to radiofluorinate the Cy7 hydrocyanine dye, though for use as a 
PET coupled on-off optical probe which would fluoresce in the presence of reactive oxygen 
species (ROS).[59] An initial two-step radiosynthesis of the compound involved nucleophilic 
aromatic substitution of a nitro-substituted precursor (11) using [18F]fluoride with a Kryptofix 
222 phase transfer catalyst in dimethylformamide (DMF), followed by reduction of the 
iminium salt using sodium borohydride, as shown in Figure 25. This approach afforded only 
19% RCY, however, and hence direct radiofluorination of the already reduced Cy7 dye (12) 
was instead trialled which afforded the desired tracer (13) in 62% RCY and with 5.2 GBq.μmol-
1 molar activity, thus demonstrating the aforementioned value of simplifying radiosyntheses to 
a single time-efficient radiofluorination step as to avoid any unnecessary loss of radioactivity. 
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Figure 25. Cy7 dye with a 2-[18F]fluoropyridine prosthetic group for the PET imaging and 
on-off optical sensing of ROS.[59] Initial syntheses starting from 11 involved a 
multistep radiofluorination and reduction reaction which afforded 13 in only 
19% RCY. An alternative direct single step radiofluorination from the reduced 
non-radioactive analogue (12) afforded 13 in 62% RCY. 
 
An ambitious goal by Wang, et al. was to PET-optical label red blood cells, using the 
alternative trimethine cyanine (Cy3) and pentamethine cyanine (Cy5) dyes coupled with 
fluorine-18, as a means of imaging intracranial haemorrhages.[60] An initial PET-optical 
labelling reagent was synthesised by conjugating an N-hydroxysuccinimide (NHS) ester to the 
fluorine-18 labelled Cy3 dye (14), which was then demonstrated to react with the free amine 
groups of lysine units present on the surface of the red blood cells, as shown by the mechanism 
in Figure 26. The resulting radiolabelled red blood cells were reportedly achieved in greater 
than 2.96 GBq.μmol-1. Similar red blood cell conjugation experiments were also performed 
using the Cy5 hydrocyanine dye PET-optical tag (15) additionally shown in Figure 26. 
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Figure 26. Design of a Cy3 hydrocyanine dye (red) complexed to a fluorine-18 labelled 
trifluoroborate salt and NHS ester (14) by Wang, et al., which allows for 
bioconjugation to the terminal amino group of lysine residues present on the 
surface of red blood cells.[60] The resulting PET-optical labelled red blood cells 
were subsequently used to image intracranial haemorrhages. Substitution for a 
Cy5 hydrocyanine dye (red) also allowed for an analogous red blood cell 
conjugate (15) with differing excitation and emission properties. 
 
 
 
Red 
blood 
cells 
Red 
blood 
cells 
33 
 
Having developed a novel sulfonated prosthetic group (16), shown in Figure 27, as a less 
lipophilic alternative to the fluorine-18 prosthetic groups which were currently available, Priem, 
et al. also sought to conjugate 16 to an alternative pentamethine cyanine (Cy5.5) dye for 
development as a PET-optical agent.[61] The Cy5.5 precursor (17) reacted with the NHS ester 
group of the prosthetic group (16) in the presence of an N,N-diisopropylethylamine (DIPEA) 
base in acetonitrile to afford the PET-optical dye (17) in purportedly ≤ 70% RCY, although the 
molar activity was not specified. Commendably however, the quantum yield of 17 was 
compared against the original Cy5.5 dye and the precursor derivative 16 to assess its viability 
as an optical probe. In dimethylsulfoxide (DMSO) solution, probe 17 exhibited a quantum yield 
of 42%, slightly decreased from the 45% quantum yield of 16. This trend was inverted, however, 
when measuring the quantum yields in phosphate-buffered saline (PBS) solution with the 5% 
addition of bovine serum albumin (BSA) to better represent a biological medium and to prevent 
the formation of non-emissive aggregates. In such a solution 17 afforded a quantum yield of 
38%, slightly greater than 16 which afforded 34% and much greater than the Cy5.5 dye which 
alone afforded a 23% quantum yield. While the emission maxima of both 17 and 16 were not 
dissimilar at 712 and 710 nm respectively, both were red shifted with respect to the emission 
maxima of the Cy5.5 dye at 694 nm in the PBS plus BSA solution. These differences in 
photophysical parameters demonstrate the importance of measuring the quantum yields and 
excitation/emission properties not only in organic solvents, though also in aqueous or 
biological media where solvatochromic effects can influence the efficiency of an optical tracer 
in its intended environment. 
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Figure 27.  Radiolabelling of a Cy5.5 fluorescent precursor (17) with a fluorine-18 labelled 
NHS ester prosthetic group (16) to afford the PET-Optical product (18) by 
Priem, et al.[61] 
 
An alternative use of a prosthetic group was also trialled by Heinrich, et al. in the radiolabelling 
of the rhodamine B fluorescing dye for use as a myocardinal perfusion imaging agent, 
analogous to the mentioned works of Liu, et al. and Chansaenpak, et al.[62] As shown in Figure 
28, the precursor (19) was reacted with a 2-[18F]fluoroethyl tosylate prosthetic group heated to 
reflux in anhydrous acetonitrile in the presence of a DIPEA base, which afforded the fluorine-
18 labelled rhodamine B product in 35% decay corrected RCY following purification by solid-
phase extraction. While the time of synthesis required approximately 90 mins the PET-optical 
tracer was still acquired with a satisfactory 1.3 GBq.μmol-1 molar activity. Unfortunately, the 
tracer showed no appreciable uptake in myocardial tissue during subsequent biodistribution 
studies, invalidating its potential use as a myocardinal perfusion imaging agent, and no 
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measurements of the quantum yield or other photophysical parameters were undertaken to 
develop the probe for further PET-optical applications. 
 
 
Figure 28. Radiolabelling of Rhodamine B (20) using an [18F]fluoroethyl tosylate 
prosthetic group under basic conditions by Henrich, et al. which afforded the 
tracer in 35% RCY post-purification, though required a synthesis time of 
approximately 90 mins.[62] 
 
A unique approach to designing PET-optical agents was experimented by Damont, et al. whom 
first sought to conjugate water-soluble biotin (vitamin B7) to two differing fluorescent dyes, 
Atto-425 (21) and Atto-680 (22) as shown in Figure 29.[63] A third biotin precursor (23) was 
also developed which was radiofluorinated via a traditional nucleophilic aromatic substitution 
for a nitro leaving group in anhydrous conditions, affording the 2-[18F]fluoropyridine labelled 
derivative (24) in 44 ± 9% RCY and 153 ± 45 GBq.μmol-1 molar activity. Each of the three 
biotin groups were then bound to avidin, a tetrameric protein capable of binding to four units 
of biotin with high affinity, in order to create the scaffold for a PET-optical tracer to which a 
fourth biotin unit could be bound as a targeting vector. Neither the photophysical properties 
nor the molar activity of the final biotin-bound avidin complex were determined, though the 
approach demonstrated a novel means by which additional imaging modalities could be 
appended. 
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Figure 29. Biotin (green) was conjugated to two fluorescent dyes (red), Atto-425 (21) and 
Atto-680 (22). A 2-nitropyridine analogue of biotin (23) was radiofluorinated 
to form a 2-[18F]fluoropyridine biotinylated analogue (24). The PET modality 
(24) and optical modality (21 or 22) were then combined via biotin-avidin 
binding to develop a novel PET-optical agent.[63] 
 
Aside from the use of organic fluorophores, two researchers have also published work on the 
fluorine-18 labelling of quantum dots (QDs) as PET-optical agents. The first example, reported 
in 2008 by Duconge, et al., encapsulated a CdSe/CdZnS core/shell QD within a phospholipid 
micelle functionalised with thiol groups.[64] A fluorine-18 labelled maleimido reagent, 1-[3-(2-
[18F]-fluoropyridin-3-yloxy)propyl]pyrrole-2,5-dione ([18F]FPyME), was then reacted with the 
thiol groups in order to add PET imaging functionality to the optically emitting QDs (25) as 
shown by the resulting structure in Figure 30. The molar activity of the QDs formed by 
Duconge, et al. ranged from 370 – 740 GBq.μmol-1 and while the RCY of the fluorine-18 
labelled QDs were not calculated, the radiochemical synthesis hitherto afforded [18F]FPyME 
in 17 – 20% RCY, though not corrected for decay (as the Society of Radiopharmaceutical 
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Sciences (SRS) did not publish guidelines requiring decay correction for reported RCYs until 
2017).[65] The photophysical properties of the PET-optical functionalised QD (25) were 
unfortunately not measured, however, QDs of this nature have been reported to achieve 
quantum yields greater than 80% in some instances.[66] An alternative PET-optical fluorine-18 
labelled QD tracer developed later by Hu, et al. in 2015 sought to bioconjugate not only a cyclic 
RGD peptide for specific binding to integrin αvβ3, similar to the earlier attempts of Liu, et al. 
towards targeting glioblastoma, though also bombesin, an analogue of gastrin-releasing peptide, 
for targeting the gastrin-releasing peptide receptor (GRPR) which is over-expressed in certain 
prostate cancers.[67] The researchers utilised ZnS coated CdTe QDs functionalised with 
polyethyleneglycol (PEG) to which the group bearing the fluorine-18 radioisotope, cyclic RGD 
peptide and bombesin peptide sequence was attached to give the PET-optical QD (26) shown 
in Figure 30. Despite reasonable tumour uptake of 26 being observed using both modalities in 
biodistribution experiments of prostate tumour bearing mouse models, neither the 
photophysical characteristics nor the molar activity and RCY were reported for the final tracer. 
 
 
Figure 30. Two fluorine-18 labelled quantum dots (QDs) for PET-optical imaging 
designed by Duconge, et al. using CdZnS coated CdSe QDs (25) and Hu, et al. 
using ZnS coated CdTe QDs bioconjugated to cyclic RGD and a bombesin 
peptide sequence (26).[64, 67] 
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A final class of PET-optical tracers incorporating [18F]fluoride directly into the core of Yb3+ 
and Er3+ upconversion luminescence nanoparticles was developed independently by Liu, et al., 
Sun, et al. and Zhou, et al. in 2011.[68-70] The rationale for the use of nanoparticles was the 
added possibility of co-doping the nanoparticles with paramagnetic Gd3+ as a contrast agent 
for additional MRI trimodal functionality, which was explored in each of these studies via the 
implementation of NaYF4 nanophosphors. Despite the impressive feat of consolidating PET, 
MRI and optical modalities into a single molecular probe, as well as the wealth of 
biodistribution data which was acquired from each study, no attempts to bioconjugate these 
probes for disease diagnosis have since been performed. While Zhou, et al. did not report any 
RCYs for their radiolabelling experiments, leaving the design efficiency in question, Liu, et al.  
and Sun, et al. both reported fluorine-18 labelling yields of greater than 90%. No measurements 
of molar activities, nor quantum yields were commented on, however, and thus remain critical 
parameters to be explored should the implementation of nanoparticle PET-optical probes be 
expanded upon. 
 
A comprehensive summary of all the above known fluorine-18 labelled PET-optical tracers in 
the present literature is provided in Table 3. The table details, where published by the authors, 
the fluorophore and biological target, RCY, molar activity (Am), quantum yield (ϕ) and 
excitation/emission maxima (λex/λem) measured in the listed solvent for each multimodal tracer; 
save for the fluorine-18 labelled nanoparticles where these experiments were not performed. It 
is evident from this list that no radiofluorinations of luminescent transition metals, such as 
rhenium tricarbonyl complexes, have yet been performed and thus signify a critical gap in the 
research efforts to discover new fluorine-18 PET-optical hybrid agents. 
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Table 3. Properties of each of the fluorine-18 labelled PET-optical tracers currently 
reported in literature. *RCY reported was not decay corrected (published before 
2017 SRS guidelines required decay corrections for RCYs).[ 65] **5% BSA also 
present in the tested PBS solution. ***Radiochemical data is provided for the 
radiolabelled prosthetic groups rather than the final tracer. 
Tracer Fluorophore Target 
RCY 
(%) 
Am 
(GBq.μmol-1) 
ϕ (%) 
Solvent 
λex/λem 
Solvent 
4[48] BODIPY - 22 ± 3 0.925 ± 0.148 
14.3 
CHCl3 
506/528 
CHCl3 
5[51] BODIPY Integrin αvβ3 82 0.703 ± 0.148 - - 
6[52] BODIPY 
Brown 
adipose 
tissue 
76 0.220 - - 
7[53] BODIPY Caspase 11 ± 6 ≥166 
12.0 ± 0.5 
CH3CN 
500/509 
CH3CN 
8[54] BODIPY - 
42.5 ± 
7.5 
0.900 ± 0.100 - 
580/590 
MeOH 
9[55] Cy7 
Sentinel 
lymph nodes 
- 4.70 × 10-3 
2.7 
H2O 
755/772 
H2O 
10a[58] Cy7 EpCAM - 595 - - 
10b[58] Cy7 EGFR - 0.181 - - 
13[59] Cy7 ROS 62 5.2 - - 
14[60] Cy3 
Red blood 
cells 
- 2.96 - - 
17[61] Cy5.5 - ≤ 70 - 
0.42 
DMSO 
0.38  
PBS** 
689/714 
DMSO 
697/712 
PBS** 
20[62] 
Rhodamine 
B 
Myocardium 
Tissue 
35 1.3 - - 
24[63]*** 
Atto-425, 
Atto-680 
- 44 ± 9 0.153 ± 0.045 - - 
25[64]*** QD - 17 – 20* 370 – 740 - - 
26[67] QD 
Integrin αvβ3 
GRPR 
- - - - 
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1.5 Proposal for Fluorine-18 Labelled Rhenium Complexes as 
PET-Optical Hybrid Imaging Agents 
 
To date there has only been one example of a fluorine-18 labelled rhenium complex which was 
performed in 2017 by Lipowska, et al. during the time of this thesis investigation.[ 71] The study 
involved complexing 2-[18F]fluoroethyl iminodiacetic acid ([18F]FEDA) to a rhenium 
tricarbonyl source for use as a preclinical PET imaging agent for evaluating renal plasma flow. 
Figure 31 demonstrates the synthesis of the non-radioactive standard, reacting FEDA with the 
triaquatricarbonylrhenium(I) cation to obtain ReFEDA, alongside the radiosynthesis of 
[18F]ReFEDA which was attained by reacting a tosylated precursor with a source of 
tetrabutylammonium [18F]fluoride ([18F]TABF). Despite having successfully radiofluorinated 
the rhenium complex, the potential luminescent properties were lost due to the absence of 
aromatic diimine and ancillary N-heterocyclic ligands (required for the low energy dπ → π* 
transitions to the MLCT excited state), which were unable to be introduced due to the tridentate 
nature of the FEDA ligand. Thus, no literature examples have yet existed which posit the 
fluorine-18 labelling of rhenium (or any other transition metal) complexes as viable PET-
optical hybrid imaging agents. 
Herein it is proposed that the fluorine-18 radiolabelling of rhenium tricarbonyl diimine 
complexes could serve as useful PET-optical molecular scaffolds for subsequent 
bioconjugation. The value of these rhenium complexes in PET-optical imaging is substantiated 
by their resistance to photobleaching, phosphorescence decay channel and tuneable emission 
properties as a function of the diimine ligand structure. Towards realising this goal, the research 
described herein began with the principle aim of synthesising the first radiofluorinated optically 
emitting rhenium complex, followed by an in-depth evaluation of its radiochemical and 
photophysical properties (i.e. to prove that such a complex can be synthesised in reasonable 
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RCY and with sufficient molar activity, quantum yield and emission lifetime). While pursuing 
this objective it was serendipitously also discovered that a novel rhenium-mediated method 
could fluorine-18 label pyrindyl-bidentate ligands which were unable to be synthesised via 
traditional radiochemical techniques, and thus also redirected research interest towards 
defining the scope of this novel method and applying it towards the improved radiosynthesis 
of existing PET nuclear medicines. 
 
 
Figure 31. Non-radioactive (top) and radioactive (bottom) syntheses of ReFEDA and its 
radiofluorinated analogue [18F]ReFEDA, respectively, by Lipowska, et al.[71] 
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CHAPTER TWO 
EXPERIMENTAL METHODS 
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2.1 Non-Radioactive Syntheses of Standards and Precursors 
 
The synthetic methods required for each of the non-radioactive fluorinated standards and the 
precursor compounds are described in each separate chapter. The molecular structures and 
purities of each compound were verified by a suite of analytical techniques prior to 
radiochemical and photophysical analyses. NMR analyses were performed using a Bruker 
Spectrospin 400 MHz UltraShield NMR spectrometer. Fourier transform infrared (FTIR) 
analyses were performed using a Brucker ALPHA-p IR spectrometer. UV-Vis analyses were 
performed using an Agilent technologies Cary 100 UV-Vis spectrometer. MP analyses were 
performed using a Stanford Research Systems Optimelt automated MP system with digital 
imaging processing technology. Low resolution mass spectrometry (LRMS) analyses were 
performed using a Waters micromass ZQ, equipped with an electrospray ionisation (ESI) 
source running in positive ionisation mode with the following parameters applied; voltages: 3 
kV capillary voltage, 25 V cone voltage for organic molecules or 70 V cone voltage for rhenium 
complexes (required to dissociate Re−Br & Re−Cl bonds), 5 V extractor voltage and 0.2 V 
radiofrequency (RF) lens voltage; Temperatures: 45 °C source temperature and 300 °C 
desolvation temperature; and gas flows: 350 L.h-1 desolvation nitrogen gas flow and 90 L.h-1 
cone nitrogen gas flow. Samples for HRMS were sent to the mass spectrometry user resource 
and research facility at the University of Wollongong and samples for EA were sent to the 
Campbell Microanalytical Laboratory at the University of Otago. All synthetic reagents were 
purchased from Sigma-Aldrich except for trifluoroacetic acid (TFA) and 18-crown-6 ether 
which were purchased from Alfa Aesar. Any precursor compounds whose syntheses are not 
described herein were additionally purchased from Bepharm. Finally, all solvents were 
purchased from Merck and any water used for syntheses and analyses were first purified using 
a Merck Millipore Milli-Q integral water purification system. 
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2.2 Assignment of Radiotracer Identities 
 
Radionuclides used in PET diagnostic scans are typically prepared in substantially high molar 
activities, such that nanomolar to picomolar amounts of the synthesised tracer afford sufficient 
radioactivity for patient imaging.[72] Most common analytical techniques used in chemistry lack 
the sensitivity to detect the low picomolar concentrations of the radiotracer produced. Thus, 
the assignment of radiotracer identities in this study was achieved by equipping a radioactivity 
detector to a high-performance liquid chromatography (HPLC) instrument, referred to as a 
radioHPLC. The radioactivity detector was placed in series alongside a photodiode array 
(PDA) detector to concurrently monitor eluents via both channels following injection of the 
sample. Prior to radiosyntheses, non-radioactive standards of the fluorinated products were 
injected on the HPLC to determine the retention time via the UV-absorbance channel at the 
PDA detector. Radioproducts whose peaks shared the same retention time via radioactivity 
detection as the non-radioactive standards via UV-detection (within a 0.3 min tolerance due to 
the placement of the detectors) were assigned the same molecular identity. All radiochemical 
separations were performed on a  Chromolith C18 reverse phase (RP) monolithic column 
(Merck 50 × 4.6 mm) demonstrated to have < 8% [18F]fluoride retention in low pH ranges.[73] 
The standard radioHPLC analyses used in this study consisted of gradient conditions, 
comprised of water and acetonitrile solvents each containing 0.05% trifluoroacetic acid (TFA) 
modifier, eluting with a 2 mL.min-1 flow rate. The composition of the mobile phase over the 
15 min run time is illustrated in Figure 32. The first 3 mins consisted only of 95% water to 
elute off any residual DMSO or unreacted [18F]fluoride and polar analytes. Thereafter, the 
composition was ramped from 5% to 95% acetonitrile in water over a period of 7 mins to 
gradually elute more non-polar analytes as a function of their interaction with the stationary 
phase. The mobile phase composition was held at 95% acetonitrile for 2 mins to ensure all 
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remaining lipophilic analytes were eluted from the column and then finally switched back to 
5% acetonitrile for 3.5 mins to equilibrate the column in preparation for the subsequent analysis.  
 
 
Figure 32. Chromatographic conditions employed for the separation of radioanalytes using 
a flow rate 2 mL.min-1 over a monolithic C18 stationary phase. Both water and 
acetonitrile mobile bases contained 0.05% TFA modifier in solution. 1-3 mins: 
95% water held to elute DMSO and unreacted [18F]fluoride. 3-10 mins: gradient 
switched from 5% to 95% acetonitrile to elute analytes from the stationary phase. 
10-12 mins: 95% acetonitrile held to elute off any remaining lipophilic analytes. 
12.5-15 mins: 95% water held to equilibrate the column before the next injection. 
 
Each of the radioHPLC analyses were carried out on a Shimadzu system comprised of a CBM-
20 controller, LC-20AD pump, SIL-20AHT autoinjector, SPD-M20A PDA detector for the 
UV analyses and a Lablogic Posi-RAM gamma detector for the radioanalyses. The number of 
counts detected at the radioactivity detector are proportional to the quantity of the fluorine-18 
radioisotope, and thus the radioproduct, as reflected in Equation (3). Thus, non-isolated 
radioHPLC derived RCYs were calculated via the ratio between the integrated peak area (pA) 
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and integrated chromatographic area (cA) expressed as a percentage, as per equation (12). 
Calculating the amount of radioactivity incorporated within the tracer as a ratio of the total 
radioactivity, measured in the same instance of time, circumvented the need to correct for decay 
correction within this equation (assuming negligible loss of radioactivity during the 15 min 
duration of the HPLC method). 
𝑅𝐶𝑌 = (𝑝𝐴)(𝑐𝐴)−1(102)       (12) 
Further confirmation was also achieved, where necessary, by analysing the same samples using 
thin layer chromatography (TLC) technique. The standard conditions used for these radioTLC 
analyses involved separation of the radioanalytes on normal phase (NP) silica using an ethyl 
acetate mobile phase. The radioactive analytes were then imprinted on a phosphor plate and 
scanned using a PerkinElmer Cyclone Plus phosphor imager to determine the RCYs as per 
equation (12). 
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2.3 Automated Radiosyntheses using Microfluidics 
 
Automating reactions is becoming increasingly common in radiopharmaceutical industries 
which aim to achieve a consistent supply of radiotracers while minimising operating expenses 
and radiation doses to the chemists involved in production. Assembling such automated 
synthesisers using microfluidic technologies has a significant number of advantages; namely 
this reduces costs by using fewer reagents, miniaturises the workstation by occupying less 
space, improves the molar activity of the final product by reducing the contamination of stable 
isotopes, affords quicker reaction times due to the smaller volumes requiring heating and is 
particularly advantageous in the syntheses of products, such as PET radiotracers, where only 
small quantities are required to be produced.[74] Automated microfluidic systems are also 
especially valuable in radiochemical research whereupon method development of a 
radiochemical reaction can be performed multiple times on the same precursor while adjusting 
one or several parameters in each iteration. Thus, an Advion NanoTek LF Microfluidic 
Synthesis System was implemented with microfluidic components for the radiosyntheses 
described herein. A schematic of the automated system constructed for the purposes of this 
research is shown in Figure 33. Following production on an IBA Cyclone 18 Twin cyclotron 
particle accelerator hosted at ANSTO using the 18O(p,n)18F nuclear reaction, an aqueous 
solution of [18F]fluoride in oxygen-18 enriched water was drawn into a syringe by pump 1 (P1) 
and eluted through a QMA ion-exchange cartridge which traps the [18F]fluoride while 
disposing of the oxygen-18 enriched water solution for recycling. The entrapment of the 
[18F]fluoride was monitored via the placement of a radioactivity detector in proximity of the 
QMA cartridge. Thereafter tetraethylammonium (TEA) bicarbonate, dissolved in a solution 
consisting of 10% water in acetonitrile, was passed through the QMA ion-exchange cartridge 
to elute off TEA [18F]fluoride. A solenoid valve (SV) was switched, thus redirecting the 
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solution to an azeotropic distillation vial. This process was monitored by the loss of 
radioactivity measured by the detector located near the QMA cartridge followed by the sharp 
increase in signal measured by the radioactivity detector placed near the azeotropic distillation 
vial. To improve the nucleophilicity of the [18F]fluoride we then azeotropically dried the 
solution by switching two SVs enabling both a nitrogen gas flow and vacuum into and out of 
the vial while heating. This reduced the volume of the solution such that it could then be 
reconstituted in an anhydrous acetonitrile solution supplied from a solvent reservoir plumbed 
to P1. As much as an 84% w/w content of acetonitrile (boiling point of 82 °C) in water (boiling 
point of 100 °C) under standard pressure conditions can lower the boiling point of the overall 
solution down to 76 °C via formation of an azeotrope, allowing for efficient removal of water 
from the system.[75] By repeating the process of reducing and reconstituting the [18F]fluoride 
in anhydrous acetonitrile at least three times in succession, the TEA [18F]fluoride was found to 
be sufficiently free of water to perform nucleophilic reactions. The TEA [18F]fluoride was thus 
dissolved in a volume of anhydrous DMSO supplied from P1 thereafter and aspirated into the 
syringe of pump 2 (P2), whereupon it was dispensed into the P2 storage loop. The solution 
could be traced from the loss of radioactivity detected at the distillation vial which correlated 
with the increase in radioactivity sensed by the detector at the storage loop. Simultaneously the 
precursor solution was loaded by pump 3 (P3) and dispensed into the P3 storage loop. Both the 
radioactive and precursor solutions in P2 and P3 storage loops respectively were re-aspirated 
and dispensed three times over to ensure homogeneity of the solutions. Defined volumes of the 
radioactive and precursor solutions were then concurrently passed through a 15.6 μL 
microreactor made of fused silica tubing which was coiled tightly into a brass rig containing a 
thermoresistant polymer to hold the tubing in place. A defined temperature and flow rate were 
then programmed into the Discovery Mode of the NanoTek software (V1.4.0 GMP Lite) for 
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each reaction, the latter of which determined the reaction time (t) as defined by equation (13) 
per volume (V) of solution. 
𝑡𝑟𝑒𝑎𝑐𝑡𝑖𝑜𝑛 = 𝑉 (
𝑑𝑉
𝑑𝑡
)
−1
     (13) 
Applying the standard flow rate of 20 μL.min-1, used in most reactions herein, to the 15.6 μL 
volume of the microreactor, for instance, afforded reaction times of 47 s. The radioactivity was 
monitored via the final detector in the set-up as the solution eluted through and out of the 
microreactor before finally dispensing in the final product vial for subsequent gamma counting 
and analyses by radioHPLC and/or radioTLC. 
 
Figure 33. Automated synthesis module assembled for drying and reacting the cyclotron 
produced [18F]fluoride solution with a precursor for subsequent analysis. 
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The reaction was likewise monitored via the pressure profiles, of which an example is shown 
in Figure 34. An increase in pressure was observed as P2 and P3 delivered their respective 
[18F]fluoride and precursor solutions from the storage loop to the microreactor. Thereafter a 
valve in P2 was switched, thus pumping DMSO to push the [18F]fluoride and precursor 
solutions through the microreactor where they were heated and reacted under laminar flow 
regime. It is worth mentioning that no active quenching was applied here to avoid introducing 
further reagents to the solution and as rapid cooling may have exerted excessive pressure on 
the pumps. After pumping the precursor solution, the pump valve was turned away from the 
reactor thus relieving P3 of pressure, whereas P2 maintained its pressure as it supplied inert 
DMSO solution to push the reaction bolus from the microreactor. After the reaction bolus 
exited the heated microreactor the flow rate was increased (typically to 150 μL.min-1) to 
quickly transfer the resulting radiotracer solution to the final product vial. The increase in flow 
rate created greater back pressure, particularly at lower temperatures due to the high viscosity 
of DMSO, though exhibited a characteristic sharp dip in pressure as P2 momentarily paused to 
adjust to the newly set transfer rate. Ensuring the same pressure profile was observed between 
each radiolabelling experiment was imperative as it confirmed that the same reaction 
environments were being consistently maintained. 
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Figure 34.  Pressure profiles observed in between radiolabelling reactions for P2 supplying 
the [18F]fluoride solution and P3 supplying the precursor solution. This 
consistent pressure profile was maintained during each experiment to ensure the 
repeatability of each reaction. 
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2.4 Photophysical Analyses of Quantum Yields and Lifetimes 
 
The photophysical analyses were performed using an Edinburg FLS980 photospectrometer. 
Following confirmation of the excitation wavelength for the dπ → π* transition to the MLCT 
excited state using UV-vis spectroscopy, emission scans of the rhenium complexes were 
subsequently performed on the same solution with the excitation wavelength set to the MLCT 
absorption maxima. The excitation light was emitted from a 450 W xenon arc lamp source and 
passed through a monochromator to selectively filter the excitation wavelength. Integration of 
the emission spectrum then provided an area representative of the number of emitted photons. 
The process was repeated with a reference standard, tris(bipyridine)ruthenium(II) chloride 
([Ru(BiPy)3]Cl2), in an aqueous solution of known quantum yield (0.028). By substituting the 
quantum yield (ϕ) of the reference solution as well as correction factors for the integrated area 
of the emission spectra (I), absorbances of the solutions at the MLCT excitation wavelengths 
(A) and the refractive indices of the solvents (n) for both the reference and the analyte solution 
into equation (14) the quantum yield of the rhenium complexes were able to be determined. 
𝜙 = 𝜙𝑟 [
(𝐼)(𝐴𝑟)(𝑛
2)
(𝐼𝑟)(𝐴)(𝑛𝑟
2)
]      (14) 
 
The luminescent lifetimes were determined using time-correlated single photon counting 
(TCSPC) to detect emissive photons with picosecond resolution. Excitation was achieved using 
a 377 nm pulsed picosecond light emitting diode (LED) and photon counting was performed 
after each iteration of the pulsed excitation. The goodness of fit of the attained data was 
assessed by minimising the reduced chi-squared (χ2) function and by visual inspection of the 
weighted residuals. 
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CHAPTER THREE 
RHENIUM-PHENANTHROLINE RADIOFLUORINATION 
TO CIRCUMVENT AZEOTROPIC DISTILLATION 
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3.1 Initial Rhenium Radiofluorination Strategies and Non-
Radioactive Syntheses 
 
Towards testing the hypothesis that a rhenium complex could be labelled with the fluorine-18 
radioisotope for PET-optical imaging, initial radiolabelling experiments were trialled to 
directly radiofluorinate the rhenium centre. Verifying the identity of the radioproduct first 
required the synthesis of a non-radioactive standard as shown by the Re−F bond in Figure 35. 
While analogues of this product had been reported by Horn, et al. in the Australian Journal of 
Chemistry, the authors also noted that such complexes were particularly unstable and would 
consistently polymerize to form the non-luminescent [Re(CO)3F]4.4H2O tetranuclear cluster 
instead.[76,77] No Re−F bonds of tricarbonyl complexes had been published since. Indeed, all 
attempted syntheses of fluorinated rhenium tricarbonyl centres bearing phenanthroline ligands 
performed within the scope of this thesis work were found to be unsuccessful, despite 
employing a range of fluorinating media and reaction conditions. Thus, an alternative synthetic 
target was conceived which involved appending the fluorine atom to the phenanthroline ligand 
as shown in Figure 35. 
 
 
Figure 35. Initial attempt of fluorinating the rhenium centre (left) proved to be unsuccessful, 
thus leading to the revised attempt to fluorinate the phenanthroline ligand (right). 
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The revised fluorinated standard, tricarbonylchloro(2-fluoro-1,10-phenanthroline)rhenium(I) 
(Re2FPhen), was synthesised via the scheme depicted in Figure 36. In brief, N-oxidation of 
1,10-phenanthroline (Phen) afforded 1,10-phenanthroline-N-oxide (Phen-NO) based on 
literature examples.[78-80] Thereafter, generation of a Vilsmeier reagent from DMF and 
phosphorous(V) oxychloride allowed for selective chlorination ortho to the oxidised nitrogen 
atom of Phen-NO, thus forming 2-chloro-1,10-phenanthroline (2ClPhen). Nucleophilic 
aromatic substitution of 2ClPhen using fluoride in the presence of a phase transfer catalyst 
then yielded 2-fluoro-1,10-phenantholine (2FPhen), which was then complexed to a source of 
rhenium to afford the desired Re2FPhen non-radioactive standard. Tricarbonylchloro(2-
chloro,1,10-phenanthroline)rhenium(I) (Re2ClPhen) was envisioned to also be a precursor 
which, if successfully radiolabelled, would eliminate the need for a multiple step radiosynthesis. 
The synthesis of Re2ClPhen was likewise achieved by complexing 2ClPhen to a source of 
rhenium. 
 
Figure 36. Synthetic route used to synthesise the desired radiolabelling precursor 
Re2ClPhen and the fluorinated standard Re2FPhen, annotated with the optimal 
reaction conditions discovered and the corresponding yields for each reaction.  
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3.1.1 Imine Oxidation of 1,10-Phenanthroline 
 
 
Figure 37. Ideal reaction conditions discovered to afford Phen-NO from Phen in 79% 
yield. 
 
A volume of TFA (42.8 mL, 554.9 mmol, 10.0 eq.) was slowly added to a mass of Phen (10.0 
g, 55.5 mmol, 1.0 eq.). The dissolution of Phen in TFA was exothermic and temperature 
monitoring was employed to ensure that the reaction mixture did not exceed 30 °C to avoid the 
formation of a 1,10-phenanthroline-N,N-dioxide by-product. Upon cooling the reaction 
mixture to 5 °C on an ice bath, hydrogen peroxide (30% w/v, 9.4 mL, 83.2 mmol, 1.5 eq.) was 
added drop wise and the solution was stirred at room temperature for 3 hours. A volume of 
sodium hydroxide solution (150 mL, 6 mol.L−1) was then added to adjust the solution to pH 9 
while the temperature was kept below 20 °C, which resulted in the formation of a white solid. 
The solution was filtered and then extracted with DCM (6 x 100 mL). The organic extracts 
were combined, dried over magnesium sulphate, vacuum filtrated and evaporated under 
reduced pressure to yield a white solid. The crude product was purified via hot filtration 
recrystallisation from ethanol, yielding off-white crystals (8.630 g). 
Initial synthesises of this compound did not account for the exothermic dissolution of Phen in 
TFA solvent, nor the exothermic addition of hydrogen peroxide. For these reasons an additional 
eluting compound, suspected to be the 1,10-phenanthroline-N,N-dioxide by-product based 
upon literature reports,[81, 82] was shown to elute in quality control (QC) HPLC analyses, as 
shown in Figure 38. The formation of this by-product prevented sufficient recovery of the 
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desired Phen-NO compound, affording no greater than 45% yield until repeated under cold 
conditions. Nonetheless, purification of Phen-NO from this by-product was still able to be 
achieved by recrystallisation from hot ethanolic solvent. 
 
Figure 38. HPLC chromatogram depicting the formation of a suspected 1,10-
phenanthroline-N,N-dioxide by-product (approx. 0.9 mins) forming from the 
N-oxidation of Phen to obtain Phen-NO (approx. 0.75 mins). PDA detection 
wavelength was 254 nm. Separation performed using a water/acetonitrile 
gradient mobile phase on a C18 stationary phase column. 
 
Confirmation of the Phen-NO product was easily assessed by 1H-NMR due to the loss of 
symmetry which now formed eight unique proton environments, unlike the four unique proton 
environments exhibited in the C2V point group of Phen. Figure 39 illustrates the aromatic 
region of the 1H-NMR spectrum for Phen-NO, with peak area integrations which approximate 
the eight expected protons. The same loss of symmetry is reflected also in the 13C-NMR 
spectrum, shown in Figure 40, which similarly exhibits twelve carbon signals rather than six, 
due to the loss of molecular symmetry. Figure 41 depicts the LRMS spectrum which further 
attests to the formation of Phen-NO, given an observed m/z ratio of 197.27 against the 
calculated 197.07. This was additionally backed up by HRMS results in Figure 42 which 
provided several signals for m/z ratios, arising from protonation of the molecule (m/z 197.07094 
calculated vs. m/z 197.07108 observed (∆ 0.71 ppm) for [M+H]+ = C12H9N2O+); protonation 
with subsequent loss of oxygen (m/z 181.07657 calculated vs. m/z 181.07615 observed (∆ 2.30 
ppm) for [M+H-O] + = C12H9N2
+); and loss of oxygen and hydrogen atoms (m/z 179.06092 
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calculated vs. 179.06052 observed (∆ -2.23 ppm) for [M-OH]+ = C12H7N2+). Further 
confirmation was attained in the FTIR spectrum, which exhibited weak absorption bands at 
3060 and 3008 cm-1 for the expected C−H bond stretches exhibiting sp2 hybridised orbitals, 
alongside absorption peaks at 1519, 1411 and 1335 cm-1 corresponding to the C=C π-aromatic 
bond stretches of the phenanthroline ring. Hartree-Fock calculations were performed to assign 
the IR band associated with N−O bond stretching, with an input generated by first constraining 
an initial Phen-NO structure (with formal changes of +1 and -1 applying to the N and O atoms 
of the N-oxide respectively) via the Merck Molecular Force Field 94 (MMFF94) using the 
steepest descent algorithm (2000 steps, 10E-10 convergence) to attain the required Z-matrix. 
Geometry optimisation, followed by frequency optimised restricted Hartree-Fock (RHF) 
calculations, were then applied using the split-valance polarization def2-SVP basis set, a 
restricted self-consistent field (SCF) of normal accuracy, and the RijCosX approximation to 
reduce computational demand. The computation revealed a strong N−O stretching frequency 
at 1474 cm-1 (coupled with other C=C and C−H vibrational modes), which roughly matches 
the observed IR absorption band at 1432 cm-1 given similar amplitudes and the accuracy of the 
quantum modelling performed. The experimental and theoretically obtained spectra can be 
viewed in Figure 43 and Figure 44, respectively. 
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Figure 39. 1H-NMR spectrum of Phen-NO, showing the expected peak area integration 
for eight protons in the aromatic region. 
 
Figure 40. 13C-NMR spectrum of Phen-NO, showing the expected twelve carbon signals 
in the aromatic region. 
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Figure 41. LRMS spectrum showing the major observed m/z ratio of 197.27, which 
corresponds with the protonated analogue of Phen-NO having a calculated m/z 
ratio of 197.07. 
 
Figure 42. HRMS spectrum complimenting the LRMS data of Phen-NO by showing more 
detailed m/z ratios for alternative ions; such as the expected [M+H] + m/z ratio 
of 197.07108 (Δ 0.71 ppm), the [M+H-O] + m/z ratio of 181.07615 (∆ 2.30 ppm) 
and [M-OH]+ m/z ratio of 179.06052 (∆ -2.23ppm). 
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Figure 43. FTIR spectrum of PhenNO, showing the IR absorption band for the N−O 
stretching frequency at 1432 cm-1, as determined from theoretical RHF 
geometry and frequency optimisation calculations, alongside distinctive C−H 
vibrational excitations at higher wavenumbers (3060 cm-1 & 3008 cm-1). 
 
 
Figure 44. Theoretical IR spectrum for Phen-NO calculated from RHF quantum modelling 
using geometry and frequency optimisation methods with the def2-SVP basis 
set to determine the stretching frequency of the N-O bond (calculated as 1474 
cm-1). 
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3.1.2 Attempted Coordination of 1,10-Phenanthroline-N-
Oxide to a Rhenium Pentacarbonyl Complex 
 
To by-pass the chlorination step, we hypothesised that complexing the Phen-NO ligand to the 
rhenium would enable a single step fluorination of the complex. Acetonitrile was used as the 
solvent, as it was hypothesised that displacement of the carbonyl ligands by the solvent at high 
temperatures may aid in the complexation of the oxygen atom in the N-oxide functional group, 
based off literature examples. Intriguingly however, NMR spectroscopic data revealed that 
RePhen formed instead of RePhen-NO. A summary of this discovery is shown in Figure 45. 
 
 
Figure 45. Complexation of Phen-NO to pentacarbonylchlororhenium(I) was 
hypothesised to form the RePhen-NO complex via co-ordination through the 
nitrogen atom of the imine, and the oxygen atom of the oxide. However, it was 
instead discovered that RePhen formed. 
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3.1.3 Chlorination of 1,10-Phenanthroline-N-Oxide via a 
Vilsmeier Reagent 
 
 
Figure 46. Ideal reaction conditions which afforded 2ClPhen from Phen-NO in 40% yield. 
 
A mass of Phen-NO (2.000 g, 10.194 mmol, 1.0 eq.) and sodium chloride (11.910 g, 203.799 
mmol, 20.0 eq.) were suspended in a volume of anhydrous DMF (35 mL). A volume of 
phosphorus(V) oxychloride (2.8 mL, 30.6 mmol, 3.0 eq.) was added drop wise while the 
reaction temperature was kept below 10°C. The reaction was then heated to 100°C while 
stirring under a constant stream of nitrogen gas for 8 hours, during which time the solution 
turned from white to yellow to brown in colour. The reaction was then added to a volume of 
water (200 mL) and adjusted to pH 9 via the addition of ammonia solution (25% w/v). The 
solution was then extracted with chloroform (10 x 100 mL), whereupon the organic extracts 
were combined and then washed with water (8 x 100 mL). The organic layer was then filtered 
to remove brown particulates, dried over sodium sulphate and the chloroform removed under 
reduced pressure to yield a light yellow solid. The crude 2ClPhen was then dissolved in DCM 
(20 mL) and purified via NP chromatography using a silica column (330 g, 40 µm). Using an 
AB solvent system where A = Ethyl Acetate and B = Hexane, and a 55 mL.min−1 flow rate; a 
gradient was then applied where B% was ramped from 10% to 30% over 2.3 CV, from 30% to 
70% over 3.3 CV, from 70% to 76% over 1.1 CV and finally from 76%  to 100% over 8.7 CV. 
The eluents absorbing at a wavelength of 254 nm were combined and evaporated down under 
reduced pressure to yield a purified product. Further purification was achieved by dissolving 
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the product in a volume of methanol/acetonitrile (3:1, 10 mL) and performing a series of 100 
µL injections via RP preparative HPLC, whereby an Alltima C18 column (10 µm, 250 x 22 
mm) was employed alongside an isocratic mobile phase consisting of 30% acetonitrile and 
70% water. A flow rate of 20 mL.min−1 was applied. Eluents absorbing at a wavelength of 254 
nm were then combined, evaporated down under vacuum to remove excess acetonitrile and 
finally dried by lyophilisation to yield a white powder (880 mg). 
Figure 47 illustrates the proposed mechanism of reaction for the formation of 2ClPhen from 
Phen-NO. The DMF solvent catalyses the formation of the Vilsmeier reagent, which is 
believed to enable selective chlorination in the 2-position due to its spatial proximity of the 
chlorine upon forming an ether group with the oxygen atom from the N-oxide. The 
phosphorus(V) oxychloride is consumed from the reaction, however, and is subject to 
hydrolysis to hydrochloric and phosphoric acids if not performed under strictly anhydrous 
conditions. Thus, a three-equivalence molar excess of phosphorus(V) oxychloride was added 
in order to maintain production of the Vilsmeier reagent during the reaction. Twenty molar 
equivalence of sodium chloride was also added, as it provided a continuous source of chloride 
from the biphasic mixture which is a driving force to produce the Vilsmeier reagent, as 
demonstrated in an early step of the mechanism. 
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Figure 47. Proposed mechanism for the chlorination of Phen-NO to form 2ClPhen, 
showing how the Vilsmeier reagent is understood to be formed from DMF and 
phosphorus(V) oxychloride (POCl3), as well as how the Vilsmeier reagent 
enables selective chlorination in the 2-position of the molecule. 
 
Confirmation of 2ClPhen was evident by the integration of seven unique proton environments 
in the 1H-NMR spectrum of the molecule, as opposed to eight for Phen-NO, as one of the 
hydrogen atoms had been displaced for a chlorine. Figure 48 illustrates this integration of the 
1H-NMR spectrum. The 13C-NMR spectrum still exhibited the expected twelve signals as 
shown in Figure 49, albeit these signals experienced an overall downfield shift with chemical 
shift ranges between 123 and 152 ppm in the aromatic region. The LRMS spectrum for 
2ClPhen in Figure 50 shows the expected approximate 3:1 ratio of m/z signals corresponding 
to the 35Cl isotope with 75.78% abundance, affording an m/z ratio of 215.24 against a calculated 
m/z ratio of 215.04; and the 37Cl isotope with 24.22% abundance, which afforded an m/z ratio 
of 217.24 with a similar mass difference to the calculated m/z ratio of 217.04. Identification of 
the major m/z signal was further verified in the HRMS spectrum, shown in Figure 51, for 
protonation of 2ClPhen (m/z 215.03705 calculated vs. m/z 215.03726 observed (Δ 0.96 ppm) 
for [M+H]+ = C12H8N2Cl
+), alongside the charge-induced loss of a chlorine atom (m/z 
calculated 179.06050 vs. m/z 179.06092 observed (Δ 2.36 ppm) for [M-Cl]+ = C12H7N2+). The 
FTIR spectrum of 2ClPhen, shown in Figure 52 shows the distinctive sp2 hybridised C−H 
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vibrational stretching frequencies consistent with the hydrogens on the phenanthroline ring, 
and UV/Vis spectroscopy revealed π → π* excitations with maxima at wavelengths 266, 229 
and 201 nm in acetonitrile, with respective molar absorptivities of 31022, 50456 and 17929 
L.mol-1.cm-1. Elemental analysis attested to the purity of the ligand by returning experimental 
compositions of 66.66% carbon, 3.42% hydrogen and 12.95% nitrogen against theoretical 
values of 67.15% carbon, 3.29% hydrogen and 13.05% nitrogen. 
 
 
Figure 48. 1H-NMR spectrum of 2ClPhen in DMSO-d6, showing the expected peak area 
integration for seven protons in the aromatic region. 
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Figure 49. 13C-NMR spectrum of 2ClPhen in chloroform-d, showing the expected twelve 
signals for  carbon-13 nuclei in the aromatic region. 
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Figure 50. LRMS spectrum showing the major observed m/z ratios of 215.24 and 217.24, 
consistent with the expected isotopic abundances for 35Cl (75.78%) and 37Cl 
(24.22%), which correspond with the protonated analogue of 2ClPhen having 
calculated m/z ratios of 215.04 and 217.04. 
 
Figure 51. HRMS spectrum further verifying the presence of the major [M+H]+ signal with 
an observed m/z ratio of 215.03726 against a calculated m/z ratio of 215.03705 
(Δ 0.96 ppm). Also present is the [M-Cl]+ signal generated from loss of a 
chlorine atom, with an observed m/z ratio of 179.06092 against a calculated m/z 
ratio of 179.06050 (Δ 2.36 ppm). 
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Figure 52. FTIR spectrum of 2ClPhen showing the distinctive sp2 hybridised C−H 
stretching frequencies at higher wavenumbers, representative examples include 
3098 cm-1 and 3040 cm-1. 
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3.1.4 Fluorination of 2-Chloro-1,10-Phenanthroline via 
Nucleophilic Aromatic Substitution 
 
 
Figure 53. Ideal reaction conditions which afforded 2FPhen from 2ClPhen in 71% yield. 
 
Masses of 18-crown-6 ether (1.110 g, 4.199 mmol, 3.0 eq.) and potassium fluoride (1.626 g, 
28.986 mmol, 20.0 eq.) were azeotropically dried via the addition of 20 x 1 mL aliquots of 
anhydrous acetonitrile while heating at 90°C under a constant stream of nitrogen gas. A mass 
of 2ClPhen (300 mg, 1.398 mmol, 1.0 eq.) was then added to the resulting hot crust, followed 
by a volume of anhydrous DMSO (10 mL). The reaction mixture was then stirred at 110°C for 
92 h. Afterwards the reaction was removed from heat and allowed to cool to room temperature. 
The crude 2FPhen in DMSO solution was then purified via RP chromatography using a C18 
column (40 g, 40 µm). Using an AB solvent system where A = water and B = acetonitrile, and 
a 40 mL.min−1 flow rate; a gradient was then applied where B% was ramped from 5% to 35% 
over 6.7 CV, held at 35% for 4.0 CV and then finally ramped from 35% to 100% over 13.9 CV. 
The fractions with significant absorbance at a wavelength of 254 nm were then combined, 
evaporated under vacuum to remove excess acetonitrile and finally dried by lyophilisation to 
yield a white powder (249 mg). Further purification was then achieved by dissolving the 
product in a volume of methanol (450 µL) and performing a series of 20 µL injections via RP 
preparative HPLC, whereby an Alltima C18 column (10 µm, 250 x 22 mm) was employed 
alongside an isocratic mobile phase consisting of 30% acetonitrile and 80% water containing 
0.1% TFA modifier, and a flow rate of 25 mL.min−1 applied. Eluents absorbing at 254 nm were 
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then combined, evaporated under reduced pressure to remove excess acetonitrile and then dried 
via lyophilisation to afford a pink salt (the TFA salt of the compound). The pink solid was then 
reconstituted in water (10 mL) and extracted with DCM (15 x 100 mL). The organic phases 
were then combined, dried over sodium sulphate for 15 mins, vacuum filtrated and then 
evaporated under reduced pressure to yield a white solid (196 mg). 
 
 
Figure 54. Formation of 2FPhen (rt = 2.6 mins) from 2ClPhen (rt = 4.2 mins) via HPLC 
monitoring using PDA detection across multiple wavelengths (200 – 400 nm). 
Water/acetonitrile gradient mobile phase employed on a C18 RP stationary phase. 
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Figure 55. Selective chromatogram at detection wavelength λ = 245nm for fluorination of 
2ClPhen (rt = 4.2 mins) to form 2FPhen (rt = 2.6 mins). 
 
 
Figure 56. Mechanism for the fluorination of 2ClPhen to afford 2FPhen via nucleophilic 
aromatic substitution. The mechanism involves the formation of a 
Meisenheimer complex intermediate, which is generated faster from the 
consumption of 2FPhen (k-2) than from 2ClPhen (k1). 
 
The mechanism in Figure 56 illustrates the competing nucleophilic aromatic substitutions of 
both chloride and fluoride anions to form the intermediate Meisenheimer complex, alongside 
the associated qualitative rate constants (kx). Reactions with rate constants k1 and k-2 are slower 
processes as they result in the loss of aromaticity, thus requiring higher activation energy 
barriers. Conversely, the reactions with rate constants k-1 and k2 are faster processes as they 
restore aromaticity, thus requiring only low activation energy barriers. From a qualitative point 
of view, k-2 is also a slightly larger rate constant than k1, because the already present fluorine 
has a greater electron inductive withdrawal effect to stabilise the Meisenheimer complex. Also 
apparent is that k-1 should be slightly smaller than k2 in theory, because fluoride is typically a 
poor leaving group given the intramolecular strength of the C−F bond (evident by the lower 
internal energy of 326.7 KJ.mol-1 for 2FPhen vs. 331.7 KJ.mol-1 for 2ClPhen calculated using 
the steepest descent algorithm with the MMFF94 force field constraint in Avogadro). Thus, in 
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order of magnitude it can be qualitatively assigned that k2 > k-1 >> k-2 > k1. The synthetic 
challenge this presents is that while the production of 2FPhen is slightly more favoured than 
2ClPhen when restoring aromaticity, it is still thermodynamically more favourable for 2FPhen 
to be consumed than 2ClPhen to form the Meisenheimer complex, which is the rate-
determining step of the reaction. Thus to counter this unfavourable fluorination process, the 
reaction equilibrium was shifted in favour of consuming the 2ClPhen reactant by increasing 
the molar equivalence of fluoride in the system, increasing the reaction temperature to 
overcome the high activation energy barrier associated with the formation of the Meisenheimer 
complex, and the reaction left for a considerably long time with daily HPLC monitoring to 
determine when the reaction had achieved equilibrium. A phase transfer reagent was also used 
to aid in solubilising the potassium fluoride in the organic DMSO solution. Early attempts at 
this synthesis applied TBAF as the source of fluorine, however, yields no greater than 7% were 
able to be attained due to the highly hygroscopic nature of TBAF which reduced the 
nucleophilicity of the fluoride rendering it less susceptible to nucleophilic aromatic substitution. 
Improved yields were obtained upon switching to an 18-crown-6 ether phase transfer catalyst 
instead. Also, of great importance was the need to azeotropically distil the potassium fluoride 
while immersed in a heated solution of the 18-crown-6 ether to efficiently remove water from 
the reaction mixture. In the early instances of relying on vacuum techniques to dry the fluoride 
source, an unintended 1,10-diaza-1H-phenanthren-2-one by-product formed from what was 
hypothesised to be the reaction between hydroxides generated from the residual water and the 
2-chloro or 2-fluoro substituted phenanthrolines, followed by subsequent tautomerisation as 
proposed by the mechanism shown in Figure 57. 
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Figure 57. Mechanism for the formation of the hydroxy-substituted by-product in the 
presence of non-azeotropically distilled conditions, which tautomerises to form 
1,10-diaza-1H-phenanthren-2-one. 
 
The water catalysed by-product was isolated and spectroscopically characterised to determine 
whether the 2-hydroxy-1,10-phenanthroline or 1,10-diaza-1H-phenanthren-2-one 
tautomerized product had formed. The first confirmation was attained by FTIR spectroscopy, 
with the spectrum shown in Figure 58. The spectrum provides evidence in favour of the 1,10-
diaza-1H-phenanthren-2-one product given the absence of the broad O−H stretching frequency 
at higher wavenumbers which is characteristic of alcohols, and the presence of both a strong 
secondary amide N−H amide vibrational band at 3345 cm-1 and amide C=O vibrational band 
at 1654 cm-1, having been shifted to slightly lower wavenumbers due to the resonance 
stabilisation afforded within the aromatic ring. The 1H-NMR spectrum of the compound also 
supported the assignment of the 1,10-diaza-1H-phenanthren-2-one by-product by not only 
integrating for the eight expected 1H nuclei within the molecule, though by also including a 
broad downfield shifted signal for the 1H nuclear resonance within an N−H bond.  
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Figure 58. FTIR spectrum of the non-azeotropically dried by-product. The presence of a 
strong secondary N−H amide vibrational band at 3345 cm-1, alongside the 
resonance stabilised C=O stretching frequency at 1654 cm-1 and the absence of 
a broad O−H stretching signal at higher wavenumbers provides evidence for the 
assignment of the 1,10-diaza-1H-phenanthren-2-one product. 
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Figure 59. 1H-NMR spectrum of the 1,10-diaza-1H-phenanthren-2-one by-product, 
depicting the eight expected signals for 1H nuclei within the molecule, inclusive 
of a broad downfield shifted signal characteristic of the 1H nuclear resonance 
within an N−H bond. 
 
Figure 60 illustrates the expected peak area integration for the seven protons in the attained 
2FPhen 1H-NMR spectrum. The spectrum exhibited noticeable shifts from the 2ClPhen 1H-
NMR spectrum due to the difference in electron withdrawal effects from the more 
electronegative fluorine atom, and differences in peak splitting due to the additional spin-spin 
coupling with the fluorine-19 isotope which consists of a spin ½ nucleus and high gyromagnetic 
ratio. The differences in these chemical shifts and peak splitting patterns are evident in Figure 
61, which superimposes the two 1H-NMR spectra for 2ClPhen and 2FPhen. The 13C-NMR 
spectrum for 2FPhen, shown in Figure 62, also depicts the presence of three additional carbon-
13 signals resulting from the spin-spin coupling between the carbon-13 and fluorine-19 spin ½ 
nuclei. The coupling within the 19F-NMR spectrum is likewise evident in Figure 63. The LRMS 
spectrum further confirms the identity of the 2FPhen compound with an m/z ratio of 199.27 
for the protonated [M+H]+ ion being apparent against the calculated m/z ratio of 199.07, as 
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shown in figure 4.1.26. The presence of this m/z signal was further verified in the HRMS 
spectrum which not only illustrated the observed protonated cation (m/z 199.06660 calculated 
vs. m/z 199.06673 observed (Δ 0.64 ppm) for [M+H]+ = C12H8N2F+), though also the positive 
charge induced loss of a fluorine atom (m/z calculated 179.06092 vs. m/z 179.06050 observed 
(Δ 2.36 ppm) for [M-F]+ = C12H7N2+), which was similarly observed in the HRMS spectrum 
for 2ClPhen as well. The FTIR spectrum of 2FPhen exhibited the expected C−H stretching 
vibrational frequencies at higher wavenumbers consist with the 1,10-phenanthroline analogue, 
as shown in Figure 66, and UV/Vis spectroscopy revealed similar π → π* excitations to 
2ClPhen, with absorption maxima at 262, 227 and 283 nm though with slightly lower molar 
absorptivities of 28596, 47402 and 16445 L.mol-1.cm-1 respectively in acetonitrile solution. 
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Figure 60. 1H-NMR spectrum of 2FPhen in chloroform-d, showing the expected peak area 
integration for seven protons in the aromatic region. 
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Figure 61. Differences arising in the chemical shifts and peak splitting from spin-spin 
couplings between 2ClPhen (red) and 2FPhen (blue) in chloroform-d within 
the superimposed 1H-NMR spectra. 
 
 
Figure 62. 13C-NMR spectrum of 2FPhen in chloroform-d. Three additional 13C signals 
are present due to the coupling between the 19F nucleus present in the molecule. 
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Figure 63. 19F-NMR spectrum of 2FPhen in chloroform-d, showing the single peak 
arising for the fluorine atom in the molecule. 
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Figure 64. LRMS spectrum showing the major observed m/z ratio of 199.27, which 
corresponds with the protonated analogue of 2FPhen having a calculated m/z 
ratio of 199.07. 
 
 
Figure 65. HRMS spectrum further verifying the presence of the major [M+H]+ signal with 
an observed m/z ratio of 199.06673 against a calculated m/z ratio of 199.06660 
(Δ 0.64 ppm). Also present is the [M-F]+ signal generated from loss of a fluorine 
atom, with an observed m/z ratio of 179.06050 against a calculated m/z ratio of 
179.06092 (Δ 2.36 ppm). 
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Figure 66. FTIR spectrum of 2FPhen exhibiting the typical C−H stretching vibrational 
frequencies (2949 – 3053 cm-1) consist with the 1,10-phenanthroline analogue. 
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3.1.5 Rhenium Complexation of 2-Chloro-1,10-
Phenanthroline 
 
 
Figure 67. Ideal reaction conditions discovered to afford Re2ClPhen from 2ClPhen in 
89% yield. 
 
A mass of 2-chloro-1,10-phenanthroline (100 mg, 466 µmol, 1.1 eq.) was dissolved in a volume 
of toluene (15 mL), to which a mass of pentacarbonylchlororhenium(I) (150 mg, 415 µmol, 1.0 
eq.) was added. The solution was heated at reflux for 2 h, after which a yellow solid precipitate 
formed from solution. The solution was then cooled to around 4°C to encourage further 
precipitation. The yellow solid was isolated via vacuum filtration and washed with n-hexane 
to afford a pure product (216 mg). 
Initial purity of the product was assessed by QC HPLC, whereupon the rhenium complex 
demonstrated an increased retention time on the C18 reverse phase column in comparison with 
the free ligand. This result is consistent with the expected polarity of the compounds given the 
presence of a TFA modifier in the mobile phase, as the free amine of the ligand is easily 
protonated to increase polarity and elute earlier. The formation of a rhenium complex was first 
confirmed by FTIR spectroscopy, whereupon the two distinctive IR active carbonyl stretching 
frequencies belonging to the A’(1) and co-exciting A’(2) and A’’ vibrational modes exhibited 
strong absorbances around 2021 cm-1 and 1889 cm-1 wavenumbers respectively. Weak sp2 
hybridised C−H bond stretches were also observed, with a distinctive stretching frequency 
occurring at approximately 3042 cm-1. These stretching frequencies can be viewed in the ATR 
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corrected FTIR spectrum of RePhenCl in Figure 68. The A(1), A’’ and A’(2) vibrational 
modes of the carbonyl groups are also illustrated in the highlighted FTIR spectrum in Figure 
69. 
 
 
Figure 68. FTIR spectrum of Re2ClPhen exhibiting the two distinctive C≡O stretching IR 
absorption bands at 2020 cm-1 and 1889 cm-1 belonging to A’(1) and A’(2) & 
A’’ coupled irreducible representations respectively. A weak sp2 hybridised 
C−H bond stretch is also observed at 3042 cm-1 from the phenanthroline ligand. 
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Figure 69. Carbonyl vibrational modes corresponding to the A’(1) irreducible 
representation at 2021 cm-1 and the overlapping A’’ and A’(2) irreducible 
representations in the FTIR spectrum of Re2ClPhen. 
 
The acquired NMR spectrum also support the formation of the Re2ClPhen complex with the 
1H-NMR spectrum exhibiting the expected integration for seven protons in the aromatic region 
(Figure 70), alongside simple splitting patterns which occur upfield from those chemical shifts 
observed in the 2ClPhen ligand, as shown in Figure 71, suggesting an electron withdrawal 
effect consistent with complexation to the rhenium tricarbonyl centre. In Figure 72, the 13C-
NMR spectrum of Re2ClPhen exhibits the expected fifteen carbon-13 environments. Twelve 
of the carbon-13 signals occur between 120 – 160 ppm, corresponding to the twelve carbon 
atoms of the substituted phenanthroline ring. The remaining three carbon-13 signals occur 
between 185 – 200 ppm and correspond to the carbon nuclei in the C≡O carbonyl ligands 
bonded to the rhenium through the carbon atom. These carbon atoms are significantly electron 
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withdrawn due to the π-back bonding effect thus resulting in their downfield chemical shift to 
higher resonant frequencies. Additionally, these 13C-NMR signals are significantly less intense 
due to the long spin-lattice (T1) relaxation times resulting from the metal-carbonyl bond.[83] 
 
 
Figure 70. 1H-NMR spectrum of Re2ClPhen showing the expected integration for seven 
protons in the aromatic region, alongside simplified splitting patterns and the 
corresponding chemicals shifts for each signal in DMSO-d6 solution. 
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Figure 71. Downfield shift of aromatic 1H-NMR signals caused by electron withdrawal in 
the π-aromatic phenanthroline ring by having complexed the 2ClPhen ligand 
(red, above) to form the Re2ClPhen complex (blue, below). 
 
Figure 72. 13C-NMR spectrum of Re2ClPhen showing the expected fifteen carbon signals 
for each carbon nuclei within the molecule. The twelve carbon-13 signals 
between 120 – 160 ppm correspond with the carbon atoms on the 
phenanthroline ring, whereas the three less intense signals between 185 – 200 
ppm correspond with the heavily electron withdrawn carbonyl groups bonded 
to the rhenium centre. 
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The transition to the MLCT excited state for Re2ClPhen is depicted by the characteristic broad 
low-energy dπ → π* absorption band at 368 nm shown in the UV-Vis spectrum in Figure 73, 
alongside the higher energy π → π* absorption bands to LC excited states. The HRMS 
spectrum provides further confirmation of the Re2ClPhen complex through the presence of 
the bromine-dissociated sodium adduct ion signal (m/z 540.9261 calculated vs. 540.9266 
observed (Δ 0.5 ppm) for [M-Br+Na]+ = 185ReC15H7N2O3Na+) for both the 185Re and 187Re 
isotopes as shown in Figure 74. As none of these prior mentioned analyses were able to verify 
the identity of the chloro ancillary ligand the compound was sent off for elemental analysis 
specifically to quantity the chlorine composition of the complex. An experimental composition 
of 13.55% was returned which aligned closely with the theoretical composition of 13.65% 
chlorine. Molecular compositions of 34.45% carbon, 0.95% hydrogen and 5.36% nitrogen were 
also measured against calculated compositions of 34.62% carbon, 1.36% hydrogen and 5.38% 
nitrogen. A crystal structure was also attainted from XRD analysis at the Australian 
Synchrotron, as shown in Figure 75, which provided unequivocal evidence for the assigned 
molecular structure of Re2ClPhen. 
 
 
Figure 73. UV-Vis spectrum of Re2ClPhen exhibiting the typical dπ → π* transition to 
the MLCT excited state at 368 nm. Higher energy transitions at the lower 
wavelengths correspond to the intraligand π → π* electronic transitions with 
greater molar absorptivities. 
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Figure 74. HRMS spectrum of Re2ClPhen verifying the presence of the bromine 
dissociated [Na+M-Br]+ sodium-adduct ion signal with an observed m/z ratio 
of 540.9266 against a calculated m/z ratio of 540.9261 (Δ 0.5 ppm) for the 185Re 
isotope (37.4% abundance). The accompanying MS signal for the more 
abundant 187Re isotope (62.6 %) is also observed at m/z 542.9286. 
 
 
Figure 75. Crystal structure obtained for Re6ClPhen via XRD analysis at the Australian 
Synchrotron. Crystals were grown from the slow evaporation of DMSO solution.  
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3.1.6 Rhenium Complexation of 2-Fluoro-1,10-
Phenanthroline 
 
 
Figure 76. Ideal reaction conditions discovered to afford Re2FPhen from 2FPhen in 65% 
yield. 
 
A mass of 2-fluoro-1,10-phenanthroline (39 mg, 198 µmol, 1.1 eq.) was dissolved in a solution 
of toluene (6 mL), to which a mass of pentacarbonylchlororhenium(I) (65 mg, 180 µmol, 1.0 
eq.) was added. The solution was then heated 80°C for 1 h, whereupon a yellow solid formed. 
The solution was then cooled to room temperature to promote further precipitation of the solid. 
The yellow solid was isolated via vacuum filtration and washed with cold n-hexane to yield a 
pure product (65 mg). 
The FTIR spectrum in Figure 77 shows the two distinctive absorption bands for the C≡O IR 
stretching frequencies at 2021 cm-1 (A’(1) irreducible representation) and 1890 cm-1 (A’(2) & 
A’’ irreducible representations). Weak sp2 hybridised C−H bond stretching frequencies from 
the phenanthroline ligand are also observed at higher wavenumbers. The 1H-NMR spectrum of 
Re2FPhen in Figure 78 depicts the expected integration for seven protons, downfield shifted 
with respect to the proton resonance signals of 2FPhen due to the electron withdrawing nature 
of the rhenium centre, alongside complex splitting patterns due to coupling between the protons 
and the fluorine-19 nucleus. The complex splitting patterns are likewise observed in the 13C-
NMR spectrum shown in Figure 79 and the 19F-NMR spectrum shown in Figure 80. The UV-
Vis spectrum in Figure 81 shows the expected dπ → π* absorption to the MLCT excited state 
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at 368 nm, alongside higher energy π → π* absorptions to LC excited states characteristic of 
rhenium tricarbonyl diimine complexes. The HRMS spectrum is also indicative of the 
Re2FPhen complex with the presence of the chlorine-dissociated sodium adduct ion signal 
(m/z 524.9557 calculated vs. 524.9579 observed (Δ 2.2 ppm) for [M-Cl+Na]+ = 
185ReC15H7N2O3Na+) for the 185Re isotopic signal in 37.4% abundance, accompanied also by 
the analogous 187Re isotopic signal in 62.6% abundance at m/z 526.9622, shown in Figure 82. 
To verify the identity of the chloro ancillary ligand, which could not be assigned due to 
dissociation of the Re−Cl bond, the sample was sent off for elemental analysis specifically to 
measure the composition of chlorine in the complex. The analysis returned an experimental 
composition of 6.83% chlorine against a closely aligned theoretical composition of 7.04% 
chlorine, suggesting that the chloro group was indeed the ancillary ligand. Measurements of 
35.73% carbon, 0.98% hydrogen and 5.59% nitrogen against calculated compositions of 
35.75% carbon, 1.40% hydrogen and 5.56% nitrogen also attested to the purity of the ligand. 
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Figure 77. FTIR spectrum of Re2FPhen exhibiting the two distinctive C≡O stretching IR 
absorption bands at 2021 cm-1 and 1890 cm-1 with A’(1) and A’(2) & A’’ 
coupled irreducible representations respectively. Weak sp2 hybridised C−H 
bond stretches are also observed at 3077 cm-1 and 3043 cm-1 from the complexed 
phenanthroline ligand. 
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Figure 78. 1H-NMR spectrum of Re2FPhen showing the expected integration for seven 
protons in the aromatic region in DMSO-d6 solution. The splitting patterns are 
slightly more complicated due to the additional spin-spin coupling between the 
hydrogen protons and NMR active fluorine-19 nucleus. 
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Figure 79. Complex splitting patterns observed in the 13C-NMR spectrum of Re2FPhen in 
DMSO-d6 due to coupling with the fluorine-19 nucleus. 
 
 
Figure 80. Coupling observed in the 19F-NMR spectrum of Re2FPhen in DMSO-d6 leads 
to a doublet of doublets splitting pattern arising from unequal F−H coupling 
constants. 
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Figure 81. UV-Vis spectrum of Re2FPhen exhibiting the typical dπ → π* transition to the 
MLCT excited state at 368 nm. Higher energy transitions at the lower 
wavelengths correspond to the intraligand π → π* electronic transitions with 
greater molar absorptivities. 
 
 
Figure 82. HRMS spectrum of Re2FPhen verifying the presence of the chlorine 
dissociated [Na+M-Cl]+ sodium-adduct ion signal with an observed m/z ratio of 
524.9579 against a calculated m/z ratio of 524.9557 (Δ 2.2 ppm) for the 185Re 
isotope (37.4% abundance). The accompanying MS signal for the more 
abundant 187Re isotope (62.6%) is also observed at m/z 526.9622. 
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3.1.7 Characterisation Data for Products and Intermediates 
in the Synthesis of 2-Chloro and 2-Fluoro Substituted 
Phenanthroline Complexes 
 
1,10-phenanthroline-N-oxide (Phen-NO). White Solid; MP: 185°C (dec.); 79% yield. 1H NMR 
(400 MHz, DMSO-d6, δ/ppm): δ 9.31 (dd, Jd=4.36, 1.88 Hz, 1H), δ 8.74 (dd, Jd = 6.32, 1.16 Hz, 
1H), δ 8.23 (dd, Jd = 8.08, 1.88 Hz, 1H), δ 7.74 (dd, Jd = 8.12, 1.16 Hz, 1H), δ 7.66 (dd, Jd = 
8.08, 4.36 Hz, 1H), δ 7.46 (dd, Jd = 8.08, 6.32 Hz, 1H). 13C{1H} NMR (100 MHz, CDCl3, 
δ/ppm): δ 150.04, δ 142.67, δ 140.82, δ 138.39, δ 135.87, δ 133.31, δ 129.08, δ 128.93, δ 126.51, 
δ 124.51, δ 123.18, δ 122.85. FTIR (ATR corr. ṽ/cm-1): ṽ 3060 (w, C−H sp2 str.), ṽ 3008 (w, 
C−H sp2 str.), ṽ 1519 (s, C=C πAr str.), ṽ 1432 (s, N −O str.), ṽ 1411 (s, C=C πAr str.), ṽ 1335 
(s, C=C πAr str.). UV/Vis (CH3CN, λ/nm, ε/L.mol-1.cm-1): λ 335 (π→π*, ε 4197.08), λ 271 
(π→π*, ε 14324.82), λ 243 (π→π*, ε 21304.74), λ 211 (π→π*, ε 20118.61), λ 194 (π→π*, ε 
19160.58). LRMS (ESI+): [M+H]+ m/z calc. 197.07, m/z obsv. 197.27. HRMS (ESI+): [M+H]+ 
m/z calc. 197.07094 (C12H9N2O
+), m/z obsv. 197.07108 (Δ 0.71 ppm); [M+H-O]+ m/z calc. 
181.07657 (C12H9N2
+); m/z obsv. 181.07615 (∆ 2.30 ppm). [M-O-H]+ m/z calc. 176.06092 
(C12H7N2
+); m/z obsv. 197.06052 (∆ 2.25 ppm). 
2-chloro-1,10-phenanthroline (2ClPhen). White solid; MP: 127°C; 40% yield. 1H NMR (400 
MHz, DMSO-d6, δ/ppm): δ 9.22 (dd, Jd=4.32, 1.72 Hz, 1H), δ 8.25 (dd, Jd = 8.08, 1.72 Hz, 1H), 
δ 8.19 (d, Jd = 8.36 Hz, 1H), δ 7.80 (d, Jd = 24.2 Hz, 1H), δ 7.80 (d, Jd = 6.6 Hz, 1H), δ 7.65 
(dd, Jd = 8.08, 4.36 Hz, 1H), δ 7.63 (d, Jd = 8.36 Hz, 1H). 13C{1H} NMR (100 MHz, CDCl3, 
δ/ppm): δ 151.55, δ 150.84, δ 146.14, δ 145.13, δ 138.71, δ 136.04, δ 129.05, δ 127.28, δ 126.99, 
δ 125.75, δ 124.37, δ 123.48. FTIR (ATR corr. ṽ/cm-1): ṽ 3098 (w, C−H sp2 str.), ṽ 3040 (w, 
C−H sp2 str.), ṽ 1580 (s, C=C πAr str.), ṽ 1490 (s, C=C πAr str.), ṽ 1385 (s, C=C πAr str.). UV/Vis 
(CH3CN, λ/nm, ε/L.mol-1.cm-1): λ 266 (π→π*, ε 31021.90), λ 229 (π→π*, ε 50456.20), λ 201 
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(π→π*, ε 17928.83). LRMS (ESI+): [M+H]+ m/z calc. 215.04 & 217.04, m/z obsv. 215.24 & 
217.24. HRMS (ESI+): [M+H]+ m/z calc. 215.03705 (C12H8N2Cl
+); m/z obvs. 215.03726 (∆ 
0.96 ppm); [M-Cl]+ m/z calc. 179.06092 (C12H7N2
+); obsv. 179.06050 (∆ 2.36 ppm). 
2-fluoro-1,10-phenanthroline (2FPhen). White solid; MP: 123°C; 71% yield. 1H NMR (400 
MHz, DMSO-d6, δ/ppm): δ 9.21 (dd, Jd = 4.32, 0.43 Hz, 1H), δ 8.37 (app. t, Jt = 8.44, 1H), δ 
8.28 (dd, Jd = 8.12, 0.43 Hz, 1H), δ 7.83 (d, Jd = 21.16, 1H), δ 7.83 (d, Jd = 3.52 Hz, 1H), δ 7.66 
(dd, Jd = 8.12, 1.08 Hz, 1H), δ 7.32 (dd, Jd = 8.56, 0.79 Hz, 1H). 13C{1H} NMR (100 MHz, 
CDCl3, δ/ppm): δ 163.23, δ 160.82, δ 150.59, δ 145.23, δ 141.77 (d, Jd = 10.06 Hz), δ 136.03, 
δ 129.15, δ 127.02, δ 126.03 (d, Jd = 2.01 Hz), δ 125.63, δ 123.40, δ 111.31 (d, Jd = 41.25 Hz). 
19F NMR (376 MHz, DMSO-d6, δ/ppm): δ -46.79 (dd, Jd = 3.27, 10.05 Hz), δ -106.00 (ISTD: 
para-DFB). FTIR (ATR corr. ṽ/cm-1): ṽ 3053 (w, C−H sp2 str.), ṽ 3026 (w, C−H sp2 str.), ṽ 
1588 (s, C=C πAr str.), ṽ 1497 (s, C=C πAr str.), ṽ 1416 (s, C=C πAr str.). UV/Vis (CH3CN, 
λ/nm, ε/L.mol-1.cm-1): λ 262 (π→π*, ε 28595.96), λ 227 (π→π*, ε 47402.32), λ 200 (π→π*, ε 
16444.83). LRMS (ESI+): [M+H]+ m/z calc. 199.07, m/z obsv. 199.27. HRMS (ESI+): [M+H]+ 
m/z calc. 199.06660 (C12H8N2F+); m/z obsv. 199.06673 (∆ 0.64 ppm); [M-F]+ m/z calc. 
179.06092 (C12H7N2
+); m/z obsv. 179.06050 (∆ 2.36 ppm). 
1,10-diaza-1H-pehanthren-2-one. White solid. 1H NMR (400 MHz, DMSO-d6, δ/ppm): δ 10.68 
(br. s, 1H), δ 8.90 (d, Jd = 4.20 Hz, 1H), δ 8.20 (d, Jd = 7.87 Hz, 1H), δ 6.84 (d, Jd = 9.52 Hz, 
1H), δ 7.55 (dd, Jd = 8.64, 4.52 Hz, 1H), δ 7.57 (dd, Jd = 32.08, 8.40 Hz, 1H). FTIR (ATR corr. 
ṽ/cm-1): ṽ 3345 (s, 2° N−H str.), ṽ 3035 (w, C−H sp2 str.), ṽ 1654 (s, C=O str.). 
Tricarbonylchloro(2-chloro-1,10-phenanthroline)rhenium(I) (Re2ClPhen). Yellow solid; MP: 
316°C (dec.); 89% yield. 1H NMR (400 MHz, DMSO-d6, δ/ppm): δ 9.46 (dd, Jd = 5.12, 1.36 
Hz, 1H), δ 8.98 (d, Jd = 8.52 Hz, 1H), δ 8.97 (d, Jd = 8.24 Hz, 1H), δ 8.37 (d, Jd = 8.56, 1H), δ 
8.34 (s, 2H), δ 8.12 (dd, Jd = 8.24, 5.12 Hz, 1H). 13C{1H} NMR (100 MHz, CDCl3, δ/ppm): δ 
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197.88 (C≡O), δ 197.65 (C≡O), δ 189.83 (C≡O), δ 154.75, δ 154.11, δ 147.19, δ 146.56, δ 
142.81, δ 139.92, δ 131.69, δ 129.66, δ 128.37, δ 128.09, δ 127.30, δ 127.24. FTIR (ATR corr. 
ṽ/cm-1): ṽ 3042 (w, C−H sp2 str.), ṽ 2021 (s, A’(1) C≡O str.), ṽ 1889 (s, A’(2) & A’’ C≡O str.). 
UV/Vis (CH3CN, λ/nm, ε/L.mol-1.cm-1): λ 368 (Re(dπ)→π*, ε 374.65), λ 270 (π→π*, ε 
2612.13), λ 218 (π→π*, ε 4703.92), λ 204 (π→π*, ε 4589.45). LRMS (ESI+): [M-Cl]+ m/z calc. 
484.97, m/z obsv. 485.07. HRMS (ESI+): [M+Na]+ m/z calc. 540.9261 
(C15H7N2O3FCl2ReNa
+); m/z obsv. 540.9266 (∆ 0.90 ppm). EA (%): calc. C 34.62, H 1.36, N 
5.38, Cl 13.63; obsv. C 34.45, H 0.95, N 5.36, Cl 13.55. 
Tricarbonylchloro(2-fluoro-1,10-phenanthroline)rhenium(I) (Re2FPhen). Yellow solid; MP: 
314°C (dec.); 65% yield. 1H NMR (400 MHz, DMSO-d6, δ/ppm): δ 9.47 (dd, Jd = 5.04, 1.32 
Hz, 1H), δ 9.16 (dd, Jd = 8.84, 6.80 Hz, 1H), δ 8.99 (dd, Jd = 8.32, 1.32 Hz, 1H), δ 8.36 (app. 
q, Jq = 14.72, 8.84 Hz, 2H), δ 8.14 (dd, Jd = 8.84, 1.48 Hz, 1H), δ 8.12 (dd, Jd = 8.32, 5.04 Hz, 
1H). 13C{1H} NMR (100 MHz, CDCl3, δ/ppm): δ 197.10 (C≡O), δ 196.54 (d, Jd = 14 Hz, C≡O), 
δ 189.99 (C≡O), δ 163.77, δ 161.18, δ 153.90, δ 145.79 (d, Jd = 11 Hz), δ 145.09 (d, Jd = 2 Hz), 
δ 144.07 (d, Jd = 3 Hz), δ 139.48, δ 130.99, δ 128.29 (d, Jd = 1 Hz), δ 127.32 (d, Jd = 2 Hz), δ 
127.09 (d, Jd = 61 Hz), δ 113.48 (d, Jd = 32 Hz). 19F NMR (376 MHz, DMSO-d6, δ/ppm): δ -
36.75 (dd, Jd = 6.92, 1.92 Hz), δ -106.00 (ISTD: para-DFB). FTIR (ATR corr. ṽ/cm-1): ṽ 3077 
(w, C−H sp2 str.), ṽ 2021 (s, A’(1) C≡O str.), ṽ 1890 (s, A’(2) & A’’ C≡O str.). UV/Vis 
(CH3CN, λ/nm, ε/L.mol-1.cm-1): λ 375 (Re(dπ)→π*, ε 2720.95), λ 343 (π→π*, ε 2821.73), λ 
269 (π→π*, ε 22069.94), λ 262 (π→π*, ε 22170.71), λ 215 (π→π*, ε 38798.75), λ 200 (π→π*, 
ε 40915.05). ). LRMS (ESI+): [M-Cl]+ m/z calc. 469.00, m/z obsv. 469.12. HRMS (ESI+): 
[M+Na]+ m/z calc. 524.9557 (C15H7N2O3FClReNa+); m/z obsv. 524.9579 (∆ 4.20 ppm). EA 
(%): calc. C 3575, H 1.40, N 5.56, Cl 7.04; obsv. C 35.73, H 0.98, N 5.59, Cl 6.83. 
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3.2 Rhenium-Phenanthroline Fluorine-18 Labelling and 
Testing of Non-Azeotropically Distilled Conditions 
 
Drying by azeotropic distillation is typically required for nucleophilic reactions involving 
[18F]fluoride, in order to increase the nucleophilicity of the fluoride which is otherwise 
hindered in the presence of water.[7] It remains a time-consuming process (> 15 mins), however, 
during which radioactivity (≥ 10%) is lost due to the radioactive decay of the fluorine-18 
radioisotope and non-specific adsorption of [18F]fluoride to the surface of the azeotropic 
distillation vial.[84, 85] Following the synthesis of the 2ClPhen phenanthroline precursor and its 
rhenium tricarbonyl complex, radiofluorination attempts were attempted via nucleophilic 
aromatic substitution for [18F]fluoride. However, during the radiolabelling experiments it was 
discovered that the solenoid valves enabling nitrogen gas flow and vacuum flow to and from 
the azeotropic distillation vial were not operating, as marked by the red crosses in in Figure 83. 
Thus, indicating that the [18F]fluoride was not being properly dried prior to the radiolabelling 
experiments. Despite the lack of azeotropically dried conditions, the radiolabelling of the 
rhenium complexes progressed unexpectedly and afforded considerable RCYs. This led to an 
ongoing investigation in each of the subsequent chapters whereupon azeotropically dried (dry) 
conditions and non-azeotropically dried (wet) conditions, which still containing a 10% v/v 
content of water, were compared in the radiolabelling of some rhenium complexes. In each 
case it was found that the radiolabelling of rhenium complexes can circumvent the requirement 
for azeotropic distillation of the [18F]fluoride media. 
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Figure 83. Solenoid valves supplying nitrogen gas and vacuum flow to and from the 
azeotropic distillation vial were not operating (marked by red crosses) within 
the microfluidic set-up, thus resulting in non-azeotropically dried reaction 
conditions during some radiolabelling experiments. 
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3.2.1 Fluorine-18 Labelling of 2-Chloro-1,10-
Phenanthroline 
 
The first strategy developed for attaining the radiofluorinated rhenium complex was to first 
radiolabel the 2-chloro-1,10-phenanthroline ligand via nucleophilic aromatic substitution for 
[18F]fluoride and then subsequently complex the ligand to source of rhenium via a multistep 
synthesis outlined in Figure 84. To first verify the retention time of [18F]2FPhen, a non-
radioactive standard of 2FPhen was injected on the HPLC using an isocratic mobile phase 
consisting of 8% acetonitrile and 82% water, each containing 0.05% TFA modifier, with a 1 
mL.min-1 flow rate. The retention time was determined to be approximately 3.0 mins, as shown 
by the chromatogram in Figure 85. An example radiochromatogram of the reaction affording 
[18F]2FPhen is shown in Figure 86, alongside the UV absorption chromatogram attained for 
the same reaction at 190 °C which shows the remaining unreacted 2ClPhen and a very minor 
UV peak forming, of value for determining molar absorptivities. A series of reactions were 
performed using the same precursor concentrations, amount of radioactivity and reaction time 
(0.08 µmol, 29±10 MBq and 47 s, respectively) under dry conditions, though with varying 
temperature conditions ranging from 50 to 190 °C in 20 °C increments. The non-isolated RCYs 
determined for each of these reaction temperatures by radioHPLC analysis is shown in Figure 
87. Under wet conditions no RCY was obtained for the radiolabelling of 2ClPhen, which was 
not surprising given that most radiofluorination reactions do not afford radioproducts in the 
presence of water due to the suppressed nucleophilicity of the [18F]fluoride.[7] Under dry 
conditions, however, [18F]2FPhen did indeed form, though only at temperatures greater than 
130 °C. Moderate RCYs of 24% and 38% were observed when using reaction temperatures of 
150 °C and 170 °C, respectively. Maximum RCYs of 49, 54 and 60% were attained from 
triplicate analyses at 190 °C. Higher temperatures were not trialled as the microfluidic module 
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could not heat at temperatures greater than 210 °C and it was not desirable to operate at this 
limit for multiple analyses. These results were also mirrored by radioTLC analyses, shown in 
Figure 88, attained from separating the radioactive species using an ethyl acetate mobile phase 
on a silica plate stationary phase. No [18F]2FPhen was found to form at temperatures below 
130 °C by radioTLC, and RCYs of 23, 38 and 58% were attained at the higher temperatures of 
130, 150 and 190 °C, respectively. 
 
Figure 84. Multiple-step radiosynthesis involving the radiofluorination of 2ClPhen to 
attain [18F]2FPhen, followed by rhenium complexation to attain 
[18F]Re2FPhen. 
 
 
Figure 85. UV-absorbance chromatogram of the 2FPhen standard, providing a retention 
time of approximately 3.0 mins using an isocratic mobile phase consisting of 
8% acetonitrile and 82% water (each containing 0.05% TFA) with a flow rate 
of 1 mL.min-1. 
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Figure 86. Radiochromatogram for the formation of [18F]2FPhen (top) at 190°C, with an 
RCY of 60% calculated from the peak area integration ratio between the 
[18F]2FPhen peak (3.3 min) and the entire radiochromatogram inclusive of the 
unreacted [18F]fluoride (1.3 min). The UV absorbance chromatogram (bottom) 
for the same reaction shows the early eluted DMSO (0.9 min) and the later 
eluting unreacted 2ClPhen (6.2 min) alongside a small UV absorbance peak 
with a retention time aligned with the [18F]2FPhen radioproduct. 
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Figure 87. Non-isolated RCYs for [18F]2FPhen determined by radioHPLC as a function 
of reaction temperature for both wet (blue diamonds) and dry (red crosses) 
reaction conditions. 
 
 
Figure 88. RadioTLC results for the radiofluorination reactions forming [18F]2FPhen at 
varying temperatures under dry conditions (0.08 µmol of precursor, 29±10 MBq 
of radioactivity, 47 s reaction time). The results suggest that radiolabelling 
could only be achieved at temperatures greater than 130°C. Separations were 
achieved using an ethyl acetate mobile phase on a silica plate stationary phase. 
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3.2.2 Multiple Step Fluorination and Complexation of 
[18F]2-Fluoro-1,10-Phenanthroline with Rhenium 
 
Using the optimal 190 °C dry temperature conditions for the radiosynthesis of [18F]2FPhen, a 
fourth pump (P4) was then connected in series to the microfluidic set-up in order to provide a 
second precursor solution and second microreactor in flow, as shown in Figure 89. The second 
precursor consisted of pentacarbonylchlororhenium(I) of differing equivalents in DMSO 
solution, and the temperature of the second microreactor was trialled between 70 and 190 °C 
in 30 °C increments in order to determine the ideal temperature for rhenium complexation and 
thus the formation of [18F]Re2FPhen. The UV-absorbance chromatogram for the non-
radioactive Re2FPhen standard is shown in Figure 90 using chromatographic conditions 
consisting of 35% acetonitrile and 65% water, each containing 0.05% of TFA modifier. The 
RCY for the formation of [18F]Re2FPhen for each given temperature of the second 
microreactor is shown in Figure 91 for one, five and eight equivalences (i.e. 0.08, 0.40 and 0.64 
µmol) of pentacarbonylchlororhenium(I). No RCY was obtained at 70 and 100 °C, however at 
130 °C RCYs of 5% and 21% were obtained for one and five equivalences, respectively. At 
160 °C one equivalence of the rhenium source afforded 14% RCY of [18F]Re2FPhen with the 
same yield afforded at 190 °C. Whereas using both five and eight equivalences of the 
pentacarbonylchlororhenium(I) precursor provided the greatest yield at 190 °C with  both 
affording 35% RCY. In order to determine the molar activity of the [18F]Re2FPhen product, 
differing concentrations of the non-radioactive Re2FPhen standard were injected onto the 
HPLC, as shown in Table 4. The integrated UV peak areas determined for each sample in 
DMSO were then plotted against the calculated molar amounts in order to construct the 
calibration curve shown in Figure 92. The correlation co-efficient (R2) value for the curve was 
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0.9992 signifying a good linear fit of the curve and provided equation (15) linking the 
integrated peak area (pA) at 254 nm with the molar amount (n) of Re2FPhen. 
𝑝𝐴 = 0.9298(𝑛) − 2.7325     (15) 
Rearrangement of equation (15) allows the molar amount (n) to be substituted into the 
previously discussed equation (6) which, provided the radioactivity (A) of the sample was 
measured at the time of injection,  can be used to determine the molar activity (AM) of 
[18F]Re2FPhen by yielding equation (16). 
𝐴𝑀 = 0.9298(𝐴)(2.7325 + 𝑝𝐴)
−1     (16) 
The molar activities of [18F]Re2FPhen determined for three of the reaction temperatures (130, 
160 and 190 °C) at the second microreactor are provided in Table 5. The injected radioactivity, 
UV integrated peak area and molar amounts used to calculate the molar activity via equations 
(15) and (16) are also provided in the table. Taking the mean of the three determined molar 
activities provides an average of 1.2 ± 0.2 MBq.nmol-1 for [18F]Re2FPhen using this multiple 
step radiosynthetic approach. 
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Figure 89. Automated microfluidic module set-up for the two-step radiosynthesis forming 
[18F]Re2FPhen. [18F]2FPhen was formed at the first reactor from 2ClPhen at 
a consistent 190 °C reaction temperature. Thereafter a fourth pump (P4) was 
plumbed to deliver the Re(CO)5Cl precursor, alongside a second microreactor 
whereby the [18F]2FPhen was complexed at varying reaction temperatures to 
synthesise the [18F]Re2FPhen radioproduct for HPLC analysis. 
 
 
Figure 90. UV-absorbance chromatogram of Re2FPhen providing a retention time of 
approximately 4.2 mins while using a mobile phase consisting of 35% 
acetonitrile and 65% water, each containing 0.05% TFA modifier, and a flow 
rate of 1 mL.min-1. 
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Figure 91. RCY of [18F]Re2FPhen plotted as a function of the complexation reaction 
temperature at the second microreactor. RCYs are plotted for one equivalence 
(0.08 µmol, blue diamonds), five equivalence (0.40 µmol, red crosses) and eight 
equivalence (0.64 µmol, green circle) of the Re(CO)5Cl precursor. 
 
Table 4. Concentration of Re2FPhen standards used to construct a calibration curve for 
the determination of the molar activity of the radioproduct. 10 μL of each 
standard was injected into the HPLC in order to plot the calculated molar 
amount against the integrated UV peak area determined for the sample. 
Concentration 
(ug/mL) 
Mass in 10uL 
(ng) 
Molar Amount 
(pmol) 
UV Integrated Peak Area 
(mAu.s) 
8.00 80.0 158.8 143.9 
4.00 40.0 79.4 73.1 
2.00 20.0 39.7 34.7 
1.00 10.0 19.8 14.1 
0.50 5.0 9.9 7.9 
0.25 2.5 5.0 0.5 
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Figure 92. Calibration curve plotting the molar amount of Re2FPhen against the integrated 
UV peak area afforded from each sample in order to determine the molar 
activity of the [18F]Re2FPhen radioproduct. 
 
Table 5. Molar activities determined from the injected activity, molar amount and 
integrated UV peak area for the multiple step radiosynthesis of [18F]Re2FPhen 
at three differing temperatures of the second microreactor. 
Temperature 
(°C) 
Activity Injected 
(MBq) 
UV Integrated Area 
(mAu.s) 
Molar Amount 
(pmol) 
Molar Activity 
(MBq/nmol) 
130 0.033 120.6 132.6 0.245 
160 0.049 470.6 509.1 0.096 
190 0.098 285.0 309.5 0.317 
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3.2.3 Radiofluorination of 2-Chloro-1,10-Phenanthroline 
Complexed to Rhenium 
 
To improve upon the low molar activity of [18F]Re2FPhen attained from the multiple-step 
radiosynthesis, a single-step radiosynthesis was trialled using the Re2ClPhen precursor. The 
same reactions conditions were employed (0.08 µmol of precursor, 29±10 MBq of activity and 
47 s reaction time) in DMSO solvent, as per the radiosynthesis of [18F]2FPhen and wet and 
dry conditions were likewise tested also. The only change in variable was the reaction 
temperature, whereupon different reactions were tested from 30 to 170 °C in 20 °C increments. 
Intriguingly, a noticeable difference in the radiochromatograms was observed for the same 
reaction temperatures under wet and dry conditions. These differences are shown in Figure 93, 
whereupon under dry conditions less of the [18F]Re2FPhen radioproduct (3.9 mins) formed at 
all, despite more of the Re2ClPhen precursor (6.2 mins) being consumed. The increased 
presence of an early eluting UV absorbing by-product (3.0 mins) appears to account for the 
loss of precursor. Surprising, under dry conditions for the same given temperature the UV 
absorbing by-product formed in much lesser abundance. This was corelated with an increased 
RCY of [18F]Re2FPhen forming from the available Re2ClPhen precursor. The determined 
RCYs for each reaction temperature under wet and dry conditions are plotted in Figure 94. 
Under dry conditions the [18F]Re2FPhen product was found to form at most in 19% RCY at 
30 °C, with reliable RCYs of 14, 15 and 17% being measured in triplicate at 50 °C. Thereafter 
RCYs of 14, 15, 10 and 6% formed at temperatures of 70, 90, 110 and 130 °C, respectively, 
and formed no yield at higher temperatures. The wet conditions, however, afforded much 
greater RCYs of 69, 70 and 78% forming at 50 °C, which likewise decreased to 38, 53, 29 and 
16% RCY at temperatures of 70, 90, 110 and 130 °C, respectively, before affording no 
[18F]Re2FPhen product at higher temperatures. This result was in contrast with the RCYs 
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obtained for [18F]2FPhen forming from 2ClPhen which not only required temperatures greater 
than 130 °C to obtain a radioproduct, though which also did not afford any radioproduct under 
wet conditions. In the case of [18F]Re2FPhen formation, wet conditions and lower 
temperatures (< 150 °C) appeared to be favourable in forming the radioproduct. The UV-
absorbing by-product was confirmed to be base-mediated via the spiked addition of sodium 
hydroxide (5 µL, 5 mol.L-1) to an HPLC injected solution of Re2ClPhen which indeed formed 
the UV by-product which was unobservable hitherto. Thus, the increased RCY of 
[18F]Re2FPhen under wet conditions may be a consequence of increased basicity of the media. 
 
Figure 93. UV absorbance chromatogram (254 nm, blue) and superimposed radioactive 
(red) profiles for the wet and dry analogous conditions (top and bottom) used to 
radiosynthesise [18F]Re2FPhen. A UV degradation by-product is observed at 
3.0 mins alongside the unreacted Re2ClPhen precursor at 6.2 mins (absorbance 
from the DMSO solvent is also observed at around 1 min). The 
radiochromatogram shows the elution of the unreacted [18F]fluoride at 1.0 min 
and the [18F]Re2FPhen radioproduct at 3.9 min elution time. 
112 
 
 
Figure 94. RCY of [18F]Re2FPhen forming from Re2ClPhen as a function of reaction 
temperature under wet (blue diamonds) and dry (red crosses) conditions. The 
reaction was found to afford greater yield under low temperature, wet conditions 
which is the opposite trend of typical nucleophilic radiofluorinations. 
 
To determine the molar activity of [18F]Re2FPhen formed in these single step radiosynthetic 
reactions the injected activity, UV integrated peak areas and molar amounts were all recorded 
for each of these tested reaction temperatures which yielded a radioproduct (Table 6). 
Substituting these values into equations (15) and (16) then allowed for the determination of the 
molar activity which, taken as an average, was calculated as 71±29 MBq.nmol-1. The 
comparative molar activities for the single-step and multiple-step radiosyntheses of 
[18F]Re2FPhen are shown in Figure 95. 
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Table 6. Molar activities determined from the injected activity, molar amount and 
integrated UV peak area for the single step radiosynthesis of [18F]Re2FPhen 
from ReClPhen at each of the reaction temperatures affording a radioproduct. 
Temperature 
(°C) 
Activity Injected 
(MBq) 
UV Integrated Area 
(mAu.s) 
Molar Amount 
(pmol) 
Molar Activity 
(MBq/nmol) 
30 1.244 13.9 17.9 69.6 
50 0.949 7.9 11.4 83.0 
70 0.523 4.0 7.2 72.2 
90 0.596 5.4 8.7 68.2 
110 0.363 2.6 5.7 63.2 
130 0.160 1.4 4.4 36.0 
  
 
 
Figure 95. Difference in molar activities acquired for the multiple-step radiosynthesis (top, 
0.2±0.1 MBq.nmol-1) and single-step radiosynthesis (bottom, 71±12 
MBq.nmol-1) of [18F]Re2FPhen. 
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Alternative experiments were also trialled, by adjusting the reaction time and the Re2ClPhen 
precursor amount, to increase the RCY of [18F]Re2FPhen. In Figure 96, increasing the reaction 
time was found to steadily increase the yield of the radioproduct with shorter reaction times of 
8, 12 and 24 seconds found to afford lesser RCYs of 27, 34 and 42%, respectively, when 
employing the optimal reaction temperature of 50 °C alongside the usual 0.08 µmol 
concentration of the Re2ClPhen precursor and 29±10 MBq of [18F]fluoride under dry 
conditions. Triplicate analyses with a reaction time of 47 s afforded between 49 and 60% RCY, 
as expected based upon the previous temperature dependent reactions. Intriguingly though, a 
longer reaction time of 94 seconds only afforded only 56% RCY, no greater than the RCYs 
attained at from the 47 second reaction time experiments. Adjusting the precursor amount, 
however, did not appear to have such a varied influence on the amount of [18F]Re2FPhen 
synthesised. Figure 97 plots the RCY as a function of differing precursor amounts used while 
keeping the reaction temperature (50 °C), reaction time (47 s) and radioactivity (29±10 MBq) 
constant. From these experiments, RCYs of 53, 49, 61 and 44% were observed when 
employing half (0.04 µmol), standard (0.08 µmol), approximately double (0.15 µmol) and 
approximately five times (0.38 µmol) the amount of Re2ClPhen in each of the reactions. 
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Figure 96. Effect on the RCY of [18F]Re2FPhen obtained when changing the reaction time 
while keeping all other parameters constant (i.e. 50 °C reaction temperature, 
0.08 µmol of Re2ClPhen precursor and 29±10 MBq of [18F]fluoride). 
 
 
Figure 97. Adjusting the precursor amount of Re2ClPhen used in the reaction while 
keeping the other reaction parameters constant (50 °C temperature, 47 s reaction 
time and 29±10 MBq of radioactivity) did not afford any substantial difference 
in the RCY of [18F]2FPhen. 
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3.3 Photophysical Analyses of Rhenium-Phenanthroline 
Complexes 
 
In accordance with the goal to evaluate the use of radiofluorinated rhenium tricarbonyl 
complexes as PET-optical probes, the photophysical properties of both the Re2ClPhen 
precursor and Re2FPhen standard were measured. An emission spectrum was initially 
obtained for Re2ClPhen in DMSO solution (10-4 mol.L-1) by applying a monochromatic 
excitation wavelength of 370 nm, which aligned closely with the MLCT absorption maxima of 
the complex determined by UV-Vis spectroscopy. The emission maximum was determined to 
be 654 nm. Thus, a wavelength of 650 nm was set to be detected to acquire the excitation 
spectrum of the complex. The excitation spectrum notably deviated from the expected gaussian 
shaped peak profile due to inner filter effects arising from the solution. These inner filter effects 
may have been caused by the reabsorption of emitted photons, or a too greater concentration 
of the absorbing analyte, such that the intensity of excitation photons was not homogeneous 
within the solution. Nonetheless an excitation maximum of 382 nm was measured. Figure 98 
shows the overlaid emission and excitation spectra of Re2ClPhen. The same experiment was 
performed on a solution of Re2FPhen in DMSO (10-4 mol.L-1), whereupon an emission 
spectrum was first obtained using a set excitation wavelength of 370 nm. From this spectrum 
the Re2FPhen complex was verified to have an emission maximum of 654 nm. The excitation 
spectrum which was subsequently obtained by applying a fixed monochromatic emission 
wavelength of 650 nm, though also appeared to be subject to inner filter effects. An excitation 
maximum of 382 nm was nonetheless determined for Re2FPhen, akin to the excitation 
maximum observed for Re2ClPhen. An overlay of the normalised emission and excitation 
spectra attained for Re2FPhen is provided in Figure 99. Experimental uncertainties are 
estimated to be ±5 nm for the absorption and emission peaks. 
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Figure 98. Normalised spectra exhibiting overlaid emission maxima of 654 nm and 
excitation maxima of 382 nm (subject to inner filter effects) for a solution of 
Re2ClPhen in DMSO, given fixed excitation and emission wavelengths of 370 
nm and 650 nm, respectively. 
 
 
Figure 99. Normalised spectra exhibiting overlaid emission maxima of 653 nm and 
excitation maxima of 396 nm (subject to inner filter effects) for a solution of 
Re2FPhen in DMSO, given fixed excitation and emission wavelengths of 370 
nm and 650 nm, respectively. 
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3.3.1 Quantum Yield Determination of 2-Chloro and 2-
Fluoro Phenanthroline Complexes 
 
The quantum yields of the Re2ClPhen and Re2FPhen complexes were determined for 
comparison with other optical emission agents. The quantum yield was determined from 
correction factors applied using a [Ru(BiPy)3]Cl2 reference standard in water solution, which 
consisted of a quantum yield of 0.028, an absorbance intensity of 0.045 at 410 nm and refractive 
index of 1.333. Integration of the emission spectrum of [Ru(BiPy)3]Cl, acquired through a fixed 
monochromatic excitation wavelength of 410 nm, afforded 4.71×106 counts⋅nm. The quantum 
yield of both Re2ClPhen and Re2FPhen were measured in both air equilibrated DMSO 
solution and an aqueous solution consisting of 5% DMSO to aid solubility, consisting of 
refractive indices of 1.479 and 1.339, respectively. The absorbances of the Re2ClPhen 
solutions at 410 nm were 0.169 and 0.333 for the complex dissolved in DMSO and 5% DMSO 
solution, respectively. Integration of the emission spectrum obtained from a fixed 
monochromatic excitation wavelength of 410 nm afforded 1.46×106 counts⋅nm and 3.00×106 
counts⋅nm for Re2ClPhen dissolved in DMSO and 5% DMSO solutions, respectively. 
Likewise, absorbances of Re2FPhen at 410 nm were 0.284 and 0.193 in DMSO and 5% 
DMSO solutions, respectively. Integrations of the emission spectra obtained via a 410 nm 
excitation wavelength afforded values of 2.51×106 counts⋅nm and 1.52×106 counts⋅nm in 
DMSO and 5% DMSO respectively. These parameters, tabulated in Table 7, were substituted 
into equation (14) to afford the quantum yields of Re2ClPhen and Re2FPhen. The quantum 
yields were calculated to be 0.3% for both Re2ClPhen and Re2FPhen in DMSO solution, and 
0.2% for both Re2ClPhen and Re2FPhen in 5% DMSO solution. Experimental uncertainties 
are estimated to be ±0.1% for the quantum yields. 
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Table 7. Air equilibrated quantum yields calculated for the Re2ClPhen and Re2FPhen 
complexes via comparison to a [Ru(BiPy)3Cl] reference standard with 
correction factors applying for the refractive index of the media, absorbance at 
the 410 nm excitation wavelength and the integration of the emission spectrum. 
Analyte Solvent 
Refractive 
Index 
Absorbance 
Emission 
Integration 
(counts⋅nm) 
Quantum 
Yield (%) 
[Ru(BiPy)3]Cl Water 1.333 0.045 4.71×10
6 2.8% 
Re2ClPhen DMSO 1.479 0.169 1.46×106 0.3% 
 5% DMSO 1.339 0.333 3.00×106 0.2% 
Re2FPhen DMSO 1.479 0.284 2.51×106 0.3% 
 5% DMSO 1.339 0.193 1.52×106 0.2% 
 
The quantum yields obtained for these rhenium tracers thus fell within the ranges reported for 
the cyanine dyes used in PET-optical tracer development. For instance, the Cy5.5 fluorescent 
precursor used in the radiosynthesis of a PET-optical marker by Priem, et al. afforded a 
quantum yield of 0.4% when measured in DMSO solution.[61] Not dissimilar to the 0.3% and 
0.2% quantum yields measured in DMSO and 5% DMSO solution for both rhenium complexes. 
These results are still at least an order of magnitude less than the quantum yields acquired for 
the BODPY conjugated PET-optical probes however which, as reported for both Li, et al. and 
Paulus, et al., measured within the range of 11 to 15%.[48, 52] Much greater quantum yields of 
rhenium complexes have been reported, however, when displacing the chloro ancillary ligands 
for π-conjugated N-heterocycles.[86-88] Such future work may thus provide competitive 
quantum yields for PET-optical tracers based on rhenium probes, however this work was not 
pursued in favour of developing alternative rhenium mediated radiofluorination methods based 
on the interesting radiochemical results obtained. 
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3.3.2 Luminescent Lifetimes and Decay Rates of 2-
Chloro and 2-Fluoro Phenanthroline Complexes 
 
The lifetimes of the rhenium complexes were determined by TCSPC technique following 
excitation with a 377 nm picosecond LED. The monoexponential decay profiles are shown in 
Figure 100 and Figure 101 for Re2ClPhen and Re2FPhen in DMSO solution, respectively. 
The profiles do not differ significantly for both complexes, however, from these decay profiles 
Re2ClPhen was determined to have a luminescent lifetime of 27 ns (χ2 = 0.876) and 
Re2FPhen was determined to have a luminescent lifetime of 41 ns (χ2 = 0.974). When testing 
these complexes in 5% DMSO solution the luminescent lifetimes proved to be shorter, with a 
lifetime of 10 ns determined for Re2ClPhen (χ2 = 1.148) and a lifetime of 14 ns determined 
for Re2FPhen (χ2 = 1.156). By substituting the lifetime and quantum yields into equation (10) 
the radiative decay rate constants were determined to be 1.05×10-4 and 7.04×10-5 for 
Re2ClPhen and Re2FPhen in DMSO solution, respectively. In 5% DMSO solution, these 
radiative decay rate constants were determined to be 1.64×10-4 and 1.60×10-4 for Re2ClPhen 
and Re2FPhen, respectively. Conversely, the non-radiative decay rate constants calculated 
from the lifetimes and quantum yields using equation (11) were determined to be 3.76×10-2 
and 2.41×10-2 for Re2ClPhen and Re2FPhen in DMSO solution, respectively. In 5% DMSO 
solution, these non-radiative decay rate constants were determined to be 1.01×10-1 and 
6.96×10-2 for Re2ClPhen and Re2FPhen, respectively. These photophysical properties are 
listed in Table 8 for Re2ClPhen and Re2FPhen in both DMSO and 5% DMSO solutions. 
Experimental uncertainties are estimated to be ±8% for the luminescent lifetime determinations.  
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Figure 100. Monoexponential decay profile of Re2ClPhen in DMSO via TCSPC following 
excitation with a 377 nm pulsed picosecond LED. The phosphorescent lifetime 
in DMSO was determined to be 27 ns with χ2 = 0.876. 
 
 
Figure 101. Monoexponential decay profile of Re2FPhen in DMSO via TCSPC following 
excitation with a 377 nm pulsed picosecond LED. The phosphorescent lifetime 
in DMSO was determined to be 41 ns with χ2 = 0.974. 
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Table 8. Comparison of air equilibrated quantum yields, lifetimes with associated 
goodness of fit, and radiative and non-radiative decay rate constants for 
Re2ClPhen and Re2FPhen in DMSO and 5% DMSO in water solvents. 
Re Complex 
(solvent) 
Luminescent 
Quantum 
Yield (ϕ) 
Luminescent 
Lifetime (τ) 
Goodness 
of Fit (χ2) 
Radiative 
Decay Rate 
Constant (kr) 
Non-Radiative 
Decay Rate 
Constant (knr) 
Re2ClPhen 
(DMSO) 
2.85×10-3 27 ns 0.876 1.05×10-4 3.76×10-2 
Re2FPhen 
(DMSO) 
2.91×10-3 41 ns 0.974 7.04×10-5 2.41×10-2 
Re2ClPhen 
(5% DMSO) 
2.43×10-3 10 ns 1.148 1.64×10-4 1.01×10-1 
Re2FPhen  
(5% DMSO) 
2.12×10-3 14 ns 1.156 1.60×10-4 6.96×10-2 
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CHAPTER FOUR 
RHENIUM-BIPYRIDINE DECOMPLEXATION AS A 
NOVEL METHOD FOR PRODUCING RADIOTRACERS 
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4.1 Synthesis of 6-Substituted 2,2’-Bipyridine 
Rhenium Tricarbonyl Complexes 
 
Following the successful radiofluorination of Re2ClPhen, it was hypothesised that rhenium 
complexed 2-2’bipyridine could afford similar RCYs under analogous conditions. Additionally, 
due to the commercial availability of the chlorinated precursor ligands, such complexes were 
an opportunity to assess how rhenium activation could assist fluorine-18 radiolabellings on 
different positions of the molecule. Three chlorinated ligands were selected to trial substitution 
reactions for [18F]fluoride in the ortho, meta and para positions; these ligands being 6-chloro-
2,2’-bipyridine (6ClBiPy), 5-chloro-2,2’-bipyridine (5ClBiPy) and 4-chloro-2,2’-bipyridine 
(4ClBiPy). Additionally, the fluorinated analogues of each ligand were required as non-
radioactive standards. Initial syntheses of these fluorinated ligands via palladium-catalysed 
Suzuki-Miyaura cross-coupling reactions with the corresponding pyridinyl halides and 
trifluoroborate salts provided unsuccessful, despite the reported syntheses of similar 
compounds via this method.[89-92] Thus, 6-fluoro-2,2’-bipyridine (6FBiPy) and 4-fluoro-2,2’-
bipyridine (4FBiPy) were synthesised via nucleophilic aromatic substitution of the chlorinated 
ligands with a source of potassium fluoride and in the presence of an 18-crown-6 ether phase 
transfer catalyst. The 5-fluoro-2,2’-bipyridine (5FBiPy) was unfortunately unable to be 
synthesised via this method and no alternative synthetic routes were explored in the interest of 
time. Each of the chlorinated ligands were synthesised to form their respective rhenium 
complexed precursors, tricarbonylchloro(6-chloro-2,2’-bipyrine)rhenium(I) (6ClBiPy), 
tricarbonylchloro(5-chloro-2,2’-bipyrine)rhenium(I) (5ClBiPy) and tricarbonylchloro(4-
chloro-2,2’-bipyrine)rhenium(I) (4ClBiPy). Both synthesised fluorine substituted ligands were 
also complex with a source of pentacarbonylchlororhenium(I) to form the non-radioactive 
standards of tricarbonylchloro(6-fluoro-2,2’-bipyrine)rhenium(I) (6FBiPy) and 
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tricarbonylchloro(4-fluoro-2,2’-bipyrine)rhenium(I) (4FBiPy). Each of these precursors and 
non-radioactive standards are illustrated in Figure 102. 
 
 
Figure 102. Each of the precursors and non-radioactive standards prepared for the 
radiolabelling experiments of 2,2’-bipyridine ligands and their corresponding 
rhenium complexes. Note that the syntheses of 5FBiPy and by extension 
Re5FBiPy were unsuccessful, though are listed due to their importance in later 
discussion.  
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4.1.1 Fluoride substitution of 6-Chloro-2,2’-Bipyridine 
 
 
Figure 103. Synthesis of 6FBiPy via nucleophilic aromatic substitution for fluoride 
provided by a potassium salt azeotropically dried in DMSO solvent in the 
presence of an 18-crown-6 ether phase transfer catalyst. The reaction afforded 
13% yield following stirring at 90°C for 96 h under an inert nitrogen gas 
environment. 
 
A mass of 6ClBiPy (318.7 mg, 1.672 mmol, 1.0 eq.) was dried under high vacuum and back-
filled with nitrogen gas over three cycles. A volume of DMSO was distilled over calcium 
hydride and further dried over 4 Å molecular sieves. Masses of potassium fluoride (1.712 g, 
29.466 mmol, 17.6 eq.) and 18-crown-6 ether (1.567 g, 5.928 mmol, 3.5 eq.) were 
azeotropically dried via small additions of acetonitrile (20 × 1 mL), with evaporation of the 
azeotrope occurring between additions, at 90°C under a constant flow of nitrogen gas. A 
homogeneous white crust resulted which was subsequently vacuumed and back-filled with 
nitrogen gas over three cycles. A volume of the recently distilled anhydrous DMSO (10 mL) 
was then added to dissolve the 6-chloro-2,2’-bipyridine which turned yellow in solution and 
was then transferred to the potassium fluoride- crown ether complex under inert conditions. No 
product was afforded at room temperature, nor any temperature approaching 90°C while 
stirring in an inert nitrogen gas environment. Thus, the solution was left to stir at 90°C until 
the reaction achieved equilibration and no increase in the peak area of the product was 
identified, as confirmed by HPLC and MS monitoring (96 h). The reaction was thus cooled to 
room temperature and afforded a brown solution. The solution was loaded onto a silica column 
wet-packed with hexane and eluted over gradient conditions with a mobile phase ramped from 
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0% to 20% ethyl acetate in hexane. Fractions containing the co-eluting 6-chloro-2,2’-bipyrine 
and 6-fluoro-2,2’-bipyridine were then evaporated down under reduced pressure which 
afforded a white crystalline powder. The crude white powder was then dissolved in a minimum 
of methanol (2.2 mL) for preparative chromatography and a series of optimised 32 μL 
injections were loaded onto an Atlantis T3 C18 reverse phase column (5 μm, 4.6 × 150 mm) 
and eluted with an isocratic mobile phase consisting of 9% acetonitrile and 91% of Milli-Q 
water with 0.1% TFA modifier at a flow rate of 1.5 mL.min-1 and PDA detection wavelength 
set at 254 nm. The collected fractions were combined and evaporated under reduced pressure 
to remove the acetonitrile before sublimating off the water via overnight lyophilisation, which 
afforded a pink salt. The pink salt was dissolved in a minimum of water (20 mL), neutralised 
with saturated sodium bicarbonate solution and extracted into DCM (15 × 10 mL) via liquid-
liquid extraction. The resulting organic fractions were then combined, dried over sodium 
sulphate, vacuum filtered and evaporated under reduced pressure before dried under high 
vacuum which afforded a white powder (39.2 mg). 
Confirmation of 6FBiPy was verified by 1H-NMR which affirmed the expected peak area 
integration for seven protons in the aromatic region, as shown in Figure 104. The 13C-NMR 
spectrum of 6FBiPy, shown in Figure 105, afforded twelve signals in the aromatic region due 
to two of the ten carbon-13 nuclei exhibiting coupling with the fluorine-19 nucleus. The CPD 
19F{1H}-NMR spectrum of the compound shows the signal for the lone fluorine-19 nucleus in 
Figure 106, alongside the para-DFB internal standard. 
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Figure 104. 1H-NMR spectrum of 6FBiPy in CDCl3, showing the expected peak area 
integration for seven protons in the aromatic region. Note the non-integrated 
peaks belong to the solvent signal and two satellite peaks of the upfield doublet 
of doublets. 
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Figure 105. 13C-NMR spectrum of 6FBiPy in CDCl3, affording twelve signals in the 
aromatic region due to two additional signals appearing from two of the ten 
carbon atoms exhibiting observable coupling with the 19F nucleus present in the 
molecule. 
 
Figure 106. CPD 19F{1H}-NMR spectrum of 6FBiPy in CDCl3. The signal at -106.00 ppm 
is the para-DFB internal standard. 
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4.1.2 Rhenium Complexation of 6-Chloro-2,2’-Bipyridine 
 
 
Figure 107. Synthesis of Re6ClBiPy via reflux of pentacarbonylchlororhenium(I) with  
6ClBiPy in toluene which afforded the desired product in 86% yield. 
 
A mass of 6ClBiP (277.5 mg, 1.456 mmol, 1.1 eq.) was dissolved in a volume of anhydrous 
toluene (5 mL) prompting the solution to turn beige in colour. A mass of 
pentacarbonylchlororhenium(I) (478.7 mg, 1.3234 mmol, 1.0 eq.) was then added and the 
solution was stirred at reflux under an inert nitrogen environment (5 h) causing the biphasic 
mixture to turn orange in colour. The solution was then cooled to room temperature and further 
cooled to -20°C to induce greater precipitation. The solution was then filtered via vacuum 
filtration and washed first with cold toluene, followed by diethyl ether. The resulting yellow 
solid was then dissolved in a minimum of DCM (7 mL) and loaded onto neutral alumina normal 
phase column (Brockman grade II, 120 g) wet packed with DCM and was eluted using an 
isocratic mobile phase consisting of only DCM. Fractions confirmed to contain the desired 
product by HPLC, MS and TLC analyses were combined and evaporated under reduced 
pressure to afford a yellow powder (564.2 mg). 
Confirmation of rhenium complexation was affirmed by 1H-NMR, with signals integrating for 
the expected seven protons as shown in Figure 108 with each signal shifted downfield with 
respect to the ligand; 13C-NMR as shown in Figure 109 which exhibited ten carbon-13 signals 
from the bipyridine ring and an additional three downfield shifted carbon-13 signals for the 
carbonyl ligands; FTIR which showed the expected A’(1) C≡O stretching IR absorption band 
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at 2018 cm-1 and the overlapping A’(2) & A’’ C≡O stretching band at 1882 cm-1 indicative of 
the carbonyl ligands alongside a weak sp2 hybridised C−H bond stretch at 3075 cm-1 from the 
bipyridine ligand as shown in Figure 110; as well as HRMS which demonstrated the chlorine-
dissociated [M-Cl]+ ion signal observable at m/z 460.9694 against the calculated m/z 460.9703 
(Δ -0.9 ppm) as shown in Figure 111. Additionally the UV-Vis spectrum of Re6ClBiPy shows 
the expected absorption band for the dπ → π* transition to the MLCT excited state, as shown 
in Figure 112, as well as higher energy absorption bands with greater molar absorptivities for 
π → π* transitions to LC excited states. Elemental analysis further confirmed the purity of the 
complex with compositions of 13.59% carbon, 1.17% hydrogen and 5.70% nitrogen measured 
against the theoretical compositions of 31.46% carbon, 1.42% hydrogen and 5.64% nitrogen. 
Finally, the XRD structure shown in Figure 113 provided unequivocal evidence for the 
structure of Re6ClBiPy. 
 
 
Figure 108. 1H-NMR spectrum of Re6ClBiPy in DMSO-d6, showing the expected peak area 
integration for the seven protons in the aromatic region which were shifted 
downfield with respect to the ligand. 
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Figure 109. 13C-NMR spectrum of Re6ClBiPy in DMSO-d6, exhibiting not only the ten 
aromatic carbon-13 signals from the bipyridine system though also showing 
the three downfield shifted carbonyl signals of the rhenium complex (189.5, 
197.3 & 197.5 ppm). 
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Figure 110. FTIR spectrum of Re6ClBiPy exhibiting the distinctive A’(1) C≡O stretching 
IR absorption band at 2018 cm-1 and the overlapping A’(2) & A’’ C≡O 
stretching band at 1882 cm-1. A weak sp2 hybridised C−H bond stretch is also 
observed at 3075 cm-1 from the bipyridine ligand. 
 
 
 
Figure 111. HRMS spectrum of Re6ClBiPy depicting the chlorine-dissociated [M-Cl]+ ion 
signal observable at m/z 460.9694 with a calculated ratio of m/z 460.9703 (Δ -
0.9 ppm) for the complex incorporating the 187Re isotope in 62.6% natural 
abundance. An additional signal with m/z 458.9688 is also observed for the 
same ion incorporating the 185Re isotope in 37.4% natural abundance. 
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Figure 112. UV-Vis spectrum of Re6ClBiPy (2 µg.mL-1 in acetonitrile) showing the 
absorption band for the dπ → π* electronic transition to the MLCT excited state 
at 380 nm, alongside higher energy π → π* transitions to LC excited states with 
greater molar absorptivities. 
 
 
Figure 113. Crystal structure obtained for Re6ClBiPy via XRD analysis at the Australian 
Synchrotron. Crystals were grown from the slow evaporation of DMSO solution. 
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4.1.3 Rhenium Complexation of 6-Fluoro-2,2’-Bipyridine 
 
 
Figure 114. Synthesis of Re6FBiPy via reflux of pentacarbonylchlororhenium(I) with 
6FBiPy in toluene which afforded the desired product in 65% yield. 
 
A mass of 6FBiPy (65.3 mg, 363 μmol, 1.1 eq.) was dissolved in a volume of anhydrous 
toluene (8 mL), to which was added a mass of pentacarbonylchlororhenium(I) (120.0 mg, 332 
µmol, 1.0 eq.). The solution was stirred at reflux under an inert nitrogen environment (3 h) 
during which time the solution turned yellow in colour. The solution was cooled thereafter first 
to room temperature, then to -20°C to induce further precipitation. The resulting yellow solid 
was isolated via vacuum filtration and was washed with cold toluene followed by diethyl ether. 
The solid was then dissolved in a minimum of DCM (4 mL) and was loaded onto a Sepaflash 
neutral alumina column (80 g) whereupon the product was eluted over gradient conditions with 
the mobile phase ramped from 0 to 10% acetonitrile in ethyl acetate. The fractions containing 
the desired product, as confirmed by HPLC, TLC and MS, were combined and evaporated 
under reduced pressure to afford a yellow powder (104.1 mg). 
Confirmation of rhenium complexation to the 2-fluoro-2,2’-bipyridine ligand was affirmed by 
1H-NMR as shown in Figure 115, which integrated for the expect seven aromatic protons with 
more complex splitting patterns when compared to the chloro substituted analogue due to the 
additional coupling between the protons and fluorine-19 isotope. Complex splitting patterns 
are also observed between the carbon-13 and fluorine-19 nuclei as shown by the 13C-NMR 
spectrum in Figure 116, which also distinctly shows the Re−C≡O carbon-13 signals shifted 
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downfield with respect to the aromatic bipyridine carbon-13 signals. The CPD 19F-NMR 
spectrum shows just the one signal pertaining to the sole fluorine-19 nucleus in the molecule, 
as shown in Figure 117. Additional confirmation was also affirmed by the FTIR spectrum 
which showed the expected A’(1) C≡O stretching IR absorption band at 2016 cm-1 and the 
overlapping A’(2) & A’’ C≡O stretching band at 1880 cm-1 indicative of the carbonyl ligands 
alongside weak sp2 hybridised C−H bond stretches around 3039 cm-1 from the bipyridine ligand 
as shown in Figure 118. The UV-Vis spectrum of Re6FBiPy, as shown in Figure 119, depicts 
the absorption band for the dπ → π* electronic transition to the MLCT excited state at 369 nm. 
Absorption bands to LC excited states are also observed due to π → π* transitions at higher 
energies. Purity of the complex was also further assessed via elemental analysis which yielded 
compositions of 32.59% carbon, 1.16% hydrogen and 5.88% nitrogen against closely aligned 
theoretical compositions of 32.54% carbon, 1.47% hydrogen and 5.64% nitrogen. 
 
 
Figure 115. 1H-NMR spectrum of Re6FBiPy in DMSO-d6, showing the expected peak area 
integration for the seven protons in the aromatic region which were shifted 
downfield with respect to the ligand. The peaks exhibit more complex splitting 
patterns on account of the coupling between the fluorine-19 isotope present in 
the molecule. 
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Figure 116. 13C-NMR spectrum of Re6FBiPy in DMSO-d6, showing the downfield shifted 
carbonyl signals with respect to the carbon-13 aromatic signals from the 
bipyridine ring. Complex splitting is observed due to the coupling between the 
carbon-13 and fluorine-19 nuclei. 
 
 
 
Figure 117. Decoupled 19F-NMR spectrum of R62FBiPy in DMSO-d6 displaying the signal 
for the sole fluorine-19 nucleus in the molecule at -50.75 ppm. 
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Figure 118. FTIR spectrum of Re6FBiPy exhibiting the distinctive A’(1) C≡O stretching 
IR absorption band at 2016 cm-1 and the overlapping A’(2) & A’’ C≡O 
stretching band at 1880 cm-1. Weak sp2 hybridised C−H bond stretches are also 
observed at higher wavenumbers (circa 3039 cm-1) from the bipyridine ligand. 
 
 
Figure 119. UV-Vis spectrum of Re6FBiPy (2 µg.mL-1 in acetonitrile) showing the 
absorption band for the dπ → π* electronic transition to the MLCT excited state 
at 369 nm, alongside higher energy π → π* transitions to LC excited states with 
greater molar absorptivities. 
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4.1.4 Fluorine substitution of 4-Chloro-2,2’-Bipyridine 
 
 
Figure 120. Synthesis of 4FBiPy via nucleophilic aromatic substitution for fluoride 
provided by a potassium salt azeotropically dried in DMSO solvent in the 
presence of an 18-crown-6 ether phase transfer catalyst. The reaction afforded 
42% yield following stirring at reflux for 3 h under an inert nitrogen gas 
environment. 
 
A mass of 18-crown-6 ether (4.060 g, 0.0154 mol, 9.8 eq.) was added alongside a mass of 
potassium fluoride (1.890 g, 0.0325 mol, 20.8 eq.) and dried under high vacuum before heating 
under an inert nitrogen environment to form a yellow crust which was then azeotropically dried 
via the dropwise addition of acetonitrile to the heated solid. A mass of 4ClBiPy (298.2 mg, 
1.564 mmol, 1.0 eq.) was then dried under high vacuum and backfilled with nitrogen gas in a 
separate flask before being dissolved in a volume of anhydrous DMSO (4 mL) resulting in a 
pale-yellow solution. The solution was then transferred to the potassium fluoride-crown ether 
complex and was heated at reflux whilst stirring in an inert nitrogen environment (3 h). The 
solution was then cooled to room temperature following HPLC-UV and MS confirmation of 
the desired product. The cooled solution was filtered through PTFE membrane filters (0.2 µm) 
to remove the excess potassium fluoride and the filtered solution was then loaded onto a C18 
RP column (80 g) primed with 0.1% TFA in water and eluted over 20 column volumes with a 
flow rate of 40 mL.min-1 with increasing acetonitrile composition (0 to 100%). Each of the 
eluted fractions were analysed for purity by HPLC, TLC and MS. Those fractions confirmed 
to contain the purified product were combined and evaporated under reduced pressure to 
remove the acetonitrile before freeze-drying the resulting aqueous suspension overnight. A 
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yellow oil resulted which was washed first with chloroform and evaporated under reduced 
pressure to afford a yellow solid. The yellow solid was then dissolved in a minimum of water 
and extracted with DCM (10 × 20 mL). The organic extracts were then combined, dried over 
sodium sulphate, filtered via vacuum filtration and evaporated under reduced pressure to afford 
a white solid which was then further dried under high vacuum and weighed (115.1 mg). 
1H-NMR analysis of the final product (Figure 121) showed the expected integration for seven 
protons in the aromatic region, 13C-NMR analysis (Figure 122) showed splitting of three of the 
ten carbon-13 nuclei due to coupling to the fluorine-19 nucleus, the resonance signal of which 
is shown in the CPD 19F-NMR spectrum of 4FBiPy in Figure 123. The LRMS spectrum of 
4FBiPy, shown in Figure 124, shows a detected signal for the [M+H]+ ion at m/z 175.12 closely 
matching the calculated m/z ratio of 175.07. 
 
 
Figure 121. 1H-NMR spectrum of 4FBiPy in chloroform-d, showing the expected peak area 
integration for seven protons in the aromatic region. Note that the most upfield 
shifted peak integral overlaps with the solvent signal. 
 
 
141 
 
 
Figure 122. 13C-NMR spectrum of 4FBiPy in chloroform-d, affording thirteen signals in the 
aromatic region due to three additional signals appearing from three of the ten 
carbon nuclei exhibiting observable coupling with the fluorine-19 nucleus 
present in the molecule. 
 
 
Figure 123. CPD 19F-NMR spectrum for 4FBiPy exhibiting one lone single for the sole 
fluorine-19 nucleus in the molecule at -75.99 ppm. 
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Figure 124. LRMS spectrum of 4FBiPy showing detection of the [M+H]+ ion at m/z 175.12 
against a calculated ratio of m/z 175.07. 
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4.1.5 Rhenium Complexation of 4-Chloro-2,2’-Bipyridine 
 
 
Figure 125. Synthesis of Re4ClBiPy via complexation of 4ClBiPy with 
pentacarbonylchlororhenium(I) for 20 h at 70°C in toluene which afforded the 
desired product in 89% yield. 
 
A mass of 4ClBiPy (181.5 mg, 952.1 mmol, 1.1 eq.) was dissolved in a volume of anhydrous 
toluene (5 mL) and to this solution was added a mass of pentacarbonylchlororhenium(I) (315.0 
mg, 870.9 mmol, 1.0 eq.). The solution was then stirred at 70°C under an inert nitrogen 
environment (20 h) promoting the formation of a yellow reaction product. The reaction mixture 
was then cooled to room temperature, further cooled to -20°C to aid the precipitation of the 
solid, filtered via vacuum filtration and washed with cold toluene followed by diethyl ether. 
The resulting yellow solid was then dried under high vacuum, dissolved in DCM and purified 
on a neutral alumina NP column Brockman grade II, 90 g) wet packed with DCM and eluted 
with 100% DCM. Fractions containing the desired product were then combined, evaporated 
under reduced pressure and dried under high vacuum to afford a yellow powder (386.1 mg). 
Formation of the 4-chloro-2,2’bipyridine rhenium complex was verified by 1H-NMR as shown 
in Figure 126, which exhibited the expected seven signals of similar integration in the aromatic 
region, each shifted downfield with respect to the ligand. The 13C-NMR spectrum, shown in in 
Figure 127, also exhibited the expected thirteen carbon-13 signals, three of which pertaining to 
the carbonyl ligands were significantly downfield shifted compared to the other aromatic 
signals. The FTIR spectrum of the compound (Figure 128) also provided additional 
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confirmation that the ligand was complexed to the rhenium, due to the observable A’(1) C≡O 
stretching and overlapping A’(2) & A’’ C≡O stretching IR absorption bands at 2019 cm-1 and 
1884 cm-1, respectively. IR absorptions of C−H sp2 hybridised bond stretches were also 
observed at higher wavenumbers (circa 3073 cm-1), evidencing the presence of the bipyridine 
ring. The HRMS spectrum of Re4ClBiPy, shown in Figure 129, shows detection of the 
chlorine-dissociated [M-Cl]+ ion signal (ReC13H7N2O3Cl) observable at m/z 460.9712 against 
a calculated ratio of m/z 460.9703 (Δ 0.9 ppm) for the complex incorporating the 187Re isotope 
in 62.6% natural abundance. An additional signal with m/z 458.9691 is also observed for the 
same ion incorporating the 185Re isotope in 37.4% natural abundance. The UV-Vis spectrum 
of Re6FBiPy in Figure 130 also shows the absorption band for the dπ → π* electronic 
transition to the MLCT excited state at 369 nm, alongside the expected higher energy π → π* 
transitions to LC excited states. Purity of the complex was also further evaluated by elemental 
analysis which measured compositions of 32.52% carbon, 1.33% hydrogen and 5.81% nitrogen 
against calculated compositions of 32.54% carbon, 1.47% hydrogen and 5.84% nitrogen. 
 
Figure 126. 1H-NMR spectrum of Re4ClBiPy in DMSO-d6, showing the expected peak area 
integration for the seven protons in the aromatic region which were shifted 
downfield with respect to the ligand. 
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Figure 127. 13C-NMR spectrum of Re4ClBiPy in DMSO-d6, showing the three downfield 
shifted carbonyl signals with respect to the carbon-13 aromatic signals from the 
bipyridine ring. 
 
Figure 128. FTIR spectrum of Re4ClBiPy exhibiting the distinctive A’(1) C≡O stretching 
IR absorption band at 2019 cm-1 and the overlapping A’(2) & A’’ C≡O 
stretching band at 1884 cm-1. Weak sp2 hybridised C−H bond stretches are also 
observed at higher wavenumbers (circa 3073 cm-1) from the bipyridine ligand. 
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Figure 129. HRMS spectrum of Re4ClBiPy depicting the chlorine-dissociated [M-Cl]+ ion 
signal observable at m/z 460.9712 with a calculated ratio of m/z 460.9703 (Δ 
0.9 ppm) for the complex incorporating the 187Re isotope in 62.6% natural 
abundance. An additional signal with m/z 458.9691 is also observed for the 
same ion incorporating the 185Re isotope in 37.4% natural abundance. 
 
 
Figure 130. UV-Vis spectrum of Re4ClBiPy (5 µg.mL-1 in acetonitrile) showing the 
absorption band for the dπ → π* electronic transition to the MLCT excited state 
at 369 nm, alongside higher energy π → π* transitions to LC excited states with 
greater molar absorptivities. 
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4.1.6 Rhenium Complexation of 4-Fluoro-2,2’-Bipyridine 
 
 
Figure 131. Synthesis of Re4FBiPy via reflux of 4FBiPy with 
pentacarbonylchlororhenium(I) in toluene which afforded the desired product 
in 38% yield. 
 
A mass of 4FBiPy (6.0 mg, 34.5 mmol, 1.0 eq.) was dissolved in a volume of anhydrous 
toluene (1 mL) to which was added a mass of pentacarbonylchlororhenium(I) (12.5 mg, 34.6 
mmol, 1.0 eq.). The solution was then stirred and heated at reflux (4 h). The resulting yellow 
solid was then cooled to 4°C to promote precipitation and was isolated via vacuum filtration 
and washed with toluene and diethyl ether. The yellow product was then loaded onto a neutral 
alumina stationary phase (Brockmann grade II) in a glass pipette and eluted with DCM. The 
eluents confirmed to contain the product were combined, evaporated under reduced pressure 
and dried under high vacuum to attain a yellow powder (6.2 mg). 
Integration of the 1H-NMR spectrum in Figure 132 provides a value of approximately seven as 
expected for the seven protons present in the bipyridine ring of Re4FBiPy. The 13C-NMR 
exhibits seventeen carbon-13 resonance signals, three of which correspond to the downfield 
shifted carbon-13 nuclei of the carbonyl ligands at 197.61, 197.58 and 189.94 ppm. The 
remaining fourteen carbon-13 resonance signals correspond to the ten carbon atoms of the 
bipyridine ring, though with the fluorine-19 nucleus coupling with four of those carbon-13 
nuclei, thus giving rise to the additional four signals. The CPD 19F-NMR spectrum of 
Re4FBiPy, as shown in Figure 134, shows the lone magnetic resonance signal for this fluorine-
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19 nucleus. The FTIR spectrum in Figure 135 provides evidence for the rhenium tricarbonyl 
center with the distinctive A’(1) C≡O stretching frequency being notably excited at 2018 cm-1 
and the overlapping A’(2) & A’’ C≡O stretching vibrations being co-excited at 1884 cm-1. 
 
Figure 132. 1H-NMR spectrum of Re4FBiPy in DMSO-d6, showing the expected peak area 
integration for the seven protons in the aromatic region which were shifted 
downfield with respect to the ligand. The peaks exhibit more complex splitting 
patterns on account of the coupling between the fluorine-19 isotope present in 
the molecule. 
 
 
Figure 133. 13C-NMR spectrum of Re4FBiPy in DMSO-d6, showing the downfield shifted 
carbonyl signals with respect to the carbon-13 aromatic signals from the 
bipyridine ring. Complex splitting is observed due to the coupling between the 
carbon-13 and fluorine-19 nuclei. 
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Figure 134. CPD 19F-NMR spectrum of Re4FBiPy in DMSO-d6 displaying the signal for 
the sole fluorine-19 nucleus in the molecule at -94.71 ppm. 
 
 
Figure 135. FTIR spectrum of Re4FBiPy exhibiting the distinctive A’(1) C≡O stretching 
IR absorption band at 2018 cm-1 and the overlapping A’(2) & A’’ C≡O 
stretching band at 1884 cm-1. Weak sp2 hybridised C−H bond stretches are also 
observed at higher wavenumbers (circa 3041 cm-1) from the bipyridine ligand. 
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4.1.7 Rhenium Complexation of 5-Chloro-2,2’-Bipyridine 
 
 
Figure 136. Synthesis of Re5ClBiPy via reflux of 5ClBiPy with 
pentacarbonylchlororhenium(I) in toluene which afforded the desired product 
in 50% yield. 
 
A mass of 5ClBiPy (195.3 mg, 1.024 mmol, 1.0 eq.) was dissolved in a volume of anhydrous 
toluene (10 mL) resulting in a pale blue coloured solution. A mass of pentacarbonylrhenium(I) 
(337.9 mg, 0.934 mmol, 1.1 eq.) was then added to the solution and heated to 70°C in an inert 
nitrogen atmosphere while stirring (24 h). The solution was then cooled first to room 
temperature, then to 4°C to induce further precipitation before isolating via vacuum filtration 
and washing with both cold toluene and diethyl ether. The yellow product was then dissolved 
in a minimum of DCM and purified on a mobile phase consisting of Brockmann grade II neutral 
alumina (approx. 30 g) eluting with an isocratic gradient of DCM. Those fractions containing 
the desired product were combined, evaporated under reduced pressure and dried under high 
vacuum to afford a yellow powder (232.6 mg). 
Complexation of the 5-chloro-2,2’-bipyridine ligand to the source of tricarbonyl rhenium(I) 
was confirmed by 1H-NMR and 13C-NMR spectroscopy, shown in Figure 137 & Figure 138 
respectively, which affirmed the expected peak area integration for seven protons and ten 
carbon-13 signals in the aromatic region alongside an additional three downfield shifted signals 
for the carbon-13 nuclei present in the carbonyl ligands. The IR absorption bands for these 
carbonyl ligands were also observed in the FTIR spectrum shown in Figure 139, which depicts 
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the A’(1) C≡O and overlapping A’(2) & A’’ C≡O stretching frequencies at 2021 cm-1 and 1883 
cm-1 respectively. Bipyridyl C−H sp2 hybridised bond stretches also gave rise to IR absorption 
bands around 3064 cm-1. The HRMS spectrum of Re5ClBiPy shown in Figure 140 depicts the 
chlorine-dissociated [M-Cl]+ ion signal (ReC13H7N2O3Cl
+) observable at m/z 460.9730 against 
a calculated ratio of m/z 460.9703 (Δ 5.9 ppm) for the complex incorporating the 187Re isotope 
in 62.6% natural abundance. An additional signal with m/z 458.9718 is also observed for the 
same ion incorporating the 185Re isotope in 37.4% natural abundance. The UV-Vis spectrum 
of Re5ClBiPy in Figure 141 shows the absorption band for the dπ → π* electronic transition 
to the MLCT excited state at 379 nm and higher energy π → π* transitions to LC excited states 
at 299 and 241 nm. Elemental analysis further attested to the purity of the complex with 
measured composition of 31.61% carbon, 1.14% hydrogen and 5.44% nitrogen against 
calculated compositions of 31.46% carbon, 1.42% hydrogen and 5.64% nitrogen. 
 
Figure 137. 1H-NMR spectrum of Re5ClBiPy in DMSO-d6, showing the expected peak area 
integration for the seven protons in the aromatic region which were shifted 
downfield with respect to the ligand. 
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Figure 138. 13C-NMR spectrum of Re5ClBiPy in DMSO-d6, showing the three downfield 
shifted carbonyl signals with respect to the carbon-13 aromatic signals from the 
bipyridine ring. 
 
Figure 139. FTIR spectrum of Re5ClBiPy exhibiting the distinctive A’(1) C≡O stretching 
IR absorption band at 2021 cm-1 and the overlapping A’(2) & A’’ C≡O 
stretching band at 1883 cm-1. Weak sp2 hybridised C−H bond stretches are also 
observed at higher wavenumbers (circa 3064 cm-1) from the bipyridine ligand. 
153 
 
 
 
Figure 140. HRMS spectrum of Re5ClBiPy depicting the chlorine-dissociated [M-Cl]+ ion 
signal observable at m/z 460.9730 with a calculated ratio of m/z 460.9703 (Δ 
5.9 ppm) for the complex incorporating the 187Re isotope in 62.6% natural 
abundance. An additional signal with m/z 458.9718 is also observed for the 
same ion incorporating the 185Re isotope in 37.4% natural abundance. 
 
 
Figure 141. UV-Vis spectrum of Re5ClBiPy (5 µg.mL-1 in acetonitrile) showing the 
absorption band for the dπ → π* electronic transition to the MLCT excited state 
at 379 nm, alongside higher energy π → π* transitions to LC excited states with 
greater molar absorptivities. 
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4.1.8 Rhenium Complexation of 6-Bromo-2,2’-Bipyridine 
 
 
Figure 142. Synthesis of Re6BrBiPy via reflux of 6BrBiPy with 
pentacarbonylchlororhenium(I) in toluene which afforded the desired product 
in 86% yield. 
 
A mass of 6BrBiPy (157.0 mg, 0.6679 mmol, 1.1 eq.) was dissolved in a volume of anhydrous 
toluene (5 mL). A mass of pentacarbonylchlororhenium(I) (219.7 mg, 0.6074 mmol, 1.0 eq.) 
was added to the solution, which was then then purged with inert nitrogen gas and stirred at 
reflux (4 h). The solution was then cooled to room temperature thereafter and further cooled to 
-20°C to induce further precipitation of the solid. The yellow solid was then isolated via 
vacuum filtration, washed with sold toluene and diethyl ether, then dried under high vacuum. 
The resulting solid was then dissolved in a minimum of DCM and loaded onto a neutral alumina 
column (Brockmann grade II, approx. 80 g) and eluted using an isocratic mobile phase 
consisting solely of DCM. The fractions containing the purified product of interest were 
combined, evaporated under reduced pressure and dried under high vacuum to afford the 
yellow powder (311.9 mg). 
The 1H-NMR spectrum for Re6BrBiPy, shown in Figure 143, shows the expected integration 
for the seven protons in the aromatic region all downfield shifted with respect to the resonance 
signals of the ligand. In Figure 144 the 13C-NMR spectrum gives rise to the expected thirteen 
carbon-13 nuclei resonance signals, ten of which exist within the aromatic region and pertain 
to the to the atoms within the bipyridine ring, and the other three being significantly downfield 
shifted at 190.0, 197.2 and 198.1 ppm pertaining to the carbonyl ligands. The FTIR spectrum 
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of Re6BrBiPy, shown in Figure 145, exhibits the distinctive A’(1) C≡O stretching IR 
absorption band at 2017 cm-1 and the overlapping A’(2) & A’’ C≡O stretching bands at 1884.31 
cm-1. A weak sp2 hybridised C−H bond stretch is also observed at 3074 cm-1 from the bipyridine 
ligand. The purity of the Re6BrBiPy complex was also verified by elemental analysis which 
measured compositions of 28.90%, 1.05% and 5.21% for carbon, hydrogen and nitrogen, 
respectively. These values closely align with the theoretical compositions of 28.87%, 1.30% 
and 5.18% for carbon, hydrogen and nitrogen, respectively. 
 
 
Figure 143. 1H-NMR spectrum of Re6BrBiPy in DMSO-d6, showing the expected peak 
area integration for the seven protons in the aromatic region which were shifted 
downfield with respect to the ligand. 
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Figure 144. 13C-NMR spectrum of Re6BrBiPy in DMSO-D6, exhibiting not only the ten 
aromatic carbon-13 signals from the bipyridine system though also showing the 
three downfield shifted carbonyl signals of the rhenium complex (190.0, 197.2 
& 198.1 ppm). 
 
Figure 145. FTIR spectrum of Re6BrBiPy exhibiting the distinctive A’(1) C≡O stretching 
IR absorption band at 2017 cm-1 and the overlapping A’(2) & A’’ C≡O 
stretching band at 1884 cm-1. A weak sp2 hybridised C−H bond stretch is also 
observed at 3074 cm-1 from the bipyridine ligand. 
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4.1.9 Characterisation Data for the Rhenium Complexed 2,2-
Bipyridine Standards and Precursors 
 
Tricarbonylchloro(6-chloro-2,2’-bipyridine)rhenium(I) (Re6ClBiPy) Yellow solid; MP: 
255 °C; 86% yield. 1H NMR (400 MHz, DMSO-d6, δ/ppm): δ 9.06 (d, Jd=4.76 Hz, 1H), δ8.76 
(d, Jd=8.12 Hz, 2H), δ 8.35 (app. td, Jd=1.96, Jt=8.04 Hz, 2H), δ 8.08 (dd, Jd=0.68, 8.04 Hz, 
1H), δ 7.78 (app. td, Jd=1.80, Jt=4.56 Hz, 1H). 13C{1H} 
 NMR (100 MHz, DMSO-d6, δ/ppm): δ 197.5C≡O, δ 197.3C≡O, δ 189.5C≡O, δ 157.2, δ 155.6, δ 
153.2, δ 152.8, δ 142.7, δ 140.3, δ 128.0, δ 127.7, δ 125.3, δ 123.1. FTIR (ATR corr. ṽ/cm-1): 
ṽ 3075 (w, C−H sp2 str.), ṽ 2018 (s, A’(1) C≡O str.), ṽ 1882 (s, A’(2) & A’’ C≡O str.). UV/Vis 
(λ/nm, ε/L.mol-1.cm-1): λ 380 (dπ→π*, ε 3375.36), λ 301 (π→π*, ε 14990.57), λ 326 (π→π*, ε 
10920.28), λ 233 (π→π*, ε 19259.41). LRMS (ESI+): [M-Cl]+ m/z cald: 460.97, m/z obvs 
460.95. HRMS (ESI+): [M-Cl]+ m/z cald: 460.9703, m/z obvs 460.9694 (Δ -2.0 ppm). EA (%): 
calc. C 31.46, H 1.42, N 5.64. found C 31.59, H 1.17, N 5.70. 
Tricarbonylchloro(6-fluoro-2,2’-bipyridine)rhenium(I) (Re6FBiPy) Yellow solid; MP: 294 °C, 
65% yield. 1H NMR (400 MHz, DMSO-d6, δ/ppm): δ 9.06 (app. tq, Jt =5.48 Hz, Jq=0.80 Hz, 
1H), δ 8.80 (d, Jd=8.16 Hz, 1H), δ 8.70 (d, Jd=7.92 Hz, 1H), δ 8.52 (q, Jq=8.04 Hz, 1H), δ 8.36 
(td, Jt=8.08 Hz, Jd=1.52 Hz, 1H), δ 7.80 (m, 2H). 13C{1H} NMR (100 MHz, DMSO-d6, δ/ppm): 
δ 197.2C≡O, δ 196.6C≡O (d, Jd=16.59 Hz), δ 188.9C≡O, δ 164.0, δ 161.5, δ 154.4 (d, Jd=15.92 Hz), 
δ 153.1, δ 145.9 (d, Jd=10.15 Hz), δ 140.4, δ 128.2, δ 125.1, δ 121.4 (d, Jd=2.94 Hz), δ 112.7 
(d, Jd=30.19 Hz). 19F{1H} NMR (376 MHz, DMSO-d6, δ/ppm): δ -51.75. FTIR (ATR corr. 
ṽ/cm-1): ṽ 3040 (w, C−H sp2 str.), ṽ 2016 (s, A’(1) C≡O str.), ṽ 1880 (s, A’(2) & A’’ C≡O str.). 
UV/Vis (λ/nm, ε/L.mol-1.cm-1): λ 369 (dπ→π*, ε 2768.36), λ 296 (π→π*, ε 12485.88), λ 235 
(π→π*, ε 15367.33). LRMS (ESI+): [M-Cl]+ m/z cald: 445.00, m/z obvs 445.10. EA (%): calc. 
C 32.54, H 1.47, N 5.84. found C 32.59, H 1.16, N 5.88. 
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4-fluoro-2,2’-bipyridine (4FBiPy). White solid; 42% yield. 1H NMR (400 MHz, DMSO-d6, 
δ/ppm): δ 8.87 (s, 1H), δ 8.79 (s, 1H), δ 8.62 (d, Jd=5.58 Hz, 1H), δ 8.34 (t, Jt=7.28 Hz, 1H), δ 
7.70 (s 1H), 7.28 (s 1H). 13C{1H} NMR (100 MHz, DMSO-d6, δ/ppm): δ 127.04, δ 169.37, δ 
159.4 (d, Jd=39 Hz), δ 158.7 (d, Jd=39 Hz), δ 151.26, δ 146.70, δ 143.20, δ 125.7 (d, Jd=239 
Hz), δ 116.70, δ 113.84. 19F{1H} NMR (376 MHz, DMSO-d6, δ/ppm): δ -75.99. LRMS (ESI+): 
[M+H]+ m/z cald: 175.07, m/z obvs175.12. 
Tricarbonylchloro(4-chloro-2,2’-bipyridine)rhenium(I) (Re4ClBiPy). Yellow solid; MP: 
283 °C; 89% yield. 1H NMR (400 MHz, DMSO-d6, δ/ppm): δ 9.04 (d, Jd=4.68 Hz, 1H), δ 9.01 
(d, Jd=2.04 Hz, 1H), δ 8.96 (d, Jd=6.00 Hz, 1H), δ 8.85 (d, Jd=8.16 Hz, 1H), δ 8.36 (app. td, 
Jt=8.04 Hz, Jd=1.32, 1H), δ 7.88 (dd, Jd=2.12, 6.00 Hz, 1H), δ 8.36 (app. td, Jd=1.12, Jt=5.56 
Hz, 1H). 13C{1H} NMR (100 MHz, DMSO-d6, δ/ppm): δ 197.6C≡O, δ 197.5C≡O, δ 189.7C≡O, δ 
156.9, δ 154.3, δ 153.8, δ 153.1, δ 147.0, δ 140.3, δ 128.4, δ 127.7, δ 125.0, δ 124.7. FTIR 
(ATR corr. ṽ/cm-1): ṽ 3117 (w, C−H sp2 str.), ṽ 2019 (s, A’(1) C≡O str.), ṽ 1884 (s, A’(2) & 
A’’ C≡O str.). UV/Vis (λ/nm, ε/L.mol-1.cm-1): λ 380 (dπ→π*, ε 7548.93), λ 292 (π→π*, ε 
38022.44), λ 235 (π→π*, ε 48347.07). LRMS (ESI+): [M-Cl]+ m/z cald: 460.97, m/z obvs 
460.95. HRMS (ESI+): [M-Cl]+ m/z cald: 460.9703, m/z obvs 460.9712 (Δ 2.0 ppm). EA (%): 
calc. C 31.46, H 1.42, N 5.64. found C 31.81, H 1.20, N 5.32. 
Tricarbonylchloro(4-fluoro-2,2’-bipyridine)rhenium(I) (Re4FBiPy). Yellow solid; MP: 
302 °C; 38% yield. 1H NMR (400 MHz, DMSO-d6, δ/ppm): δ 9.04 (app. t, Jt=6.72 Hz, 2H), δ 
8.78 (m, 2H), δ 8.36 (td, Jd=1.44, Jt=7.92 Hz, 1H), δ 7.79 (qd, Jd=1.12, Jq=7.56 Hz, 1H), δ 7.69 
(qd, Jd=1.00, Jq=7.36 Hz, 1H). 13C{1H} NMR (100 MHz, DMSO-d6, δ/ppm): δ 197.6C≡O, δ 
197.6C≡O, δ 189.9C≡O, δ 168.3, δ 168.3, δ 158.9 (d, Jd=10.26 Hz), δ 156.2 (d, Jd=9.99 Hz), δ 
154.6, δ 153.1, δ 140.5, δ 128.5, δ 124.9, δ 116.0 (d, Jd=19.7 Hz), δ 113.0 (d, Jd=22.79 Hz). 
19F{1H} NMR (376 MHz, DMSO-d6, δ/ppm): δ -94.71. FTIR (ATR corr. ṽ/cm-1): ṽ 3117 (w, 
C−H sp2 str.), ṽ 2018 (s, A’(1) C≡O str.), ṽ 1884 (s, A’(2) & A’’ C≡O str.). LRMS (ESI+): [M-
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Cl]+ m/z cald: 445.00, m/z obvs 444.92. EA (%): calc. C 32.54, H 1.47, N 5.84. found C 32.52, 
H 1.33, N 5.81.  
Tricarbonylchloro(5-chloro-2,2’-bipyridine)rhenium(I) (Re5ClBiPy). Yellow solid; MP: 
292 °C, 50% yield. 1H NMR (400 MHz, DMSO-d6, δ/ppm): δ 9.03 (d, Jd=2.28 Hz, 2H), δ 8.80 
(t, Jt=8.92 Hz, 2H), δ 8.55 (dd, Jd=8.84, 2.28 Hz, 1H), δ 8.35 (td, Jt=8.04 Hz, Jd = 1.32 Hz, 1H), 
δ 7.77 (app. qd, Jq=5.68 Hz, Jd=1.16 Hz, 1H). 13C{1H} NMR (100 MHz, DMSO-d6, δ/ppm): δ 
197.5C≡O, δ 197.2C≡O, δ 189.6C≡O, δ 154.2, δ 154.1, δ 153.0, δ 150.9, δ 140.4, δ 140.2, δ 133.9, 
δ 128.1, δ 125.3, δ 124.8. FTIR (ATR corr. ṽ/cm-1): ṽ 3113 (w, C−H sp2 str.), ṽ 2021 (s, A’(1) 
C≡O str.), ṽ 1883 (s, A’(2) & A’’ C≡O str.). UV/Vis (λ/nm, ε/L.mol-1.cm-1): λ 379 (dπ→π*, ε 
7346.37), λ 299 (π→π*, ε 36136.21), λ 241 (π→π*, ε 42589.10). LRMS (ESI+): [M-Cl]+ m/z 
cald: 460.97, m/z obvs 460.95. HRMS (ESI+): [M-Cl]+ m/z cald: 460.9703, m/z obvs 460.9730 
(Δ 5.9 ppm). EA (%): calc. C 31.46, H 1.42, N 5.64. found C 31.61, H 1.14, N 5.44. 
Tricarbonylchloro(6-bromo-2,2’-bipyridine)rhenium(I) (Re6BrBiPy). Yellow solid; MP: 
260 °C, 86% yield. 1H NMR (400 MHz, DMSO-d6, δ/ppm): δ 9.06 (dd, Jd=5.48 Hz, 0.80 Hz, 
1H), δ 8.77 (q, Jq=5.16 Hz, 4.08 Hz, 1H), δ 8.71 (d, Jd=8.24 Hz, 1H), δ 8.33 (td, Jt=8.08 Hz, 
Jd=1.52 Hz, 1H), δ 8.20 (d, Jd=1.40 Hz, 1H), δ 8.19 (s, 1H), δ 7.76 (qd, Jq=5.52 Hz, 1.24 Hz, 
Jd=1.04 Hz, 1H). 13C{1H} NMR (100 MHz, CD3CN, δ/ppm): δ 198.1C≡O, δ 197.2C≡O, δ 190.0C≡O, 
δ 157.6, δ 156.0, δ 152.7, δ 146.2, δ 142.0, δ 140.2, δ 131.9, δ 127.8, δ 125.3, δ 123.3. FTIR 
(ATR corr. ṽ/cm-1): ṽ 3074 (w, C−H sp2 str.), ṽ 2017 (s, A’(1) C≡O str.), ṽ 1884 (s, A’(2) & 
A’’ C≡O str.). LRMS (ESI+): [M-Cl]+ m/z cald: 504.92, m/z obvs 505.04. EA (%): calc. C 
28.87, H 1.30, N 5.18. found C 28.90, H 1.05, N 5.21.  
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4.2 Radiosyntheses of Rhenium-Bipyridine Complexes 
 
4.2.1 Fluorine-18 Radiolabelling of Rhenium Complexed 6-
Chloro-2,2’-Bipyridine 
 
The synthesised non-radioactive standards of 6FBiPy and Re6FBiPy were first injected onto 
the radio-HPLC using the standard chromatographic conditions described in the experimental. 
The UV-absorption profiles of both compounds are superimposed on the chromatogram in 
Figure 146 and affirm an approximate 2.1 min elution time for 6FBiPy and 7.7 min for 
Re6FBiPy which were then used to identify the radioproducts. A series of radiolabelling 
reactions were then performed on the Re6ClBiPy precursor under dry microfluidic conditions 
using standard reaction conditions (0.08 µmol of precursor, 29±10 MBq of [18F]fluoride and 
47 s reaction time) with the temperature raised by 20 °C between each experiment, ranging 
from 50 to 190 °C. Surprisingly, not only was fluorine-18 labelling of the complex observed 
to form [18F]Re6FBiPy though the radiolabelled complex was also found to dissociate at higher 
temperatures to afford the [18F]6FBiPy ligand. This phenomenon is illustrated by the 
superimposed radiochromatographic profiles for the reaction at 130 °C (blue trace) and 190 °C 
(orange trace) in Figure 147. At temperatures of 130 °C and lower the reaction was found to 
reliably form [18F]Re6FBiPy, with little or no dissociation observed at all. At temperatures 
greater than 170 °C, dissociation of the complex appeared to form the [18F]6FBiPy 
radiolabelled ligand in greater concentration than the initial [18F]Re6FBiPy product. An 
unknown by-product was also found to form concurrently with the dissociation process, 
however, with a retention time of 6.6 mins between both the ligand and precursor. This 
uncharacterised compound could potentially be due to [18F]fluoride substitution for the chloro 
ancillary ligand bonded to the rhenium, however a non-radioactive standard of such a 
compound would first need to be synthesised to assign such an identity. 
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Figure 146. UV-absorbance chromatograms for 6FBiPy (orange trace) and Re6FBiPy (blue 
trace) providing approximate elution times of 2.1 min and 7.7 min, respectively, 
which were used to assign the identities of the radioproducts. DMSO is also 
observed to elute early at 0.5 min with the initially aqueous mobile phase. 
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Figure 147. Radiochromatogram profiles for the fluorine-18 radiolabelling of Re6ClBiPy 
at 130 °C (blue trace) and 190 °C (orange trace). At 130 °C [18F]Re6FBiPy (7.6 
min) reliably forms, whereas at 190 °C the complex dissociates to form the 
otherwise unobtainable [18F]6FBiPy (2.2 min) as well as an unknown by-
product (6.6 min). 
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To confirm that the Re6ClBiPy precursor was not in fact dissociating to form the 6ClBiPy 
ligand, which in turn may have been radiolabelled to afford the observed [18F]6FBiPy 
radioproduct, we performed the same reactions under analogous conditions using the only the 
6ClBiPy precursor. To our surprise, despite several attempts the 6ClBiPy would not radiolabel 
to afford the [18F]6FBiPy radioproduct. Thus, it was found that the [18F]6FBiPy radiolabelled 
ligand could only be attained by radiolabelling the Re6ClBiPy precursor with [18F]fluoride 
under temperatures which also enabled decomplexation to liberate [18F]6FBiPy. This process 
is illustrated in Figure 148, which also plots the RCYs of the [18F]Re6FBiPy, [18F]6FBiPy and 
unknown radioproducts as a function of the reaction temperature. Within this plot we observe 
the RCY of [18F]Re6FBiPy increase from 8% at 50 °C to a maximum of 82% at 130 °C, where 
after the complex dissociates forming only 3% at a higher temperature of 190 °C. Meanwhile, 
[18F]6FBiPy was not found to form at 70 °C or lower, though did start to form in 5% RCY at 
90 °C and steadily increased at higher temperatures affording 65% RCY at 190 °C. The 
unidentified by-product appeared to form in a similar trend to the ligand, forming in only 2% 
RCY at 90 °C and then steadily increasing at higher temperatures to yield 20% at 190 °C. In 
an effort to increase the RCY of the [18F]6FBiPy, experiments were further trialled under the 
same conditions at 190 °C though with the flow rate adjusted to 5 µL.min-1 and 2 µL.min-1 
(reaction times of 3.12 min and 7.8 min, respectively). In the reaction applying a flow rate of 
5 µL.min-1, [18F]6FBiPy was found to form in 56% RCY and the uncharacterised product was 
found to form in 27%. Whereas in the reaction applying a flow rate of 2 µL.min-1, [18F]6FBiPy 
was found to form in 38% RCY and the unknown product was found to form in 25%, 
suggesting that longer reaction times were inhibiting the formation of the [18F]6FBiPy 
radioproduct. In both experiments the [18F]Re6FBiPy radioproduct did not form in any 
measurable yield. Given that none of these reactions formed greater than 65% RCY observed 
using a flow rate of 20 µL.min-1 a 190 °C, the reaction was again repeated though using a ten-
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fold equivalence of the Re6ClBiPy precursor (0.80 µmol) while applying a 4 µL.min-1 flow 
rate (3.9 min reaction time). In this experiment [18F]Re6FBiPy was found to form in 66% RCY, 
though [18F]6FBiPy only dissociated to form in 20% RCY. These conditions did suppress the 
formation of the unknown product, however, which only formed in 3% RCY. 
 
Figure 148. RCYs of [18F]Re6FBiPy (blue diamonds), [18F]6FBiPy (orange crosses) and 
the unknown by-product (green circles) as a function of the reaction temperature. 
The above scheme also shows how the fluorine-18 radiolabelling of 6ClBiPy 
was unable to afford the [18F]6FBiPy radioproduct, whereas the complex 
Re6ClBiPy was able to form the [18F]Re6FBiPy radioproduct which could then 
be thermally dissociated to form the [18F]6FBiPy ligand in considerable RCY. 
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The reactions were also performed under wet conditions, given how the 10% v/v content of 
water improved the yield of the fluorine-18 labelled rhenium complexes of the phenanthroline 
ligands. The RCY of [18F]Re6FBiPy, [18F]6FBiPy and the unknown product are each plotted 
in Figure 149 as a function of the reaction temperature for these experiments employing the 
same reaction conditions (0.08 µL of Re6ClBiPy, 29±10 MBq of radioactivity and a 47 s 
reaction time) though with wet DMSO solvent. These experiments greatly favoured the 
formation of the unidentified by-product which formed in 15% RCY for the experiment at 
90 °C and then stabilised with maximal RCYs of 37%, 41%, 42% and 36% for reactions at 
temperatures of 110 °C, 130 °C,  150 °C and 170 °C, respectively. The yield of uncharacterised 
by-product then decreased considerably to 4% RCY when performing the reaction at 190 °C. 
By contrast,  [18F]Re6FBiPy revealed the same reaction profile, whereupon the RCY of the 
reaction steadily increased as a function of reaction temperature before steadily decomplexing 
at higher temperatures; as evident by 1% RCY forming at 50 °C, 3% RCY forming at 70 °C, 
6% RCY forming at 90 °C, 17% RCY forming at 110 °C and a maximum 29% RCY forming 
at 130 °C, before decreasing to 25% RCY at 150 °C, 6% RCY forming at 170 °C and finally 
forming again only 1% RCY at 190 °C. The fluorine-18 labelled [18F]6FBiPy ligand also 
followed the expected trend, though with no radioproduct forming up to 110 °C, followed by 
an incremental increase to 7% RCY at 130 °C, 15% RCY at 150 °C, 22% RCY at 170 °C and 
24% RCY at 190 °C as the  [18F]Re6FBiPy radioproduct steadily decomplexed. These 
experiments were also repeated at 190 °C while applying different flow rates of 5 µL.min-1 and 
2 µL.min-1 as per the dry  conditions. With the wet reaction conditions repeated at 5 µL.min-1, 
[18F]6FBiPy formed in 15% RCY and the unknown by-product formed in 27% RCY, whereas 
[18F]Re6FBiPy did not form at all. When repeating the reaction at 2 µL.min-1 [18F]6FBiPy 
formed in 10% RCY and the unidentified by-product formed in 26% RCY, with the 
[18F]Re6FBiPy again forming 0% RCY. A final experiment performed under wet conditions 
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applied a flow rate of 4 µL.min-1 with a ten-fold increase of the precursor amount to 0.80 µmol 
of Re6ClBiPy (analogous to the dry reaction experiment), which afforded 54% of 
[18F]Re6FBiPy, 5% of [18F]6FBiPy and 19% of the uncharacterised product, respectively. 
Thus, unlike the dry reaction conditions, applying a greater molar amount of the precursor 
under the wet reaction conditions afforded a considerably greater yield of the fluorine-18 
labelled rhenium complex. 
 
 
Figure 149. RCYs of [18F]Re6FBiPy (blue diamonds), [18F]6FBiPy (orange crosses) and 
the unknown by-product (green circles) plotted as function of reaction 
temperature for the same reaction parameters employing wet DMSO solvent 
(10% v/v content of water). 
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4.2.2 Fluorine-18 Radiolabelling of Rhenium Complexed 6-
Bromo-2,2’-Bipyridine 
 
Given the successful fluorine-18 radiolabelling of Re6ClBiPy and its thermal decomplexation 
to yield the [18F]6FBiPy ligand, which could not be attain via traditional fluorine-18 labelling 
of the ligand, the reactions were again repeated using the Re6BrBiPy precursor to determine 
whether grater RCYs for both the [18F]Re6FBiPy complex and [18F]6FBiPy ligand could be 
achieved. Figure 150 shows the superimposed radiochromatographic profiles for the fluorine-
18 radiolabelling of Re6BrBiPy at 110 °C (blue trace) and 190 °C (orange trace). A similar 
trend was observed whereupon the [18F]Re6FBiPy labelled complex reliably formed at 
temperatures up to 110 °C. At 190 °C the [18F]Re6FBiPy radioproduct had almost entirely 
dissociated to liberate the earlier eluting radiolabelled [18F]6FBiPy ligand, as well as an 
unknown by-product. Curiously, this radioactive by-product formed from the high-temperature 
radiolabelling of Re6BrBiPy shared the same 6.6 min retention time as the uncharacterised by-
product formed from the fluone-18 labelling of Re6ClBiPy. This may suggest either suggest 
that the familiar by-product is not due to [18F]fluoride substitution for the chloro ancillary 
ligand bonded to the rhenium, or that the rhenium-[18F]fluoride bonded complexes were not 
dissimilar enough in their chemical properties to be separated given the standard 
chromatographic conditions employed. The radiolabelling of the 6BrBiPy precursor gave no 
radioproduct, akin to the results attained for the 6ClBiPy precursor. Thus the [18F]6FBiPy 
ligand could only be radiosynthesised via fluorine-18 radiolabelling and subsequent 
decomplexation of the Re6BrBiPy and Re6ClBiPy precursors. Figure 151 plots the RCY of 
[18F]Re6FBiPy, [18F]6FBiPy and the unidentified product formed from the radiolabelling of 
Re6BrBiPy as a function of reaction temperature. Evidently the plot exhibited a similar trend 
to the radiolabelling of Re6ClBiPy, with [18F]Re6FBiPy having formed in 5% RCY at 50 °C 
before plateauing with maximum RCYs of 69%, 72% and 70% at temperatures of 90 °C, 
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110 °C and 130 °C, respectively. The RCY of  [18F]Re6FBiPy then decreased at higher 
temperature conditions, eventually forming only 4% RCY at 190 °C. Conversely, the 
[18F]6FBiPy radiolabeled ligand did not form at 50 °C, though afforded 5% RCY at 70 °C and 
continued to synthesise in greater amounts peaking at 51% RCY at 190 °C as [18F]Re6FBiPy 
decomplexed. The unknown product, also not forming at 50 °C, appeared in only trace amounts 
between 1 to 3% RCY for reaction temperatures between 70 and 150 °C, before also increasing 
to form in 8% and 25% RCY at temperatures of 170 °C and 190 °C, respectively. 
 
Figure 150. Radiochromatogram profiles for the fluorine-18 radiolabelling of Re6BrBiPy 
at 110 °C (blue trace) and 190 °C (orange trace). At 110 °C [18F]Re6FBiPy (7.6 
min) reliably forms, whereas at 190 °C the complex dissociates to form the 
otherwise unobtainable [18F]6FBiPy (2.2 min) as well as an unknown by-
product (6.6 min). 
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Figure 151.  RCYs of [18F]Re6FBiPy (blue diamonds), [18F]6FBiPy (orange crosses) and 
the unknown by-product (green circles) as a function of the reaction temperature. 
The above scheme also shows how the fluorine-18 radiolabelling of 6BrBiPy 
was unable to afford the [18F]6FBiPy radioproduct, whereas the rhenium 
complexed Re6BrBiPy was able to form the [18F]Re6FBiPy radioproduct 
which could then be thermally dissociated to form the [18F]6FBiPy ligand in 
considerable RCY. 
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4.2.3 Fluorine-18 Radiolabelling of Rhenium Complexed 4-
Chloro-2,2’-Bipyridine 
 
To determine whether rhenium complexation could also mediate [18F]fluoride radiolabelling 
in the para position of 2,2’-bipyridine rings, radiofluorinations were additionally performed on 
the Re4ClBiPy precursor. The non-radioactive standards were again injected on the radio-
HPLC to determine their retention times via UV-absorption detection. The UV-absorption 
chromatograms of both the 4FBiPy and Re4FBiPy standards are superimposed in Figure 152 
and affirm approximate retention times of 2.1 mins and 7.6 mins, respectively. Figure 153 
shows the profile of the radiochromatogram obtained for the fluorine-18 radiolabelling of 
Re4ClBiPy at 130 °C (blue trace) and 190 °C (orange trace). At 130 °C the [18F]Re6FBiPy is 
found to form almost exclusively, as expected based upon the radiolabeling of Re6ClBiPy and 
Re6BrBiPy. However, while decomplexation did occur to form the [18F]4FBiPy radioligand 
in considerable RCY, the unknown product was instead found to form in slightly higher 
abundance from integration of the radiochromatographic peak areas. The unidentified peak 
forming from Re4ClBiPy was found to elute at 6.7 mins, slightly offset from the shared identity 
of the unknown peak forming from both Re6ClBiPy and Re6BrBiPy, further supporting the 
theory that the product could be due to [18F]fluorine substitution at site of the Re−Cl bond. 
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Figure 152. UV-absorbance chromatograms for 4FBiPy (orange trace) and Re4FBiPy (blue 
trace) providing approximate elution times of 2.1 min and 7.6 min, respectively, 
which were used to assign the identities of the radioproducts. DMSO is also 
observed to elute early at 0.5 min with the initially aqueous mobile phase. 
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Figure 153. Radiochromatogram profiles for the fluorine-18 radiolabelling of Re4ClBiPy 
at 130 °C (blue trace) and 190 °C (orange trace). At 130 °C [18F]Re4FBiPy (7.5 
min) reliably forms, whereas at 190 °C the complex dissociates to form the 
otherwise unobtainable [18F]4FBiPy (2.1 min) as well as an unknown by-
product (6.7 min). 
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To likewise confirm that the radioligand was not being radiosynthesised from [18F]fluoride 
substitution with the 4ClBiPy ligand thermally decomplexed from the Re6ClBiPy precursor, 
analogous radiolabelling experiments were performed solely on the ligand in the absence of 
rhenium. In each of these experiments, under analogous conditions, no [18F]4FBiPy product 
was observed, which was unsurprising given no radioproduct had formed from fluorine-18 
labelling experiments with the 6ClBiPy and 6BrBiPy precursors either. Thus, it was 
discovered that [18F]4FBiPy could also only form from subsequent decomplexation of the 
[18F]Re4FBiPy radioproduct. Figure 154 portrays a representation of this scheme, alongside a 
plot detailing the RCYs obtained for [18F]Re4FBiPy, [18F]4FBiPy and the unknown by-
product as a function of reaction temperature for the fluorine-18 labelling of the Re4ClBiPy 
precursor. The RCY of [18F]Re4FBiPy was found to increase with temperature up until 130 °C, 
with RCYs of 5%, 11%, 35%, 54% and 68% forming at temperatures of 50 °C, 70 °C, 90 °C, 
110 °C and 130 °C respectively. Thereafter, decomplexation resulted in lower RCYs for 
reaction temperatures greater than 130 °C, decreasing to as low as 2% RCY at 190 °C. With 
the rise in reaction temperature, [18F]4FBiPy was found to first form in 6% RCY at 130 °C, 
followed by 16% RCY at 150 °C, 24% RCY at 170 °C and finally plateauing in 27% RCY at 
190 °C. The reason for [18F]4FBiPy not forming until 130 °C, whereas [18F]6FBiPy had 
decomplexed at temperatures as low as 50 °C or 70 °C, is likely due to the slightly lesser RCY 
yielded for  [18F]Re4FBiPy compared to [18F]Re6FBiPy, which in turn would suggest there 
was less of the radiolabeled complex available for thermal dissociation to liberate the 
radiolabeled ligand. The surprising quantity of the radioactive by-product, having formed from 
the radiofluorination of Re4ClBiPy, is also observed in 2% to 6% RCY between 90 °C and 
150 °C, before rising to 17% RCY at 170 °C and ultimately surpassing the concentration of 
[18F]4FBiPy with 31% RCY forming at 190 °C. Wet reaction temperatures were not tested 
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given the considerable yield of the by-product that was observed when radiolabellings 
Re6ClBiPy under such conditions. 
 
Figure 154. RCYs of [18F]Re4FBiPy (blue diamonds), [18F]4FBiPy (orange crosses) and 
the unknown by-product (green circles) as a function of the reaction temperature. 
The above scheme also shows how the fluorine-18 radiolabelling of 4ClBiPy 
was unable to afford the [18F]4FBiPy radioproduct, whereas the rhenium 
complexed Re4ClBiPy was able to form the [18F]Re4FBiPy radioproduct 
which could then be thermally dissociated to form the [18F]4FBiPy ligand in 
considerable RCY. 
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4.2.4 Fluorine-18 Radiolabelling of Rhenium Complexed 5-
Chloro-2,2’-Bipyridine 
 
The fluorine-18 radiolabelling of Re5ClBiPy was also trialled in order to determine whether 
nucleophilic aromatic substitution for [18F]fluoride could be achieved in the meta position of 
2,2’-bipyridine ligands. This test was important towards determining whether rhenium-
mediated nucleophilic aromatic substitution for [18F]fluoride could occur in an electronically 
unfavoured position on the molecule. The reason for the meta position of Re5ClBiPy being 
resistant to radiofluorination compared to the ortho and para positions of the Re6ClBiPy and 
Re4ClBiPy complexes could likely be due to the inability of the complex to form a resonance 
stabilised intermediate following nucleophilic substitution, as shown by the proposed reaction 
mechanisms in Figure 155. Such radiofluorinations in these meta positions of pyridinyl 
compounds are reportedly difficult to achieve and it was questioned whether metal activation 
from the rhenium centre could aid in such radiolabellings. However, under analogous 
conditions to the previous reaction no radioproduct was observed. A peak of comparatively 
low signal-to-noise ratio was however observed at 190°C when decreasing the flow rate from 
20 µL.min-1 down to 5 µL.min-1 (i.e. from a 47 s reaction time to a 188 s reaction time as per 
equation (14)). This peak eluted at 5.1 min, as shown in Figure 156, using non-standard 
chromatographic conditions which omitted the 3 min held aqueous phase and thus consisted of 
only a 12 min run time. The peak occurs alongside a significant amount of unreacted 
[18F]fluoride, and peak area integration revealed the radioproduct to have only formed in less 
than 1% RCY. This peak is hypothesised to correspond to the radiolabelled [18F]Re5FBiPy 
complex, however, because the non-radioactive standard was unable to be synthesised there is 
currently no means of assigning an identity to the radioproduct. 
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Figure 155. Unlike the ortho and para substituted Re6ClBiPy and Re4ClBiPy complexes, 
the meta substituted Re5ClBiPy formed no resonance stabilised intermediate 
during nucleophilic aromatic substitution for [18F]fluoride. 
 
Figure 156. Radiochromatogram for the radiolabelling of Re5ClBiPy with [18F]fluoride 
(0.65 min). A small peak is observed at 5.1 min which may pertain to the 
[18F]Re5FBiPy radioproduct, however a non-radioactive standard was unable 
to be synthesised to confirm the identity. 
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With a mechanistic understanding of the differing reaction pathways, two microreactors used 
in series could potentially improve the RCYs of the desired fluorine-18 labelled ligands using 
such a rhenium complexation-dissociation approach. Figure 157 illustrates the reaction 
pathways which are known to lead to the radiolabelled complex and ligands, therein simply 
labelled as [18F]ReFBiPy and [18F]FBiPy to express that the scheme could represent fluorine-
18 labelling in any position of the bipyridine ligand. Because [18F]FBiPy has been shown not 
to form from the radiofluorination of the ligand precursor via nucleophilic aromatic substation, 
any rate of ReXBiPy precursor dissociation (kpd) would inhibit the ligand from being 
radiofluorinated due to the absence of the rhenium activation effect. Thus, the rate constant for 
radiofluorination (krf) of the rhenium precursor would need to compete with this process, such 
that subsequent [18F]ReFBiPy radioproduct dissociation (krd) could afford the maximum 
amount of the radiolabelled [18F]FBiPy ligand. As the ideal reaction conditions influencing the 
processes defined by the kpd and krd rate constants are likely to be similar, future work could 
be used to determine the optimal temperature conditions which would allow for the 
optimisation of the radiofluorination process governed by the krf rate constant. The first 
microreactor in the series would then ideally afford a lower temperature to optimise the rate of 
radiofluorination (krf) while reducing the rate of precursor dissociation (kpd), thus producing 
the maximum amount of  [18F]ReFBiPy. The second microreactor, thereafter, would ideally 
afford a higher temperature which would optimise radioproduct dissociation (krd) to produce 
more of the [18F]FBiPy ligand. Multiple analyses would need to be undertaken, however, to 
ensure that the radioproduct is not lost due to the formation of the uncharacterised by-product 
whose identity, and thus reaction pathways, are currently unknown. The minor non-radioactive 
impurities indicated by the chromatographic peaks at circa 7 mins in both Figure 146 and 
Figure 152 for the [18F]Re6FBiPy and [18F]Re4FBiPy standards, if removed or isolated, could 
potentially aid identification of these uncharacterised by-products in future experiments. 
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Figure 157. Differing optimal temperature conditions (among other factors) may influence 
the dissociation of the rhenium precursor (kpd) and the radiofluorination of the 
rhenium complex (krf) prior to its dissociation to form the radiolabelled ligand 
(krd) which could not be attained from the radiofluorination of any of the ligand 
precursors. 
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4.3 Determination of Rhenium-Bipyridine Quantum Yields 
 
Quantum yields were determined for Re6ClBiPy, Re5ClBiPy, Re4ClBiPy and Re6FBiPy 
complexes in DMSO solution. Figure 158 to Figure 161 illustrate the emission spectra for each 
complex following fixed monochromatic excitation at 410 nm, the integration of which were 
substituted into equation (14) alongside the 1.479 refractive index of the DMSO solvent the 
compounds were dissolved in and the absorbance of the compounds at 410 nm, each listed in 
Table 9. The refractive index, absorbance at 410 nm and integration of the emission spectrum 
attained from a 410 nm excitation wavelength for the [Ru(BiPy)3]Cl reference standard were 
likewise substituted into equation (14) to attain the quantum yield for each complex in DMSO 
solution. The quantum yield of Re6ClBiPy proved to be 0.5% given an absorbance of 0.337 at 
410 nm and an emission integration of 5.14×106 counts⋅nm. Comparatively the quantum yield 
of Re5ClBiPy proved to be twice as large at 1.0% given an absorbance of 0.321 at 410 nm and 
an emission integration of 9.57×106 counts⋅nm. The quantum yields of both Re4ClBiPy and 
Re6FBiPy were determined to be 0.6% given absorbances of 0.369 and 0.2380 at 410 nm and 
emission integrations of 6.19×106 counts⋅nm and 4.95×106 counts⋅nm, respectively. 
Experimental uncertainties are estimated to be ±0.1% for each of these determined quantum 
yields. While each of these quantum yields are greater than the 0.3% quantum yield determined 
for both Re2ClPhen and Re2FPhen phenanthroline coordinated complexes, they were still an 
order of magnitude below the quantum yields reported for BODIPY based PET-Optical tracers. 
Thus, reinforcing the need for coordination of an N-heterocyclic ligand to the ancillary ligand, 
to improve quantum yields as reported in the literature, though which feel outside of the scope 
for the work reported herein.[86-88] 
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Table 9. Quantum yields calculated for the Re6ClBiPy, Re5ClBiPy, Re4ClBiPy and 
Re6FBiPy complexes via comparison to a [Ru(BiPy)3]Cl2 reference standard 
with correction factors applied for the refractive index of the media, 
absorbances at the 410 nm excitation wavelength and the integrations of the 
emission spectra. 
Analyte Solvent 
Refractive 
Index 
Absorbance 
Emission 
Integration 
(counts⋅nm) 
Quantum 
Yield (%) 
[Ru(BiPy)3]Cl Water 1.333 0.045 4.50×10
6 2.8% 
Re6ClBiPy DMSO 1.479 0.337 5.14×106 0.5% 
Re5ClBiPy DMSO 1.479 0.321 9.57×106 1.0% 
Re4ClBiPy DMSO 1.479 0.369 6.19×106 0.6% 
Re6FBiPy DMSO 1.479 0.280 4.95×106 0.6% 
 
 
 
Figure 158. Emission spectrum of Re6ClBiPy in DMSO solution obtained using a 410 nm 
excitation wavelength. Dashed orange line is a moving average over 20 periods 
to help visualise the spectrum. The 5.14×106 counts⋅nm integration of this 
spectrum was used to calculate the quantum yield. 
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Figure 159. Emission spectrum of Re5ClBiPy in DMSO solution obtained using a 410 nm 
excitation wavelength. Dashed orange line is a moving average over 20 periods 
to help visualise the spectrum. The 9.57×106 counts⋅nm integration of this 
spectrum was used to calculate the quantum yield. 
 
Figure 160. Emission spectrum of Re4ClBiPy in DMSO solution obtained using a 410 nm 
excitation wavelength. Dashed orange line is a moving average over 20 periods 
to help visualise the spectrum. The 6.19×106 counts⋅nm integration of this 
spectrum was used to calculate the quantum yield. 
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Figure 161. Emission spectrum of Re6FBiPy in DMSO solution obtained using a 380 nm 
excitation wavelength. Dashed orange line is a moving average over 20 
periods to help visualise the spectrum. The 4.95×106 counts⋅nm integration of 
this spectrum was used to calculate the quantum yield. 
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CHAPTER FIVE 
RHENIUM-HYDROXYQUINOLINE PRECURSORS FOR 
ALZHEIMER’S DISEASE IMAGING 
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5.1 Role of Fluorine-18 Labelled 8-Hydroxyquinolines in the 
PET imaging of Alzheimer’s Disease 
 
Alzheimer’s disease is a neurodegenerative disease which can be characterised by two 
pathological markers in the cerebral cortex. One of these markers is neurofibrillary tangles, 
which are characterised by the disaggregation of tau proteins within the neuron.[93, 94] The 
second diagnostic marker is amyloid beta (Aβ) plaques which form from the aggregation of Aβ 
proteins between the neurons, thus disrupting synaptic connections as shown in Figure 162a.[95, 
96] Many diagnostics designed for the treatment of Alzheimer’s disease are based on the metal 
hypothesis, which postulates that elevated concentrations of iron, zinc and copper ions in the 
brain provide a nucleation site for the Aβ proteins, thus accelerating the rate of Aβ plaque 
aggregation.[97-99] One PET diagnostic agent designed for the imaging of Alzheimer’s disease 
was [18F]CABS13 which, as a fluorine-18 labelled hydroxyquinoline, has been shown to 
chelate to metal ionophores to not only image Aβ plaques in vivo, though to also promote the 
disaggregation of these plaques by displacing the entangled proteins in vitro as a potential 
Alzheimer’s disease treatment.[100-102] Administration of [18F]CABS13 to transgenic mouse 
models of Alzheimer’s disease performed by Liang, et al. exhibited far greater brain uptake 
and retention of the radiotracer when compared to a wild type (WT) mouse model, with 
example PET-CT scans shown in Figure 162b.[103] The radiotracer did fail, however, when 
translated to a non-human primate due to rapid metabolism and low brain uptake.[104] Other 
fluorinated hydroxyquinolines have shown greater promise as Aβ plaque diagnostic agents, 
based on ionophore and disaggregation assays.[100] These alternative agents were unable to be 
fluorine-18 labelled via traditional means, however. Thus, it was hypothesised that the rhenium 
complexation-dissociation strategy, formerly discovered to radiolabel challenging bipyridine 
structures, could be used to improve the radiosynthesis of [18F]CABS13 and enable the 
fluorine-18 labelling of alternative hydroxyquinoline systems. 
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Figure 162. a) Molecular structure of the [18F]CABS13 PET Alzheimer’s disease imaging 
agent (left), alongside a representation of Aβ plaques between neurons and tau 
neurofibrillary tangles within neurons which are known pathological markers 
for the characterisation of Alzheimer’s disease (right), and b) PET-CT scans 
acquired 5-10 mins post-injection following tail vein administration of 
[18F]CABS13 to a transgenic mouse model of Alzheimer’s disease (left) and to 
a WT mouse model (right). Standardised uptake values (SUV) revealed greater 
brain uptake and retention of the radiotracer in the diseased model than 
compared to the WT model. Scans performed by Liang, et al.[103] 
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To test this hypothesis a non-radioactive analogue of [18F]CABS13 (referred to herein as 
2F8HQ) first required synthesis and chelation to rhenium to form the acetonitriletricarbonyl(2-
fluoro-8-hydroxyquinolinato)rhenium(I) (Re2F8HQ) standard. While the chlorinated 
precursor 2-chloro-8-hydroxyquinoline (2Cl8HQ) was readily available, subsequent rhenium 
complexation was also required to attain the acetonitriletricarbonyl(2-chloro-8-
hydroxyquinolinato)rhenium(I) (Re2Cl8HQ) precursor for fluorine-18 labelling. Benzyl 
protection of 2Cl8HQ, thus forming 2-chloro-8-benzoxyquinoline (2Cl8HQ-OBn), enabled 
fluorination via nucleophilic aromatic substitution without side reactions occurring with the 
hydroxyl group on the molecule. The 2-fluoro-8-benzoxyquinoline (2F8HQ-OBn) product 
was then subsequently deprotected using hydrogen gas in the presence of palladium on carbon 
catalysts, which afforded the desired 2F8HQ product. Complexation of 2F8HQ with 
pentacarbonylchlororhenium(I) in acetonitrile then afforded the required Re2F8HQ standard. 
This synthetic route is shown in Figure 163. Precursors to [18F]5-fluoro-8-hydroxyquinoline 
([18F]5F8HQ),  an alternative analogue of [18F]CABS13, were also synthesised by complexing 
5-chloro-8-hydroxyquinoline (5Cl8HQ) and 5-nitro-8-hydroxyquinoline (5NO28HQ) ligands 
with pentacarbonylchlororhenium(I) thus forming acetonitriletricarbonylchloro(5-chloro-8-
hydroxyquinolinato)rhenium(I) (Re5Cl8HQ) as well as acetonitriletricarbonylchloro(5-nitro-
8-hydroxyquinolinato)rhenium(I) (Re5NO28HQ), respectively. While the 5F8HQ non-
radioactive standard was commercially available, rhenium complexation of the compound was 
required to obtain the acetonitriletricarbonylchloro(5-fluoro-8-hydroxyquinolinato)rhenium(I) 
(Re5F8HQ) standard. 
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Figure 163. Synthetic route used to obtain the Re2Cl8HQ precursor as well as the 2F8HQ 
(CABS13) and Re2F8HQ non-radioactive standards for the radiosynthesis of 
the [18F]CABS13 Alzheimer’s disease imaging agent. 
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5.1.1 Benzyl Protection of 2-Chloro-8-Hydroxyquinoline 
 
 
Figure 164. Protection of the 2Cl8HQ alcohol in the 8-position using benzyl chloride to 
afford 2Cl8HQ-OBn in 85% yield. 
 
A mass of 2Cl8HQ (2.40 g, 13.362 mmol, 1.0 eq.) was dissolved in a volume of anhydrous 
DMF (2.5 mL) to which a mass of potassium carbonate (3.69 g, 26.693 mmol, 2.0 eq.) was 
added. A volume of benzyl chloride (3.1 mL, 27.360 mmol, 2.0 eq.) was then added dropwise 
to the solution. The reaction mixture was stirred at 60 °C for 3 hours, where after HPLC 
reaction monitoring confirmed near complete conversion to the product. The product was 
extracted into DCM (20 × 10 mL) and the combined organic fractions were back extracted with 
brine (2 × 20 mL). The organic layer was then dried over sodium sulphate, filtered via vacuum 
filtration and evaporated under reduced pressure to afford a light pink solid. The solid was then 
recrystallised from hot ethanolic solution and filtered via vacuum filtration to afford a purified 
pink product (3.02 g). 
Confirmation of the product was simply assessed by NMR analysis, with the 1H-NMR 
spectrum of 2Cl8HQ-OBn shown in Figure 165 exhibiting the expected integration for twelve 
protons. Ten of which existed in the aromatic region, pertaining to the hydrogen atoms bonded 
within the quinoline and benzene rings, and the other two being relatively upfield shifted as 
expected for the methylene group protons. The 13C-NMR spectrum, shown in in Figure 166, 
further evidenced the assigned structure with fourteen carbon-13 nuclear resonance signals 
found present, as expected given the similar magnetic environment for two pairs of the sixteen 
carbon atoms. 
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Figure 165. 1H-NMR spectrum depicting the integrations of the resonance signals for the 
twelve expected protons in 2Cl8HQ-OBn. Ten of these protons exhibit 
resonance in the aromatic region, whereas the two protons of the methyl group 
are upfield shifted by comparison (top left corner). 
 
 
Figure 166. 13C-NMR spectrum of 2Cl8HQ-OBn in chloroform-d, depicting the fourteen 
expected fourteen signals for the sixteen carbon-13 nuclei as two pairs of carbon 
atoms share the same magnetic environment as shown by the yellow highlighted 
regions of the molecule. The carbon-13 nucleus of the methyl group is notably 
upfield shifted by comparison. 
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5.1.2  Fluorination of 2-Chloro-8-Benzoxyquinoline 
 
 
Figure 167. Fluorination of 2Cl8HQ-OBn using potassium fluoride and an 18-crown-6 
ether phase transfer catalyst to afford 2F8HQ-OBn in 26% yield. 
 
A mass of 2Cl8HQ-OBn (1.48 g, 5.487 mmol, 1.0 eq.) was purged under nitrogen and vacuum 
before being dissolved in a volume of freshly distilled, anhydrous DMSO (10 mL). Masses of 
potassium fluoride (3.84 g, 66.093 mmol, 12.0 eq.) and 18-crown-6 ether (5.84 g, 22.094 mmol, 
4.0 eq.) were azeotropically dried at 90 °C via the dropwise addition of anhydrous acetonitrile 
under an inert nitrogen environment. The ligand in DMSO solution was then transferred to the 
potassium-crown ether complex and the solution was slowly heated to 160 °C and stirred in an 
inert nitrogen environment for 12 days. As reaction monitoring suggesting no greater product 
formation was eventuating, the solution was then cooled to room temperature. The solution 
was then filtered through a PTFE membrane (0.2 µm) before loading onto a C18 reverse phase 
column (220 g, 40 µm) and eluted over a gradient mobile phase consisting of 1 to 100% 
acetonitrile in water, each containing 0.1% TFA modifier. Fractions found to contain the 
desired 2F8HQ-OBn product were combined and evaporated under reduced pressure to 
remove the acetonitrile before freeze-drying overnight to pink salt. The presumed TFA salt was 
then dissolved in a minimum volume of water and extracted into DCM (10 × 5 mL). The 
combined organic extracts were then dried over sodium sulphate, filtered via vacuum filtration 
and evaporated under reduced pressure to afford the pure product (357.4 mg). 
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1H-NMR spectrometry revealed differing splitting patterns, owing to coupling with the 
fluorine-19 nucleus, though still retained the expected integration for twelve protons with ten 
of those signals existing within the aromatic region of the spectrum, shown in Figure 168, as 
expected. The 13C-NMR spectrum, shown in Figure 169, exhibited twenty-one signals due to 
five instances of carbon-13 nuclei coupling to the sole fluorine-19 nucleus whose resonance 
signal is shown at -31.07 ppm in the 19F-NMR spectrum of 2F8HQ-OBn, as shown in Figure 
170. 
 
 
Figure 168. 1H-NMR spectrum depicting the integrations of the resonance signals for the 
twelve expected protons in 2F8HQ-OBn. Ten of these protons exhibit 
resonance in the aromatic region, whereas the two protons of the methyl group 
are upfield shifted by comparison (top left corner). 
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Figure 169. 13C-NMR spectrum of 2F8HQ-OBn in chloroform-d exhibiting twenty-one 
resonance signals due to five of the carbon-13 nuclei coupling to the fluorine-
19 nucleus. 
 
 
Figure 170. CPD 19F-NMR spectrum of 2F8HQ-OBn in chloroform-d showing the 
fluorine-19 magnetic resonance signal at -61.07 ppm pertaining to the lone 
fluorine-19 nucleus in the molecule. 
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5.1.3  Deprotection of 2-Fluoro-8-Benzozyquinoline 
 
 
Figure 171. Deprotection of 2F8HQ-OBn using hydrogen gas in the presence of palladium 
on activated carbon catalysts to afford 2F8HQ in 75% yield. 
 
A mass of 2F8HQ (217.6 mg, 0.859 mmol, 1.0 eq.) was dissolved in a volume of acetonitrile 
(6 mL). Masses of 10% wt. palladium on activated carbon (123.4 mg) and 20% wt. palladium 
hydroxide on activated carbon (124.7 mg) were added to the reaction mixture under an inert 
nitrogen gas environment. The nitrogen gas was then displaced with hydrogen gas and the 
mixture left to stir for 1 hour. The solution was then filtered over diatomaceous earth via 
vacuum filtration to afford a pale-yellow solution which was evaporated under reduced 
pressure to afford a golden crystalline solid (105.7 mg). 
The 1H-NMR spectrum of the product (Figure 172) shows the expected integration for six 
protons in the aromatic region alongside a broad and significantly downfield shifted signal 
suggestive of the O−H bond. The 13C-NMR spectrum in Figure 173 exhibits fourteen carbon-
13 nuclear resonance signals due to coupling of five carbon-13 nuclei with the fluorine-19 
nucleus. This fluorine-19 nucleus is evident from the single resonance signal in the CPD 19F-
NMR spectrum of 2F8HQ in Figure 174. 
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Figure 172. 1H-NMR spectrum of 2F8HQ in DMSO-d6 showing the expected integration 
for six protons in the aromatic region including a broad signal pertaining to the 
O−H bonded hydrogen atom. 
 
 
Figure 173. 13C-NMR spectrum of 2F8HQ in DMSO-d6 showing fourteen carbon-13 
nuclear resonance signals due to the carbon-13 nuclei in the pyridinyl ring 
coupling with the fluorine-19 nucleus. 
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Figure 174. CPD 19F-NMR spectrum of 2F8HQ showing the resonance single for the sole 
fluorine-19 nucleus in the molecule at -63.53 ppm. 
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5.1.4  Rhenium Complexation of 2-Chloro-8-Hydroxyquinoline 
 
 
Figure 175. Rhenium complexation with 2Cl8HQ via the formation of a diacetonitrilo 
intermediate to form the Re2Cl8HQ precursor. 
 
A mass of pentacarbonylchlororhenium(I) (116.1 mg, 0.321 mmol, 1.0 eq.) was purged under 
nitrogen gas followed by vacuum (3 cycles) before being suspended in a volume of anhydrous 
acetonitrile (10 mL). The solution was refluxed for 20 hours in an inert nitrogen gas 
environment to form the diacetonitrilotricarbonylchlororhenium(I) intermediate which was 
monitored by both HPLC and FTIR spectroscopy. To a separate flask a mass of sodium hydride 
(60% wt/wt in mineral oil, 48.0 mg, 2.000 mmol, 6.2 eq.) was washed three times in hexane 
and then dried under vacuum. A mass of 2Cl8HQ (63.4 mg, 0.3530 mmol, 1.1 eq.) dissolved 
in a volume of anhydrous acetonitrile (2 mL) was then added to the white sodium hydride 
powder and stirred for 1 hour to ensure deprotonation of the alcohol. The ligand solution was 
then filtered through a PTFE membrane (0.2 µm) and added dropwise to the rhenium solution, 
causing a vibrant colour change from green to orange. The reaction mixture was then left to 
stir for 18 hours at room temperature, whereupon reaction monitoring confirmed the formation 
of Re2Cl8HQ. The orange solution was then added to a volume of aqueous triflic acid (0.1 
mol.L-1, 10 mL) and evaporated under reduced pressure to remove the acetonitrile, thus 
precipitating out a yellow solid in the remaining aqueous suspension. The crude yellow solid 
was isolated via vacuum filtration, dissolved in acetonitrile and eluted over neutral alumina 
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(Brockmann grade II) using an isocratic acetonitrile mobile phase. The eluents containing the 
product were subsequently combined and evaporated down under reduced pressure to afford 
the pure yellow powder (49.8 mg). 
The 1H-NMR spectrum of the product, as shown in Figure 176, afforded five distinctly split 
signals each providing an integration of one, thus totalling the five expected protons in the 
aromatic region for Re2Cl8HQ. This was further verified by 13C-NMR spectroscopy, in Figure 
177, which not only revealed the expected nine carbon-13 resonance signals for the nuclei 
pertaining to the quinoline moiety, though also exhibited the three typically downfield shifted 
signals of low intensity characteristic of the carbonyl ligands coordinated to the rhenium centre. 
The FTIR spectrum of the compound (Figure 178) exhibited the distinctive A’(1) C≡O and 
overlapping A’(2) & A’’ C≡O stretching frequencies at 2017 cm-1 and 1880 cm-1, respectively, 
clearly demonstrating the existence of the rhenium tricarbonyl centre. Evidently, the absence 
of a broad O−H vibrational band at higher wavenumbers in the FTIR spectrum, alongside the 
absence of a broad downfield shifted NMR signal, suggested the loss of a hydroxyl group 
through which the quinoline had coordinated to the rhenium centre. Due to the presence of a 
neutral acetonitrile ancillary ligand, whose resonance signals were masked by the residual 
protonated solvent signal in the NMR analyses but may be the cause of the sharp IR absorption 
bands circa 2303 cm-1, the complex was unable to yield reliable m/z ratios via LRMS or HRMS 
analysis as no charges could be induced by dissociating the rhenium to ancillary ligand bond. 
The compound was examined by elemental analysis, however, which attested to both the purity 
and assigned molecular identity of Re2Cl8HQ (including the acetonitrilo ancillary ligand) by 
affording experimental compositions of 34.89% carbon, 1.54% hydrogen and 5.60% nitrogen 
against theoretically calculated compositions of 34.32% carbon, 1.65% hydrogen and 5.72% 
nitrogen. The dπ → π* electronic transition to the MLCT excited state of Re2Cl8HQ is also 
present at 437 nm in the UV-Vis spectrum in Figure 179. 
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Figure 176. 1H-NMR spectrum of Re2Cl8HQ in acetonitrile-d3 showing the expected 
integration for five protons in the aromatic region. The resonance signal for the 
methyl group of the acetonitrilo ancillary ligand is masked behind the residual 
solvent peak. 
 
 
Figure 177. 13C-NMR spectrum of Re2Cl8HQ in acetonitrile-d3 showing the three 
downfield shifted carbon-13 resonance signals of the carbonyl ligands and the 
nine carbon-13 resonance signals of the quinoline ring. 
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Figure 178. FTIR spectrum of Re2Cl8HQ exhibiting the distinctive A’(1) C≡O stretching 
frequency at 2017 cm-1 and the overlapping A’(2) & A’’ C≡O stretching 
frequencies at 1880 cm-1. Weaker sp2 hybridised C−H bond stretches are also 
observed at higher wavenumbers (circa 2925 cm-1) from the quinoline ring, and 
the absence of a broad O−H vibrational band at higher wavenumbers suggests 
the absence, and thus the coordination, of the hydroxyl group. 
 
 
Figure 179. UV-Vis spectrum of Re2Cl8HQ (5 µg.mL-1) in acetonitrile exhibiting the 
absorption band for the dπ → π* electronic transition to the MLCT excited state 
at 437 nm, alongside a very distinctive π → π* transition to a LC excited state 
at 281 nm. 
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5.1.5  Rhenium Complexation of 2-Fluoro-8-Hydroxyquinoline 
 
 
Figure 180. Rhenium complexation with 2F8HQ via the formation of a diacetonitrilo 
intermediate to form the Re2F8HQ precursor. 
 
A mass of pentacarbonylchlororhenium(I) (79.6 mg, 0.220 mmol, 1.0 eq.) was purged under 
nitrogen gas and vacuum (3 cycles) before being suspended in a volume of anhydrous 
acetonitrile (4 mL). The solution was refluxed for 20 hours in an inert nitrogen gas environment, 
which dissolved the powder to form the diacetonitriletricarbonylchlororhenium(I) intermediate 
which was verified by HPLC and FTIR spectroscopy. To a separate flask a mass of sodium 
hydride (60% wt/wt in mineral oil, 7.2 mg, 0.300 mmol, 1.4 eq.) was washed three times in 
hexane and then dried under high vacuum. A mass of 2F8HQ (31.9 mg, 0.955 mmol, 0.4 eq.) 
dissolved in a volume of anhydrous tetrahydrofuran (THF, 2 mL) was then added to the white 
sodium hydride powder and stirred for 1 hour over a 0 °C ice bath to ensure deprotonation of 
the alcohol. The ligand solution was filtered through a PTFE membrane (0.2 µm) and added 
dropwise to the rhenium solution, causing a vibrant colour change from green to yellow. The 
reaction mixture was then left to stir for 18 hours at room temperature to ensure complete 
consumption of the ligand starting material. The yellow solution was then added to a volume 
of aqueous triflic acid (0.1 mol.L-1, 10 mL) and evaporated under reduced pressure to remove 
the acetonitrile, thus precipitating out a yellow solid in the remaining aqueous suspension. The 
crude yellow solid was isolated via vacuum filtration, dissolved in acetonitrile and eluted over 
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neutral alumina (Brockmann grade II) using an isocratic acetonitrile mobile phase. The eluents 
containing the product were subsequently combined and evaporated down under reduced 
pressure to afford the pure yellow powder (12.6 mg). 
The 1H-NMR spectrum of the compound, depicted in Figure 181, provided the expected 
integration for five protons in the aromatic region. The 13C-NMR spectrum depicted the three 
highly downfield shifted and low intensity signals corresponding to the carbon-13 nuclei within 
the three carbonyl ligands, alongside fourteen carbon-13 resonance signals in the aromatic 
region due to the coupling of five carbon nuclei with the fluorine-19 nucleus. The resonance 
signal corresponding to the fluorine-19 nucleus is shown at -56.94 ppm in the CDP 19F-NMR 
spectrum in Figure 183. Furthermore, the FTIR spectrum of Re2F8HQ, as shown in Figure 
184, showed the distinctive A’(1) C≡O and overlapping A’(2) & A’’ C≡O stretching 
frequencies at 2020 cm-1 and 1875 cm-1, respectively. Higher sp2 hybridised C−H bond 
stretches were observed around 2926 cm-1 from the quinoline ring and, more significantly, the 
absence of an O−H vibrational band suggested coordination through the nitrogen and oxygen 
atoms of the quinoline ligand. 
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Figure 181. 1H-NMR spectrum of Re2F8HQ in acetonitrile-d3 showing the expected 
integration for five protons in the aromatic region. The resonance signal for the 
methyl group of the acetonitrilo ancillary ligand is masked behind the residual 
solvent peak. 
 
 
Figure 182. 13C-NMR spectrum of Re2F8HQ in acetonitrile-d3 showing the three downfield 
shifted carbon-13 resonance signals of the carbonyl ligands and the nine carbon-
13 resonance signals (five split into doublets due to fluorine-19 coupling) of the 
quinoline ring. 
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Figure 183. CPD 19F-NMR spectrum of Re2F8HQ in acetonitrile-d3, showing the magnetic 
resonance signal for the sole fluorine-19 nucleus in the molecule at -56.94 ppm. 
 
 
Figure 184. FTIR spectrum of Re2F8HQ exhibiting the distinctive A’(1) C≡O stretching 
frequency at 2020 cm-1 and the overlapping A’(2) & A’’ C≡O stretching 
frequencies at 1875 cm-1. Weaker sp2 hybridised C−H bond stretches are also 
observed at higher wavenumbers (circa 2926 cm-1) from the quinoline ring, and 
the absence of a broad O−H vibrational band at higher wavenumbers suggests 
the absence, and thus the coordination, of the hydroxyl group. 
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5.1.6  Rhenium Complexation of 5-Nitro-8-Hydroxyquinoline 
 
 
Figure 185. Rhenium complexation with 5NO28HQ via the formation of a diacetonitrilo 
intermediate to form the Re5NO28HQ precursor. 
 
A mass of pentacarbonylchlororhenium(I) (112.4 mg, 0.311 mmol, 1.0 eq.) was suspended in 
a volume of anhydrous acetonitrile (4 mL) following 3 cycles of nitrogen gas and vacuum 
purging of the environment. The solution was refluxed for 20 hours overnight in an inert 
nitrogen environment to form a diacetonitrilo intermediate, which was monitored via FTIR 
spectroscopy and HPLC analysis. Separate to this system, a mass of 5NO28HQ (65.0 mg, 0.342 
mmol, 1.1 eq.) was dissolved in a volume of THF (5 mL) within an inert nitrogen environment. 
A mass of 60% wt/wt sodium hydride in mineral oil (8.2 mg, 0.342 mmol, 1.1 eq.) was then 
washed three times in hexanes and dried under vacuum to afford a white powder. The ligand 
solution was then injected dropwise over the sodium hydride in a 0 °C ice bath. The solution 
turned a vibrant green and was left to stir at 0 °C for an hour to ensure complete deprotonation. 
The deprotonated ligand solution was then injected over the rhenium solution, immediately 
transitioning to a vibrant orange solution. The reaction mixture was left to stir overnight at 
room temperature for 18 hours, where after the solution was filtered through a 0.2 µm PTFE 
membrane filter. The solution was then loaded onto a neutral alumina phase column 
(Brockmann grade II) and eluted with an acetonitrile isocratic mobile phase. The eluted 
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fractions containing Re5NO28HQ were then combined and evaporated under reduced pressure 
to afford a pure yellow powder (41.0 mg). 
The 1H-NMR and 13C-NMR spectra of Re5NO28HQ show the expected integration for five 
protons in the aromatic region and the expected nine signals for carbon-13 nuclei in the 
aromatic region in Figure 186 and Figure 187, respectively. Additionally, three additional 
signals are present at much higher chemical shifts due to the three carbon-13 resonance signals 
from the carbonyl ligands. The FTIR spectrum also shows the two distinctive high intensity 
carbonyl stretching frequencies at 2019 cm-1 and 1900 cm-1, pertaining to the A’(1) and 
overlapping A’(2) and A’’ irreducible representations. Weaker sp2 hybridised C−H stretching 
frequencies are also present around 2918 cm-1 as shown in Figure 188. A crystal structure of 
Re5NO28HQ attained via XRD analysis at the Australian Synchrotron, grown from the slow 
evaporation of DMSO solvent, is shown in Figure 189 which assigned unequivocal evidence 
for the assigned molecular identity. 
 
 
Figure 186. 1H-NMR spectrum of Re5NO28HQ in acetonitrile-d3 showing the expected 
integration for five protons in the aromatic region. The resonance signal for the 
methyl group of the acetonitrilo ancillary ligand is masked behind the residual 
solvent peak. 
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Figure 187. 13C-NMR spectrum of Re5NO28HQ in acetonitrile-d3 showing the three 
downfield shifted carbon-13 resonance signals of the carbonyl ligands and the 
nine carbon-13 resonance signals of the quinoline ring. 
 
Figure 188. FTIR spectrum of Re5NO28HQ exhibiting the distinctive A’(1) C≡O stretching 
frequency at 2019 cm-1 and the overlapping A’(2) & A’’ C≡O stretching 
frequencies at 1900 cm-1. Weaker sp2 hybridised C−H bond stretches are also 
observed at higher wavenumbers (circa 2918 cm-1) from the quinoline ring, and 
the absence of a broad O−H vibrational band at higher wavenumbers suggests 
the absence, and thus the coordination, of the hydroxyl group. 
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Figure 189. Crystal structure of Re5NO28HQ attained via XRD analysis at the Australian 
Synchrotron. 
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5.1.7  Rhenium Complexation of 5-Fluoro-8-Hydroxyquinoline 
 
 
Figure 190. Rhenium complexation with 5F8HQ via the formation of a diacetonitrilo 
intermediate to form the Re5F8HQ precursor. 
 
A mass of pentacarbonylrhenium(I) (104.0 mg, 0.288 mmol, 1.0 eq.) was refluxed in a volume 
of anhydrous acetonitrile (3 mL) under an inert nitrogen environment for 20 hours, thus 
forming a diacetonitrile intermediate which was verified by peak shifts in HPLC and FTIR 
spectroscopic reaction monitoring. A mass of 5F8HQ (51.6 mg, 0.316 mmol, 1.1 eq.) was 
dissolved in a volume of anhydrous THF (2 mL) in an inert nitrogen environment. A mass of 
60% wt/wt sodium hydride in mineral oil (8.2 mg, 0.342 mmol, 1.2 eq.) was washed three times 
in hexanes and dried under high vacuum. The volume of 5FHQ in THF was then added to the 
hydride powder over a 0 °C ice bath and stirred for 1 hour resulting in a green solution. This 
solution was then added to the solution containing rhenium, prompting a colour change to 
orange. The solution was then allowed to stir at room temperature for 18 hours. Thereafter the 
solution was filtered through a PTFE membrane (0.2 µm), loaded onto a Brockmann II neutral 
alumina column and eluted using a 100% acetonitrile gradient. The eluents containing the 
Re5NO28HQ complex were combined and evaporated under reduced pressure to afford a pure 
yellow powder (25.5 mg). 
NMR analysis of Re5F8HQ show the expected integration for five protons in the aromatic 
region from the 1H-NMR spectrum show in in Figure 191, twenty carbon-13 signals due to 
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three downfield shifted carbonyl ligand signals and nine carbon-13 nuclei of the quinoline ring 
coupling to the fluorine-19 nucleus from the 13C-NMR spectrum in Figure 192, and the sole 
fluorine-19 resonance signal expected from the only fluorine atom in the molecule in the CPD 
19F-NMR in Figure 193. The FTIR spectrum also exhibits the expected carbonyl stretching 
frequencies belonging to the A’(1) C≡O and the overlapping A’(2) & A’’ irreducible 
representations at 2019 cm-1 and 1892 cm-1, as shown in Figure 194 respectively. Curiously the 
UV-vis spectrum of Re5F8HQ (Figure 195) exhibited an absorption band at 437 nm, formerly 
assigned to the typical dπ → π* electronic transition to the MLCT excited state, though with a 
much higher molar absorptivity (17570 L.mol-1.cm-1) than the other synthesised rhenium 
complexes of similar 5 µg.mL-1 concentration in acetonitrile, suggesting that this transition 
may instead account for an electronic transition to an intraligand charge transfer (ILCT) excited 
state. Other π → π* transitions to LC excited states at are also observed at shorter wavelengths 
as expected. 
 
Figure 191. 1H-NMR spectrum of Re5F8HQ in acetonitrile-d3 showing the expected 
integration for five protons in the aromatic region. The resonance signal for the 
methyl group of the acetonitrilo ancillary ligand is masked behind the residual 
solvent peak. 
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Figure 192. 13C-NMR spectrum of Re5NO28HQ in acetonitrile-d3 showing the three 
downfield shifted carbon-13 resonance signals of the carbonyl ligands and 
seventeen carbon-13 resonance signals in the aromatic region due to nine of the 
quinoline carbon-13 nuclei coupling with the fluorine-19 nucleus. 
 
 
Figure 193. Lone magnetic resonance signal of the fluorine-19 nucleus in the CPD 19F-NMR 
spectrum of Re5F8HQ. 
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Figure 194. FTIR spectrum of Re5F8HQ exhibiting the distinctive A’(1) C≡O stretching 
frequency at 2019 cm-1 and the overlapping A’(2) & A’’ C≡O stretching 
frequencies at 1892 cm-1. Weaker sp2 hybridised C−H bond stretches are also 
observed at higher wavenumbers (circa 2953 cm-1) from the quinoline ring, and 
the absence of a broad O−H vibrational band at higher wavenumbers suggests 
the absence, and thus the coordination, of the hydroxyl group. 
 
 
Figure 195. UV-Vis spectrum of Re5F8HQ (5 µg.mL-1) in acetonitrile exhibiting an 
absorption band for an electronic transition to either the MLCT excited state of 
uncharacteristically high molar absorptivity (17570 L.mol-1.cm-1) or an ILCT 
excited state at 437 nm. π → π* transitions to LC excited states at are also 
observed at shorter wavelengths. 
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5.1.8 Characterisation Data for the 8-Hydroxyquinoline Ligands 
and their Rhenium Complexes 
 
2-chloro-8-benzoxyquinoline (2Cl8HQ-OBn) Pink solid; MP: 101 °C, 85% yield. 1H NMR 
(400 MHz, CDCl3, δ/ppm): δ 8.06 (d, Jd=8.60 Hz, 1H), δ 7.50 (d, Jd=7.36 Hz, 1H), δ 7.40 (d, 
Jd=8.56 Hz, 1H), δ 7.36 (m, 1H), δ 7.30 (d, Jd=7.06 Hz, 1H), δ 7.06 (dd, Jd=6.08, 3.00 Hz, 1H). 
13C{1H} NMR (100 MHz, CDCl3, δ/ppm): δ 153.7, δ 150.0, δ 140.0, δ 138.7, δ 137.0, δ 128.7, 
δ 128.3, δ 127.9, δ 127.2, δ 127.1, δ 127.1, δ 123.1, δ 119.7, δ 111.8, δ 71.0. 
2-fluoro-8-benzoxyquinoline (2F8HQ-OBn) Pink solid; MP: 107 °C, 26% yield. 1H NMR (400 
MHz, CDCl3, δ/ppm): δ 8.22 (d, Jd=8.40 Hz, 1H), δ 7.51 (d, Jd=7.40 Hz, 1H), δ 8.35 (m, 5H), 
δ 7.10 (m, 2H), δ 5.42 (s, 1H). 13C{1H} NMR (100 MHz, CDCl3, δ/ppm): δ 162.0, δ 159.5, δ 
153.6 (Jd=2 Hz), δ 142.1 (Jd=9 Hz), δ 137.7 (Jd=15 Hz), δ 137.0, δ 128.8, δ 128.2 (Jd=2 Hz), δ 
128.0, δ 127.2, δ 126.3 (Jd=9 Hz), δ 119.7, δ 111.8, δ 110.9, δ 110.4. 19F{1H} NMR (376 MHz, 
DMSO-d6, δ/ppm): δ -61.07. 
2-fluoro-8-hydroxyquinoline (2F8HQ or CABS13) Yellow solid; MP: 62 °C, 75% yield. 1H 
NMR (400 MHz, DMSO-d6, δ/ppm): δ 9.89 (br. s, 1H), δ 8.51 (t, Jt=8.60 Hz), δ 7.45 (m, 2H), 
δ 7.32 (dd, Jd=8.80, 2.76 Hz, 1H), δ 7.14 (dd, Jd=7.20, 1.64 Hz, 1H). 13C{1H} NMR (100 MHz, 
CD3CN, δ/ppm): δ 159.6 (d, Jd=238 Hz), δ 152.5, δ 143.0 (d, Jd=10 Hz), δ 135.4 (d, Jd=15 Hz), 
δ 127.9, δ 126.9 (d, Jd=2 Hz), δ 117.9, δ 113.5, δ 110.2 (d, Jd=42 Hz). 19F{1H} NMR (376 MHz, 
DMSO-d6, δ/ppm): δ -63.53. FTIR (ATR corr. ṽ/cm-1): ṽ 2473 (br. m, O-H str.). 
Acetonitriletricarbonyl(2-chloro-8-quinolinolate)rhenium(I) (Re2Cl8HQ) Amber solid; MP: 
130 °C (dec.), 32% yield. 1H NMR (400 MHz, CD3CN, δ/ppm): δ 8.32 (d, Jd=8.68 Hz, 1H), δ 
7.58 (d, Jd=8.68 Hz, 1H), δ 7.43 (t, Jt=7.96 Hz, 1H), δ 7.01 (dd, Jd=7.96, 0.96 Hz, 1H), δ 6.92 
(dd, Jd=7.96, 1.04 Hz, 1H), δ 1.96 (s, 3H). 13C{1H} NMR (100 MHz, CD3CN, δ/ppm): δ 
196.6C≡O, δ 195.3C≡O, δ 195.3C≡O, δ 170.2, δ 152.3, δ 144.3, δ 142.6, δ 131.2, δ 130.1, δ 123.8, 
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δ 120.8, δ 117.7, δ 112.4, δ 30.3. FTIR (ATR corr. ṽ/cm-1): ṽ 2925 (w, C−H  sp2 str.), ṽ 2304 
(w, N≡C str.), ṽ 2017 (s, A’(1) C≡O str.), ṽ 1872 (s, A’(2) & A’’ C≡O str.). UV/Vis (λ/nm, 
ε/L.mol-1.cm-1): λ 437 (dπ→π*, ε 235.06), λ 281 (π→π*, ε 2340.84), λ 237 (π→π*, ε 3104.80). 
EA (%): calc. C 34.32, H 1.65, N 5.72. found C 34.89, H 1.54, N 5.60. 
Acetonitriletricarbonyl(2-fluoro-8-quinolinolate)rhenium(I) (Re2F8HQ) Amber solid; MP: 
134 °C (dec.), 14% yield. 1H NMR (400 MHz, CD3CN, δ/ppm): δ 8.51 (dd, Jd=8.92, 7.04 Hz, 
1H), δ 7.43 (t, Jt=7.96 Hz, 1H), δ 7.33 (dd, Jd=8.92, 1.24 Hz, 1H), δ 7.06 (d, Jd=8.00 Hz, 1H), 
δ 6.94 (d, Jd=7.92 Hz, 1H). 13C{1H} NMR (100 MHz, CD3CN, δ/ppm): δ 195.9C≡O, δ 194.9C≡O, 
δ 194.2C≡O, δ 168.0 (d, Jd=2 Hz), δ 161.5 (d, Jd=256 Hz), δ 145.0 (d, Jd=2 Hz), δ 139.7, δ 129.6 
(d, Jd=2 Hz), δ128.6, δ 116.5, δ 111.5, δ 109.8 (d, Jd=33 Hz). 19F{1H} NMR (376 MHz, CD3CN, 
δ/ppm): δ -56.94. FTIR (ATR corr. ṽ/cm-1): ṽ 2925 (w, C−H  sp2 str.), ṽ 2853 (w, C−H  sp2 
str.), ṽ 2322 (w, N≡C str.), ṽ 2020 (s, A’(1) C≡O str.), ṽ 1875 (s, A’(2) & A’’ C≡O str.). 
Acetonitriletricarbonyl(5-chloro-8-quinolinolate)rhenium(I) (Re5Cl8HQ) Yellow solid, MP: 
159-170 °C (dec.), 26% yield. 1H NMR (400 MHz, CD3CN, δ/ppm): δ 9.98 (dd, Jd=4.84, 1.24 
Hz, 1H), δ 8.64 (dd, Jd=8.64, 1.28 Hz, 1H), δ 7.64 (dd, Jd=8.64, 4.84 Hz, 1H), δ 7.55 (d, Jd=8.52 
Hz, 1H), δ 6.85 (d, Jd=8.52 Hz, 1H), δ 1.96 (s, 3H). 13C{1H} NMR (100 MHz, CD3CN, δ/ppm): 
δ 197.1C≡O, δ 196.8C≡O, δ 195.7C≡O, δ 169.6, δ 151.0, δ 144.9, δ 136.5, δ 130.9, δ 128.9, δ 124.1, 
δ 115.4, δ 113.2. FTIR (ATR corr. ṽ/cm-1): ṽ 2959 (w, C−H  sp2 str.), ṽ 2911 (w, C−H  sp2 str.), 
ṽ 2322 (w, N≡C str.), ṽ 2016 (s, A’(1) C≡O str.), ṽ 1874 (s, A’(2) & A’’ C≡O str.). 
Acetonitrilecarbonyl(5-fluoro-8-quinolinolate)rhenium(I) (Re5F8HQ) Yellow solid, MP: 
171-184 °C (dec.), 26% yield. 1H NMR (400 MHz, CD3CN, δ/ppm): δ 8.97 (dd, Jd=4.84, 1.08 
Hz, 1H), δ 8.55 (dd, Jd=8.56, 1.12 Hz, 1H), δ 7.58 (dd, Jd=8.56, 4.84 Hz, 1H), δ 7.26 (q, Jq=10.52, 
8.72 Hz, 1H), δ 6.78 (dd, Jd=4.40, 8.72 Hz, 1H). ). 13C{1H} NMR (100 MHz, CD3CN, δ/ppm): 
δ 197.3C≡O, δ 196.9C≡O, δ 196.0C≡O, δ 166.4 (d, Jd=2 Hz), δ 151.3, δ 147.1 (d, Jd=235 Hz), δ 
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143.0 (d, Jd=5 Hz), δ 133.1 (d, Jd=3 Hz), δ 123.3 (d, Jd=2 Hz), δ 121.1 (d, Jd=21 Hz), δ 144.5 
(d, Jd=20 Hz), δ 113.0 (d, Jd=7 Hz). 19F{1H} NMR (376 MHz, CD3CN, δ/ppm): δ -144.8. FTIR 
(ATR corr. ṽ/cm-1): ṽ 2954 (w, C−H  sp2 str.), ṽ 2909 (w, C−H  sp2 str.), ṽ 2298 (w, N≡C str.), 
ṽ 2019 (s, A’(1) C≡O str.), ṽ 1892 (s, A’(2) & A’’ C≡O str.). 
Acetonitriletricarbonyl(5-nitro-8-quinolinolate)rhenium(I) (Re5NO28HQ) Yellow solid, MP: 
190 - 194 °C (dec.), 26% yield. 1H NMR (400 MHz, CD3CN, δ/ppm): δ 9.57 (dd, Jd=9.00, 1.28 
Hz, 1H), δ 9.03 (dd, Jd=4.84, 1.28 Hz, 1H), δ 8.63 (d, Jd=9.24 Hz, 1H), δ 7.81 (dd, Jd=9.00, 4.84 
Hz, 1H), δ 6.88 (d, Jd=9.24 Hz, 1H). 13C{1H} NMR (100 MHz, CD3CN, δ/ppm): δ 196.3C≡O, δ 
194.4C≡O, δ 178.1C≡O, δ 151.6, δ 143.3, δ 137.1, δ 132.9, δ 130.8, δ 127.0, δ 126.9, δ 121.4, δ 
114.2. FTIR (ATR corr. ṽ/cm-1): ṽ 2939 (w, C−H  sp2 str.), ṽ 2918 (w, C−H  sp2 str.), ṽ 2328 
(w, N≡C str.), ṽ 2019 (s, A’(1) C≡O str.), ṽ 1900 (s, A’(2) & A’’ C≡O str.).  
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5.2 Fluorine-18 Radiolabellings of 8-Hydroxyquinoline 
Rhenium Complexes 
 
5.2.1 Radiosynthesis of the [18F]CABS13 Alzheimer’s Disease 
Imaging Agent via Rhenium Complexation 
 
Non-radioactive standards of CABS13 (2F8HQ) and its corresponding rhenium complex 
(Re2F8HQ) were injected onto the radioHPLC using the standard chromatographic conditions 
described in the experimental section. The UV-absorption profiles of both compounds are 
superimposed upon one another in Figure 196 and provide retention times of 6.38 mins for 
2F8HQ and 7.60 mins for Re2F8HQ, which were used to match the retention times of the 
radioproducts to affirm their molecular identities. Radiolabelling studies of the 2Cl8HQ 
precursor afforded no radiochemical yield, as affirmed by prior studies whom sought to protect 
the alcohol. Thus fluorine-18 radiolabelling experiments were instead performed on the 
Re2Cl8HQ using the standard dry conditions of 0.08 µmol of precursor, 29±10 MBq of 
[18F]fluoride and a reaction time of 47 s within a laminar flow afforded by the microfluidic set-
up. The temperature was progressive raised by 20 °C between each experiment, beginning at 
50 °C for the first experiment and ending at 190 °C for the final experiment. The hypothesis 
for using Re2Cl8HQ was that it would not only improve the nucleophilic aromatic substitution 
for [18F]fluoride in the ortho-position due to the rhenium activated electron withdrawal effect 
exhibited in the previous radiosyntheses of [18F]Re2FPhen and [18F]Re6ClBiPy, though 
would also protect the alcohol due to coordination through the oxygen atom of the alcohol 
group, thus circumventing the need for the multiple step radiosyntheses employed by other 
research groups. The [18F]2F8HQ was then hypothesised to thermally dissociate from the 
radiolabelled [18F]Re2F8HQ complex thereafter to afford the desired radiotracer in heightened 
RCY. Figure 197 shows a plot of the RCY of [18F]Re2F8HQ and [18F]2F8HQ formed as a 
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function of the reaction temperature from the Re2Cl8HQ precursor in DMSO. At both 50 °C 
and 70 °C neither radioproduct as formed, however from 90 °C to 150 °C a noticeable 2% RCY 
of the [18F]Re2F8HQ has formed, though in absence of the [18F]2F8HQ radiolabelled ligand. 
Evidently not enough heat had been supplied to the system at these temperatures to facilitate 
the thermal decomplexation of the ligand from the complex. Indeed, at a higher temperature of 
190 °C not only was 2% of the [18F]Re2F8HQ found to have formed, though this was also 
accompanied by the liberation of 2% of the [18F]2F8HQ ligand. Alternative experiments were 
trialled to improve upon the RCY of [18F]2F8HQ. These included adjusting the flow rate from 
20 µL.min-1 to 5 µL.min-1 and 2 µL.min-1 (reaction times of 3.12 mins and 7.80 mins as per 
equation (13), respectively), while maintaining same amount of precursor and radioactive at a 
temperature of 190 °C. For the reaction at 5 µL.min-1, RCYs of 2% were attained for both 
[18F]Re2F8HQ and [18F]2F8HQ indicating no improvement over the reaction conditions 
employed using a 20 µL.min-1 flow rate. For the reaction at 2 µL.min-1 [18F]2F8HQ formed in 
only 1% RCY and [18F]Re2F8HQ did not even form at all. This may have implied that the 
Re2Cl8HQ was thermally degrading a rate faster than it was being radiofluorinated, thus 
providing very little of the [18F]Re2F8HQ radioproduct to dissociate to the desired 
[18F]2F8HQ ligand. Thus, the reaction was repeated using a 2 µL.min-1 flow rate, 29±10 MBq 
of [18F]fluoride and reaction temperature of 190 °C though with ten-fold increase of the 
precursor amount to 0.80 µmol. In this experiment a 10% RCY of [18F]Re2F8HQ was obtained 
alongside a 2% RCY of [18F]2F8HQ. Intriguingly however, a repeat experiment performed 
using the same parameters (though analysed with a slightly modified chromatographic 
condition which only held the 95% water mobile phase of the standard conditions described in 
the experimental section for 1 min) afford [18F]Re2F8HQ in 18% RCY and the radiolabelled 
[18F]2F8HQ ligand in a slightly greater 5% RCY, as shown by the radiochromatograms in 
Figure 198. 
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Figure 196. Superimposed UV-absorbance profiles for the non-radioactive standards of 
2F8HQ (CABS13, orange line) and Re2F8HQ (ReCABS13, blue line) 
providing retention times of 6.38 mins and 7.60 mins for both compounds, 
respectively, which were used to assign the identity of the radioproducts 
analysed by radioHPLC. 
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Figure 197. RCYs of [18F]Re2F8HQ ([18F]ReCABS13, blue diamonds) and [18F]2F8HQ 
([18F]CABS13, orange crosses) synthesised from the Re2Cl8HQ precursor as a 
function of reaction temperature while employing the same reaction conditions 
of 0.08 µmol of the Re2Cl8HQ precursor, 29±10 MBq of [18F]fluoride and a 
47 s reaction temperature in dry DMSO solvent. 
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Figure 198. Radiochromatograms obtained using two different chromatographic conditions 
for two separate experiments affording the maximum RCYs for [18F]2F8HQ 
and [18F]Re2F8HQ using 0.80 µmol of Re2Cl8HQ, 29±10 MBq of 
[18F]fluoride, a reaction time of 468 s (7.80 mins) and a reaction temperature of 
190 °C. The experiment analysed by the standard chromatographic conditions 
described in the experimental section (top) afforded 10% RCY of 
[18F]Re2F8HQ (7.58 min) and 2% RCY of [18F]2F8HQ (6.32 min). Whereas 
the experiment analysed with the initial 95% water phase held for only 1 min 
(bottom) afforded 18% RCY of [18F]Re2F8HQ (5.72 mins) and 5% RCY of 
[18F]2F8HQ. 
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The approach undertaken by Liang, et al. to synthesis the [18F]CABS13 Alzheimer’s disease 
diagnostic agent is shown in Figure 199.[104] Beginning with 2Cl8HQ, the group first protected 
the alcohol using benzyloxymethyl chloride. This then afforded the benzyloxymethyl protected 
precursor which was subsequently reacted with TEA [18F]fluoride in DMF solution at 140 °C 
for 15 mins, allowing nucleophilic aromatic substitution for [18F]fluoride to occur in exchange 
for the chloro leaving group. Thereafter, a second reaction was required to deprotect the 
resulting radioproduct. The fluorine-18 labelled benzyloxymethyl protected quinoline was 
treated with TFA in DMF solution at 130 °C for 10 mins to afford the desired [18F]CABS13 
nuclear medicine. Repeat analyses revealed an RCY of 19±5% for the radiotracer. In contrast, 
the work described herein as also shown in Figure 199, complexed the 2Cl8HQ ligand to a 
source of pentacarbonylchlororhenium(I) to acquire the Re2Cl8HQ precursor. Fluorine-18 
radiolabelling of this precursor required only a single reaction step to afford the [18F]CABS13 
tracer while consuming lesser reagents and requiring a comparatively quicker reaction time of 
only 7.8 mins. Despite these advantages, however, only 5% RCY of [18F]CABS13 was able to 
be afforded, and thus did not improve substantially on the method developed by Liang, et al. 
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Figure 199. Comparison of the radiosynthetic routes used to obtain the [18F]CABS13 
Alzheimer’s disease imaging agent performed by Liang, et al. and in this work. 
While the multiple step method used by Liang, et al. required at least 25 mins 
of synthesis and more reagents (top) it nonetheless produced [18F]CABS13 in 
19±5% RCY.[104] Whereas using the single step rhenium complexation-
dissociation approach described herein required less than 8 mins with fewer 
reagents, though only produced [18F]CABS13 in 5% RCY at most. 
 
Additional experiments were also performed, whereupon the radiofluorinations of the 
Re2Cl8HQ precursor were undertaken in wet conditions (i.e. a 10% v/v content was present 
in the DMSO solvent). These conditions applied the same precursor amount (0.08 µmol), 
radioactivity (29±10 MBq) and reaction time (47 s) as the standard dry reaction experiments. 
Figure 200 plots the RCY attained for each experiment against the reaction temperature which 
varied in 20 °C increments from 50 to 190 °C. A noticeable difference is that [18F]2F8HQ did 
not form at all from these reactions, with [18F]Re2F8HQ being the only observable 
radioproduct. The RCY of [18F]Re2F8HQ was 0% for the first three experiments tested at 50 , 
70 and 90 °C. Thereafter the RCY increased to 1% at 110 °C, 2% at 130 °C and 3% at 150 °C. 
Overall, the reaction conditions afforded no more than 4% RCY of [18F]Re2F8HQ at 190 °C. 
Modifications to the flow rate of the reaction afforded 3% RCY and 4% RCY of 
[18F]Re2F8HQ at flow rates of 5 µL.min-1 and 2 µL.min-1 (187 s and 468 s), respectively, 
222 
 
when holding the temperature at 190 °C with the other reaction parameters kept the same. Thus, 
alternatively the Re2Cl8HQ precursor amount was increased to 0.80 µmol while applying a 
flow rate of 4 µL.min-1 (234 s) at 190 °C with the same amount of [18F]fluoride (29±10 MBq) 
applied. While the reaction produced significantly more of [18F]Re2F8HQ with an RCY of 
10%, it also produced a small 2% RCY of [18F]2F8HQ. Hence, demonstrating that the 
[18F]CABS13 Alzheimer’s disease imaging agent can be produced under non-azeotropically 
dried conditions, but that such conditions notably inhibit the yield produced via the rhenium 
complexation-dissociation approach. 
 
 
Figure 200. RCY of [18F]Re2F8HQ ([18F]ReCABS13) synthesised from the Re2Cl8HQ 
precursor under wet conditions as a function of reaction temperature while 
employing the same reaction conditions of 0.08 µmol of the Re2Cl8HQ 
precursor, 29±10 MBq of [18F]fluoride and a 47 s reaction temperature in wet 
DMSO solvent. [18F]2F8HQ ([18F]CABS13) did not form from these reactions. 
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5.2.2 An Alternative [18F]5-Fluoro-8-Hydroxyquinoline 
Radiotracer for Alzheimer’s Disease PET Imaging 
 
A 2015 study performed by Liang, et al. sought to test several fluorinated 8-hydroxyquinoline 
analogues of CABS13 towards validating the metal hypothesis for Alzheimer’s disease.[100] In 
this study it was shown that positioning the fluorine atom elsewhere on the quinoline aromatic 
ring was able to improve properties for an Alzheimer’s diagnostic agent in some cases. Among 
the molecules tested 5F8HQ had a half maximal effective concentration (EC50) of 21.5±15.9 
µmol.L-1 in a study assessing the concentration of 8-hydroxyquinoline compounds required to 
disaggregate zinc-induced Aβ oligomers, whereas CABS13 required concentrations greater 
than 120 µmol.L-1. Greater copper uptake within an in vitro neuronal cell model (SH-SY5Y 
cells) was also observed when treated with 20 µMol.L-1 of 5F8HQ for 6 hours than compared 
to the same concentration of CABS13, with approximately 6 times the concentration of cellular 
metal measured relative to CABS13 and the basal control as determined by inductively coupled 
plasma (ICP) mass spectrometry  analysis. Despite these in vitro studies which suggested that 
5F8HQ could have been a superior medicine for the treatment of Aβ plaques over CABS13, 
the drug was not radiolabelled due to the difficulties associated with incorporating the fluorine-
18 radioisotope in the 5-position of the molecule. Thus, it was hypothesised that the rhenium 
complexation-dissociation approach explored previously with [18F]CABS13 and the 
radiofluorinated 2-2’-bipyridine analogues could provide an electron withdrawal effect and 
simultaneous protection of the alcohol in the 8-position which would allow for the previously 
unachievable [18F]5F8HQ for the potential PET imaging and dissociation of Aβ plaques in 
Alzheimer’s disease. Towards testing this hypothesis, the non-radioactive standards of 
Re5F8HQ and 5F8HQ were injected onto the radioHPLC to determine the retention times 
whereby the radioproducts would be expected to elute. Figure 201 shows the retention time 
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determined for these two compounds when running the standard chromatographic conditions 
though omitting the initial 2 mins of constantly held 95% water in acetonitrile in the method 
(thus resulting in substantially shifted retention times compared to the Re2F8HQ and 
Re5F8HQ chromatographic results). Applying this method resulted in retention times of 3.42 
mins and 5.87 mins for 5F8HQ and Re5F8HQ, respectively. A series of experiments were 
then performed which used 0.08 µmol of a Re5Cl8HQ precursor, 29±10 MBq of [18F]fluoride 
and a 47 s reaction time while tuning the reaction temperature from 50 to 190 °C in 20 °C 
increments. Figure 203 plots the RCYs for each of these reactions performed in dry DMSO 
against the reaction temperature. 2% RCY of [18F]Re5F8HQ was found to form from all 
experiments with reaction temperatures between 50 and 100 °C. 3% RCY of [18F]Re5F8HQ  
was then achieved at reaction temperatures of 130 and 150 °C, which then decreased to 2% 
RCY at 170 °C and 1% RCY at 190 °C. Meanwhile, no [18F]5F8HQ was found to form at 
reaction temperatures of 50 and 70 °C, though thermal dissociation of [18F]Re5F8HQ enabled 
the radiosynthesis of [18F]5F8HQ in 1% RCY at all temperatures of 90 °C and higher. Figure 
202 shows an example radiochromatogram obtained at 150 °C which afforded 1% RCY and 
5% RCY of [18F]Re5F8HQ, respectively. The effect of the change of flow rate on the RCY of 
the radioproducts was also tested, as was also performed for the CABS13 and bipyridine 
analogues. Unfortunately, adjusting the flow rate to 5 µL.min-1 and 2 µL.min-1 at 190 °C 
afforded only 1% RCY of [18F]5F8HQ and none of the [18F]Re5F8HQ radioproduct in both 
cases. Adjusting the flow rate to 4 µL.min-1 at 190 °C while increasing the precursor amount 
to 0.80 µmol produced no RCY of [18F]5F8HQ nor [18F]Re5F8HQ. The same reactions were 
also performed using wet DMSO to assess the differences in RCY of the radioproducts 
produced. Only [18F]Re5F8HQ was obtained from the reactions applying a 20 µL.min-1 flow 
rate with 29±10 MBq of [18F]fluoride and 0.08 µmol of the Re5Cl8HQ precursor. Figure 204 
plots the formation of [18F]Re5F8HQ as a function of the reaction temperature ranging from 
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50 to 190 °C. The RCY of [18F]Re5F8HQ fluctuated between 0% and 1% RCY for reaction 
temperatures between 50 °C and 130 °C. Thereafter the RCY of [18F]Re5F8HQ increased to 
2% RCY at 150 and 170 °C and finally increased to 3% RCY at 190 °C. Adjusting the flow 
rate to 5 and 2 µL.min-1 at 190 °C still only afforded 3% RCY of [18F]Re5F8HQ and using a 
ten-fold equivalence of the Re5Cl8HQ precursor with an applied flow rate of 4 µL.min-1 
yielded only 2% RCY, each in the absence of any radiolabeled [18F]5F8HQ ligand. 
 
 
Figure 201. Superimposed UV-absorbance profiles for the non-radioactive standards of 
5F8HQ (orange trace) and Re5F8HQ (blue trace) providing retention times of 
3.42 mins and 5.87 mins for both compounds, respectively, which were used to 
assign the identity of the radioproducts analysed by radioHPLC. These retention 
times were acquired from the standard chromatographic conditions omitting 2 
mins of the initial hold of the 95% water mobile phase. 
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Figure 202. RCY of [18F]Re5F8HQ (blue diamonds) and [18F]5F8HQ (orange crosses) 
synthesised from the Re5Cl8HQ precursor as a function of reaction temperature 
while employing the same reaction conditions of 0.08 µmol of the Re5Cl8HQ 
precursor, 29±10 MBq of [18F]fluoride and a 47 s reaction temperature in dry 
DMSO solvent. 
 
227 
 
 
Figure 203. Radiochromatogram obtained for the radiofluorination of 0.08 µmol of 
Re5Cl8HQ precursor in DMSO solution with 29±10 MBq of [18F]fluoride for 
47s in dry DMSO solvent at 150 °C. These conditions afforded 1% RCY of 
[18F]5F8HQ and 5% [18F]Re5F8HQ eluting at 3.4 and 5.7 mins, respectively. 
 
Figure 204. RCY of [18F]Re5F8HQ formed from the Re5Cl8HQ precursor as a function of 
reaction temperature under wet conditions. Reaction conditions involved 0.08 
µmol of precursor, 29±10 MBq of [18F]fluoride and a 47 s reaction time in wet 
DMSO solvent. No [18F]5F8HQ was found to form from these reactions. 
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Owing to the poor RCYs of [18F]Re5F8HQ and thus [18F]5F8HQ obtained using the 
Re5Cl8HQ precursor, the same experiments were performed using an alternative 
Re5NO28HQ precursor. Radiofluorinations were hypothesised to afford greater RCYs using 
this precursor due to the greater electron withdrawing effect of the nitro group, which was also 
a better leaving group for nucleophilic aromatic substitution for [18F]fluoride. The plot for the 
RCY of [18F]Re58HQ and the dissociated [18F]5F8HQ radioproduct per reaction temperature 
using the standard radiolabelling conditions (0.08 µmol of precursor, 29±10 MBq of 
radioactivity and 47 s reaction time) is shown in Figure 205. While only 1% RCY of 
[18F]Re58HQ was achieved at 50 and 70 °C, the use of the Re5NO28HQ afforded significantly 
more of the [18F]Re5F8HQ radioproduct than compared with the Re5Cl8HQ precursor, with 
4% RCY achieved at 130 and 150 °C and as much as 6% RCY achieved at 170 °C. While none 
of the [18F]Re58HQ labelled ligand formed at temperatures equal to and lower than 110 °C, 
1% RCY was indeed found to form from 130 to 170 °C and produced as much as 2% RCY at 
190 °C. Figure 206 shows an example radiochromatogram obtained at 170 °C which depicts 
the radiodetection of [18F]5F8HQ in 1% RCY at 3.4 mins and [18F]Re5F8HQ at 5.7 mins in 
6% RCY. Non-azeotropically dried conditions were also trialed, as was consistently tested for 
the former precursors. Performing the same experiments using the Re5NO28HQ precursor in 
wet DMSO solvent afforded the plot in Figure 207, which shows the RCY of the radioproducts 
formed as a function of temperature using the standard reaction parameters (0.08 µmol of 
precursor, 29±10 MBq of radioactivity and 47 s reaction time). Here the RCY of 
[18F]Re5F8HQ increased to 1% at reaction temperatures of 70 and 90 °C, increased to 2% at 
temperatures of 130 and 150 °C, and finally increased to 3% and 4% RCY at temperatures of 
170 and 190 °C, respectively. The [18F]5F8HQ radioligand only dissociated in 1% RCY at 
190 °C, however. Decreasing the flow rate to 5 µL.min-1 at 190 °C resulted in 3% RCY of 
[18F]Re5F8HQ and 2% of [18F]5F8HQ. Whereas decreasing the flow rate to 2 µL.min-1 at 
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190 °C produced [18F]Re5F8HQ in 4% RCY and [18F]5F8HQ in 2% RCY. The final 
experiment utilising Re5NO28HQ (ten-fold equivalence of 0.80 µmol) under wet DMSO 
conditions applied a flow rate of 4 µL.min-1 and afforded [18F]Re5F8HQ in 2% RCY and 
[18F]5F8HQ in 1% RCY. Thus, while only comparatively low RCYs no greater than 2% could 
be attained, the rhenium complexation-dissociation approach was still able to afford the desired 
[18F]5F8HQ radioligand which was unable to be produced using traditional [18F]fluoride 
substitution techniques. 
 
 
Figure 205. RCY of [18F]Re5F8HQ (blue diamonds) and [18F]5F8HQ (orange crosses) 
synthesised from the Re5NO28HQ precursor as a function of reaction 
temperature while employing the same reaction conditions of 0.08 µmol of the 
Re5NO28HQ precursor, 29±10 MBq of [
18F]fluoride and a 47 s reaction 
temperature in dry DMSO solvent. 
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Figure 206. Radiochromatogram obtained for the radiofluorination of 0.08 µmol of 
Re5NO28HQ precursor in DMSO solution with 29±10 MBq of [
18F]fluoride 
for 47s in dry DMSO solvent at 170 °C. These conditions afforded 1% RCY of 
[18F]5F8HQ and 6% [18F]Re5F8HQ eluting at 3.4 and 5.7 mins, respectively. 
 
Figure 207. RCY of [18F]Re5F8HQ (blue diamonds) and [18F]5F8HQ (orange crosses) 
synthesised from the Re5NO28HQ precursor under wet conditions as a function 
of reaction temperature while employing the same reaction conditions of 0.08 
µmol of the Re5NO28HQ precursor, 29±10 MBq of [
18F]fluoride and a 47 s 
reaction temperature in wet DMSO solvent. 
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CHAPTER SIX 
RHENIUM-ETHENESULFONYL FLUORIDE 
CONJUGATION FOR PET-OPTICAL TRACER 
DEVELOPMENT 
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6.1 Ethenesulfonyl Fluoride and the Non-Radioactive 
Synthesis of its Rhenium Complexed Analogue 
 
Ethenesulfonyl Fluoride (ESF) is a small molecule reported as one of the strongest Michael 
acceptors in the current literature.[105-108] The fluorine-18 analogue of this compound, [18F]ESF, 
was developed in ANSTO laboratories for use as a prosthetic group for radiolabelling proteins, 
amino acids and other biomolecules.[109, 110] However, biomolecular conjugations to [18F]ESF 
demonstrated poor in vivo stability overall, leading to its alternative use as a radiofluoride relay 
agent. Nonetheless, conjugation of [18F]ESF to an amino-phenanthroline rhenium complex was 
hypothesised to be an alternative useful means of fluorine-18 labelling rhenium complexes for 
the development of PET-optical tracers. Thus, in order to test such conjugations of the 
radiolabelled prosthetic groups, non-radioactive standards first needed to be synthesised. 
Figure 208 shows the synthetic route used to obtain a model rhenium-ESF conjugate used in 
these experiments. The route first involved the Michael addition of ESF to 5-amino-1,10-
phenanthroline (PhenNH2) in DMF solution at room temperature, which afforded 5-N-(2-
aminoethylsulfonylfluoride)-1,10-phenanthroline (PhenESF) in 63% yield. Subsequent 
complexation of PhenESF to bromopentacarbonylrhenium(I) then afforded bromotricarbonyl 
(5-N-(2-aminoehtylsulfonylfluoride)-1,10-phenanthroline)rhenium(I) (RePhenESF) in 79% 
yield. Similarly, PhenNH2 was also complexed with bromopentacarbonylrhenium(I) via reflux 
in toluene solution to afford the bromotricarbonyl(5-amino-1,10-phenanthroline)rhenium(I) 
(RePhenNH2) precursor complex in 93% yield. 
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Figure 208. Synthetic route used to synthesise the non-radioactive standards PhenESF, via 
Michael-addition between PhenNH2, and RePhenESF via rhenium 
complexation with PhenESF. The RePhenNH2 precursor was also synthesised 
via rhenium complexation with PhenNH2. 
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6.1.1 Conjugation of ESF to 5-Amino-1,10-Phenanthroline 
 
 
Figure 209. PhenNH2 was conjugated with ESF in DMF solution to afford PhenESF in 
63% yield. 
 
Masses of PhenNH2 (1.000 g, 5.128 mol, 1.0 eq.) and ESF (847.0 mg, 7.7 mol, 1.5 eq.) were 
dissolved in a volume of DMF (10 mL) and stirred at room temperature (24 h). The resulting 
orange solution was then poured into a volume of water (300 mL), causing a yellow solid to 
precipitate. The precipitate was isolated via vacuum filtration and washed with water to remove 
residual DMF. Further purification was achieved by dissolving the crude material in a 
minimum of DMSO and eluting through a 40 g, C18 column using a gradient mobile phase 
composition of 0.1% TFA in water and acetonitrile (5% to 100% over 8 column volumes). The 
eluents containing the product were then combined, evaporated down under reduced pressure 
and dried by lyophilisation to attain a yellow powder (1.125g). 
The 1H-NMR spectrum of RePhenESF in DMSO-d6 solvent provided the expected integration 
for twelve protons, eight of which were relatively downfield shifted corresponding to the 
protons in the C−H bonds of the phenanthroline ring and the N−H bond of the secondary amine 
as shown in Figure 210. The retaining four protons existed as two signals arising from 
overlapping doublets of triplets forming apparent quartets with shared coupling constants of 
approximately 12 and 6 Hz. The 13C-NMR spectrum in Figure 211 exhibited sixteen carbon-
13 resonance signals, twelve pertaining to the carbon nuclei of the phenanthroline ring and the 
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remaining two resonance signals for the ethyl carbon-13 nuclei forming doublets due to 
coupling with the fluorine-19 nucleus. The coupling is further evident in the 19F-NMR 
spectrum of PhenESF in Figure 212, whereupon the triplet split resonance signal consisted of 
a 5.6 Hz coupling constant, closely aligned to that of the apparent quartets in the 1H-NMR 
spectrum. Elemental analysis further affirmed the purity of the compound with 54.54% carbon, 
3.63% hydrogen and 13.64% nitrogen observed against theoretical compositions of 55.07% 
carbon, 3.96% hydrogen and 13.76% nitrogen. 
 
 
Figure 210. 1H-NMR spectrum of PhenESF in DMSO-d6 showing the expected integration 
for twelve protons (eight from the phenanthroline ring and amine, four from the 
ethyl group). 
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Figure 211. 13C-NMR spectrum of PhenESF in DMSO-d6 showing the expected sixteen 
carbon-13 signals (twelve from the phenanthroline ring and four from fluorine 
splitting of the two carbon atoms within the ethylsulfonyl fluoride group). 
 
 
Figure 212. 19F-NMR of PhenESF exhibiting the fluorine-19 signal at approx. 58 ppm and 
with a 5.6 Hz coupling constant closely aligned with the coupling constants 
observed for the ethyl protons in the 1H-NMR spectrum. The expanded 
spectrum between 57.5-58 ppm, shown in the right-hand corner, clearly 
demonstrates the coupling of the fluorine-19 nucleus with the hydrogen nuclei. 
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6.1.2 Rhenium Complexation of the Phenanthroline-ESF 
Conjugate 
 
 
Figure 213. Complexation of PhenESF via reflux with bromopentacarbonylrhenium(I) to 
form RePhenESF in 79% yield. 
 
A mass of PhenESF (65.4 mg, 0.214 mmol, 1.0 eq.) was dissolved in a solution of 50% DCM 
in toluene (15 mL), to which an additional mass of pentacarbonylrhenium(I) bromide (79.1 mg, 
0.195 mmol, 1.1 eq.) was also added. The solution was then stirred and heated at reflux (2h). 
The solution was left to cool to room temperature and the DCM evaporated, where after the 
resulting precipitate was filtered via vacuum filtration, washed with diethyl ether and dried 
under vacuum to afford a yellow powder (110.4 mg). 
The 1H-NMR spectrum of RePhenESF, shown in Figure 214, depicts the same expected 
integration for twelve protons as was observed in the spectrum of PhenESF. However each of 
the proton resonance signals in the RePhenESF spectrum was downfield shifted with respect 
to PhenESF, as shown in Figure 215, due to withdrawal of electron density from the rhenium 
tricarbonyl center causing the aromatic protons to be more susceptible to the external magnetic 
field. The 13C-NMR spectrum of RePhenESF exhibits three carbon-13 resonance signals at 
197.4, 197.3 and 189.5 ppm corresponding to the carbon atoms of the three carbonyl ligands, 
as shown in Figure 216. An additional sixteen signals are also observed for the fourteen other 
carbon-13 nuclei due to coupling between the two ethyl carbon nuclei and the fluorine-19 
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nucleus of the sulfonyl fluoride group. The magnetic resonance signal of this fluorine-19 
nucleus is observed in the 19F-NMR spectrum of RePhenESF in Figure 217. The FTIR 
spectrum of the compound exhibits the two distinctive IR absorption bands for excitation of 
the A’(1) C≡O stretching frequency at 2025 cm-1 and the concurrent excitations of the A’(2) & 
A’’ C≡O stretching frequencies at 1919 and 1898 cm-1. The N−H bond stretching frequency of 
the secondary amine is also observed at 3348 cm-1, as well as weakly absorbing bands for the 
sp2 hybridised C−H stretching frequencies at 3050 cm-1 and 3005 cm-1 in Figure 218. 
Additionally, the HRMS spectrum of RePhenESF depicts the bromine-dissociated [M-Br]+ 
ion signal (ReC17H12N3O5SF
+) with m/z 576.00387 against a calculated ratio of m/z 576.00337 
(Δ 0.86 ppm) for the complex incorporating the 187Re isotope in 62.6% natural abundance, 
shown in Figure 219. An ion with m/z 574.00108 is also observed in this HRMS spectrum, 
corresponding to the same [M-Br]+ ion incorporating the 185Re isotope in 37.4% natural 
abundance. Elemental analysis further verified the purity of the complex as well as the identity 
of the bromo ancillary ligand, with compositions of 31.61% carbon, 1.85% hydrogen, 6.36% 
nitrogen, 4.79% sulfur and 12.05% bromine observed against theoretical compositions of 
31.15% carbon, 1.85% hydrogen, 6.41% nitrogen, 4.89% sulfur and 12.19% bromine. 
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Figure 214. 1H-NMR spectrum of RePhenESF in DMSO-d6 showing the expected 
integration for twelve protons in the molecule, as well as the expected downfield 
chemical shifts for the aromatic protons and the relatively upfield chemical 
shifts of the ethyl group protons. 
 
 
Figure 215. The magnetic resonance signals of the aromatic protons in RePhenESF are 
shifted downfield with respect to the aromatic protons in PhenESF in the same 
DMSO-d6 solvent due to electron withdrawal of the rhenium tricarbonyl centre. 
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Figure 216. 13C-NMR spectrum of RePhenESF in DMSO-d6 exhibiting nineteen carbon-13 
resonance signals, as expected given the perturbation of the carbon-13 nuclei in 
the three carbonyl ligands at greater than 180 ppm and the splitting of two 
carbon-13 nuclei in the ethyl group caused by coupling to the fluorine-19 
nucleus. 
 
 
Figure 217. 19F-NMR spectrum of RePhenESF in DMSO-d6 solvent showing the lone 
magnetic resonance signal of the fluorine-19 nucleus in the molecule at 71 ppm. 
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Figure 218. FTIR spectrum of RePhenESF exhibiting the two distinctive IR absorption 
bands for excitation of the A’(1) C≡O stretching frequency at 2025 cm-1 and 
overlapping excitation of the A’(2) & A’’ C≡O stretching frequencies at 1919 
and 1898 cm-1. Excitations of sp2 hybridised C−H stretching frequencies are 
also observed weakly at 3050 and 3005 cm-1, alongside the N−H bond stretching 
vibration of the secondary amine at 3348 cm-1. 
 
Figure 219. HRMS spectrum of RePhenESF depicting the bromine-dissociated [M-Br]+ 
ion signal (ReC17H12N3O5SF
+) observable at m/z 576.00387 with a calculated 
ratio of m/z 576.00337 (Δ 0.86 ppm) for the complex incorporating the 187Re 
isotope in 62.6% natural abundance. An additional signal with m/z 574.00108 
is also observed for the same ion incorporating the 185Re isotope in 37.4% 
natural abundance. 
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6.1.3 Rhenium Complexation of 5-Amino-1,10-Phenanthroline 
 
 
Figure 220. Complexation of PhenNH2 with a source of rhenium to synthesise RePhenNH2 
in 93% yield. 
 
The synthesis of RePhenNH2 was adapted from a literature method described by Bessette, et 
al.[111]. A mass of 5-amino-1,10-phenanthroline (0.49 g, 2.501 mmol, 1.0 eq.) was dissolved in 
a volume of toluene (30 mL) and heated to reflux. A mass of bromopentacarbonylrhenium(I) 
(1.00 g, 2.462 mmol, 1.0 eq.) was then added to the reaction mixture, whereupon the solution 
turned from yellow to orange in colour. The reaction mixture was left to stir under reflux under 
a constant supply of nitrogen gas for 1 hour. The solution was then cooled to room temperature 
and filtered via vacuum filtration, whereupon the precipitate was washed with n-hexane and 
dried to afford an orange powder (1.27 g). 
1H-NMR analysis of the compound revealed the expected integration for seven protons in the 
aromatic region as well as an integration for two protons of a broad resonance signal at 6.90 
ppm characteristic of the primary amine functional group, as shown in the spectrum in Figure 
221. The 13C-NMR spectrum of RePhenNH2 shown in Figure 222 exhibited the three carbon-
13 resonance signals above 180 ppm as characteristic of the three carbonyl ligands, alongside 
the expected twelve carbon-13 resonance signals in the aromatic region from the nuclei of the 
phenanthroline ligand. The FTIR spectrum, shown in Figure 223, depicts the symmetric N−H 
bond stretching frequency at 3492 cm-1 and the asymmetric bond stretching frequency at 3338 
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cm-1, providing further evidence of the presence of the primary aromatic amine. The spectrum 
also depicts the characteristic IR excitations of the A’(1) C≡O stretching vibrational mode at 
2012 cm-1 and overlapping A’(2) & A’’ C≡O stretching vibrational modes at 1894 cm-1, 
respectively, providing further evidence for the existence of the tricarbonyl centre. The HRMS 
spectrum of RePhenNH2 also showed a bromine-dissociated [M-Br]
+ ion signal 
(ReC15H9N3O3
+) observable at m/z 466.01988 with a calculated ratio of m/z 466.01959 (Δ 0.61 
ppm), corresponding to the complex incorporating the 187Re isotope in 62.6% natural 
abundance, as shown in Figure 224. An additional signal with m/z 464.01714 was also observed 
for the [M-Br]+ ion corresponding to the incorporation of the 185Re isotope in 37.4% natural 
abundance. Elemental analysis provided evidence of the bromo ancillary ligand, which was 
absent in the former analyses, as well as further evidence for the purity of the complex. 
Compositions of 33.06% carbon, 1.80% hydrogen, 7.64% nitrogen and 14.39% bromine were 
observed against closely aligned theoretical compositions of 33.04% carbon, 1.66% hydrogen, 
7.71% nitrogen and 14.65% bromine. 
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Figure 221. 1H-NMR spectrum of RePhenNH2 in DMSO-d6 exhibiting integration for the 
seven C−H aromatic protons and integration of the broad signal at 6.90 ppm for 
the two protons of the amine functional group. 
 
 
Figure 222. 13C-NMR spectrum of RePhenNH2 in DMSO-d6 exhibiting the expected fifteen 
carbon-13 resonance signals, including those for the three carbonyl ligands 
resonating at greater than 180 ppm. 
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Figure 223. FTIR spectrum of RePhenNH2 showing the two distinctive IR absorption bands 
for the A’(1) C≡O stretching vibrational mode at 2012 cm-1 and overlapping 
A’(2) & A’’ C≡O stretching vibrational mode at 1894 cm-1. The symmetric and 
asymmetric N−H bond stretches of the primary amine are also notably excited 
at 3492 cm-1 and 3338 cm-1, respectively. 
 
Figure 224. HRMS spectrum of RePhenNH2 depicting the bromine-dissociated [M-Br]
+ ion 
signal (ReC15H9N3O3
+) observable at m/z 466.01988 with a calculated ratio of 
m/z 466.01959 (Δ 0.61 ppm) for the complex incorporating the 187Re isotope in 
62.6% natural abundance. An additional signal with m/z 464.01714 is also 
observed for the same ion incorporating the 185Re isotope in 37.4% natural 
abundance. 
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6.1.4 Characterisation Data for the ESF Conjugates and 
Rhenium Complexes 
 
5-N-(2-Aminoethylsulfonylfluoride)-1,10-Phenanthroline (PhenESF) Orange Solid; MP: 200-
205 °C (dec.); 63% yield. 1H NMR (400 MHz, CDCl3, δ/ppm): δ 9.21 (dd, Jd = 4.32, 1.56 Hz, 
1H), δ 8.96 (dd, Jd = 4.32, 1.64 Hz, 1H), δ 8.26 (dd, Jd = 8.44, 1.52 Hz, 1H), δ 8.04 (dd, Jd = 
8.12, 1.64 Hz, 1 H), δ 7.65 (dd, Jd = 8.40, 4.32 Hz, 1H), δ 7.53 (dd, Jd = 8.08, 4.32 Hz, 1H), δ 
7.53 (dd, Jd = 8.08, 4.32 Hz, 1H), δ 6.71 (s, 1H), δ 5.03 (t, Jt = 6.08 Hz, 1H-NH-), δ 4.08 (app. 
q, Jq = 12.16, 6.08 Hz, 2H-CH2-SO2F), δ 3.89 (td, Jq = 6.16, 4.48 Hz, 2H-CH2-). 13C NMR (100 
MHz, CDCl3): δ 150.43, δ 147.44, δ 146.91, δ 142.31, δ 138.96, δ 129.59, δ 128.51, δ 123.27. 
δ 122.58, δ 122.02, δ 101.11, δ 49.66 (J = 15.08 Hz), δ 38.08. 19F NMR (376 MHz, CDCl3): δ 
70.67 (t, Jt = 4.63 Hz). FTIR (ATR corr. ṽ/cm-1): 3402 (w, br, N−H str.), 2933 (m, sp2 C−H 
str.), 2872 cm-1 (m, sp3 C−H str.), 1596 cm-1  (s, sh, asym. S=O str.), 1384 cm-1 (s, sh, sym. 
S=O str.), 818 cm-1 (m, S-F str.). LRMS (ESI+): m/z [M + H]+ calc. 306.07; found 306.23. 
HRMS (ESI+): [M + H]+ calc. 306.07070; found 306.07093 (Δ 0.74 ppm). UV-Vis (CH3CN, 
λ/nm, ε/L.mol-1.cm-1): λ 331 (ε 9099), λ 279 (ε 28578), λ 259 (ε 21861), λ 221 (ε 41646), λ 194 
(ε 22289). EA(%): C14H12O2N3SF calc. C 55.07, N 13.76, H 3.96. found C 54.54, N 13.64, H 
3.63. 
 
Bromotricarbonyl(5-N-(2-Aminoethylsulfonylfluoride)-1,10-Phenanthroline)rhenium(I) 
(RePhenESF) Yellow solid; MP: 295-301 °C (dec.); 79% yield. 1H NMR (400 MHz, DMSO-
d6): δ 9.28 (d, Jd = 5.04 Hz, 1H), δ 9.10 (d, Jd = 7.88 Hz, 1H), δ 9.03 (dd, Jd = 5.00, 1.12 Hz, 
1H), δ 8.53 (dd, Jd = 8.36, 1.12 Hz), δ 8.11 (dd, Jd = 8.82, 5.08 Hz, 1H), δ 7.87 (dd, Jd  = 8.36, 
5.00 Hz, 1H), δ 7.57 (t, Jt = 5.76 Hz, 1H-NH-), δ 7.16 (s, 1H), δ 4.41 (app. q, Jq = 11.88 Hz, 5.88 
Hz, 2H-CH2-SO2F), δ 3.96 (app. q, Jq = 11.56, 5.76 Hz, 2H-CH2-). 13C NMR (100 MHz, DMSO-
d6): δ 197.42, δ 197.33, δ 189.51, δ 153.48, δ 148.82, δ 146.68, δ 142.12, δ 140.37, δ 136.31, 
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δ 133.52, δ 132.52, δ 126.47, δ 125.45, δ 124.00, δ 99.41 (d, Jd = 26 Hz), δ 48.67 (d, Jd = 12 
Hz), δ 37.62. 19F NMR (376 MHz, DMSO-d6): δ 70.67 (t, Jt = 4.63 Hz). FTIR(ATR corr. ṽ/cm-
1): 3347 cm-1 (w, sh, N−H str.), 3051 cm-1 (w, sp2 C−H str.), 3003 cm-1 (w, sp3 C−H str.), 2025 
cm-1 (s, sh, A'(1) C≡O str.), 1919 cm-1 (s, sh, A'(2) C≡O str.), 1898 cm-1 (s, sh, A'' C≡O str.). 
LRMS (ESI+): m/z [M-Br]+ calc. 576.00; found 576.15. HRMS (ESI+): m/z [M-Br]+ calc. 
576.00337; found 576.00387 (Δ 0.86 ppm). UV-Vis (CH3CN, λ/nm, ε/L.mol-1.cm-1): λ 414 (ε 
2517), λ 347 (ε 7341), λ 297 (ε 16255), λ 243 (ε 25956), λ 194 (ε 39590). EA(%): 
ReC17H12O5N3SFBr calc. C 31.15, N 6.41, H 1.85, S 4.89, Br 12.19. found C 30.61, N 6.36, H 
1.85, S 4.91, Br 12.05. 
 
Bromotricarbonyl(5-amino-1,10-phenanthroline)rhenium(I) (RePhenNH2) Orange solid; MP: 
318-319 °C (dec.); 93% yield. 1H NMR (400 MHz, DMSO-d6): δ 9.40 (dd, Jd = 5.12, 1.20 Hz, 
1H), δ 9.11 (dd, Jd = 8.52, 1.20 Hz, 1H), δ 8.95 (dd, Jd = 5.00, 1.28 Hz, 1H), δ 7.24 (dd, Jd = 
8.44, 1.20 Hz, 1H), δ 8.05 (dd, Jd = 8.52, 5.12 Hz, 1H), δ 7.79 (dd, Jd = 8.36, 5.00 Hz, 1H), δ 
7.07 (s, 1H), δ 6.90 (s, br, 1H-NH2). 13C NMR (100 MHz, DMSO-d6): δ 197.50, δ 197.39, δ 
189.59, δ 153.35, δ 148.04, δ 146.68, δ 144.89, δ 139.65, δ 135.54, δ 134.29, δ 132.68, δ 126.19, 
δ 125.00, δ 123.56, δ 101.18. FTIR (ATR corr. ṽ/cm-1): 3491 cm-1 (w, asym. N−H str.), 3338 
cm-1 (w, sym. N−H str.), 3236 cm-1 (w, sp2 C−H str.), 2012 cm-1 (s, sh, A'(1) C≡O str.), 1921 
cm-1 (s, A'(2) C≡O str.), 1894 cm-1 (s, A'' C≡O str.). LRMS (ESI+, cone = 60 V): m/z [M - Br]+ 
calculated: 466.02; found: 466.17; m/z [M+H]+ calculated: 545.95 & 547.94, found: 546.05 & 
457.05. HRMS (ESI+): m/z [M-Br]+ calc. 466.01959; found 466.01988 (Δ 0.61 ppm). UV-Vis 
(CH3CN, λ/nm, ε/L.mol-1.cm-1): λ 416 (ε 2726), λ 348 (ε 10143), λ 296 (ε 24429), λ 244 (ε 
36535), λ 194 (ε 58783). EA(%): ReC15H9O3N3Br calc. C 33.04, N 7.71, H 1.66, Br 14.65. 
found C 33.06, N 7.64, H 1.80, Br 14.39. 
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6.2 Radiosynthesis of the [18F]ESF Prosthetic Group 
 
No-carrier added  [18F]ESF was first synthesised via [18F]fluoride substitution with 2,2,6-
trichlorophenylethenesulfonate (TCPE) by the mechanism proposed in Figure 225. The 
reaction was performed in DMSO using the automated microfluidic set-up assembled as per 
Figure 226. Here TCPE was supplied through pump 1, whereas the cyclotron eluted and 
azeotropically distilled [18F]fluoride was supplied through 2. Both solutions were passed 
through the 15.6 µL microreactor at a flow rate of 20 µL.min-1, whereupon a radioactivity 
detector monitored the elution of the reaction mixture. The outlet from the microreactor was 
connected to a closed vial (A) pressurized with nitrogen gas with a flow rate between 0.1 to 0.2 
L.min-1.Vial A was heated to 80 °C, resulting in the evaporation of [18F]ESF from the TCPE 
in DMSO solution. The gaseous effluents were passed through a silica light cartridge which 
trapped the radioactive impurities and eluted into another vial (B). Pressurisation of vial B from 
the nitrogen flow resulted in [18F]ESF being trapped on a likewise connected silica Plus SPE 
cartridge, with a vent attached to alleviate the pressure. An additional radioactivity detector 
was placed in proximity of the silica plus SPE cartridge to monitor the entrapment of the 
[18F]ESF radioproduct. The [18F]ESF was then eluted in water for the fluorine-18 radiolabelling 
of the PhenNH2 and RePhenNH2 precursors. 
 
Figure 225. Mechanism for the radiosynthesis of [18F]ESF from TCPE via substitution with 
complexed [18F]fluoride. 
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Figure 226. Microfluidic set-up used to produce n.c.a. [18F]ESF. TCPE in DMSO in 
supplied through pump 1 and azeotropically dried [18F]fluoride (eluent) is 
supplied through pump 2. Both solutions are passed through a 15.6 µL 
microreactor whereupon [18F]ESF is formed in solution. The outlet of the 
microfluidic system was connected to a closed vial (A) heated at 80 °C and 
pressurized with N2 gas (0.1 - 0.2 L.min
-1). The gaseous effluents from vial A 
were then directed through a silica light SPE cartridge (C) into a second vial (B). 
The outlet of vial B was connected to a Silica plus SPE cartridge (D) which 
trapped the distilled [18F]ESF. 
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6.2.1 [18F]ESF Conjugation to 5-Amino-1,10-Phenanthroline 
and its Rhenium Complex 
 
The radiolabelling experiments were performed by mixing 80 μL of 1 mg.mL-1 PhenNH2 and 
RePheNH2 solutions in DMSO with 20 µL of 93±19 MBq.mL
-1 of no-carrier added [18F]ESF 
aqueous solution. The reaction mixture was analysed by radioHPLC, with some reaction RCYs 
verified by radioTLC analyses, and the radioproduct identity was confirmed via retention time 
comparison with the non-radioactive standards. As shown in Figure 227, for the radiolabelling 
of the PhenNH2 ligand with [
18F]ESF, the radioproduct eluting at 258 s (4.30 mins) coincides 
with the UV absorbance peak of the non-radioactive PhenESF standard. Curiously, alongside 
the radiolabelled [18F]PhenESF product and unreacted [18F]ESF prosthetic group eluting at 
107 s (1.78 mins), degradation of the radiospecies to form [18F]fluoride was observed as well 
as the elution of an unknown radioactive by-product eluting at 231 s (3.85 mins). One 
hypothesis for this radioactive by-product may involve η2 coordination of the ESF allyl 
functional group to the rhenium centre via displacement of the bromo ligand. 
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Figure 227. UV absorbance chromatogram providing the 258 s retention time of the non-
radioactive PhenESF standard (red, top), which aligns with one of the 
radioproducts in the radiochromatogram (blue, bottom). 
 
An example chromatogram is also shown for the [18F]ESF conjugation of [18F]RePhenESF in 
Figure 228. The consistent degradation to form [18F]fluoride was likewise observed, alongside 
an unknown radioactive by-product eluting at 210 s (3.50 mins). A minute peak corresponding 
to the radioproduct can be shown in the zoomed in region at 414 s (6.90 mins), which 
corresponds to the retention time of the UV absorbance peak for the RePhenESF non-
radioactive standard in a separate injection. 
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Figure 228. UV absorbance chromatogram providing the 414 s retention time of the non-
radioactive RePhenESF standard (red, top), which aligns with one of the minor 
radioproducts in the zoomed in region of the radiochromatogram (blue, bottom). 
 
The non-isolated RCYs for the [18F]PhenESF and [18F]RePhenESF products provided in 
Figure 229 for reaction temperatures of 40, 70 and 100 °C. Radiolabelling of the PhenNH2 
precursor ligand increased as a function of reaction temperature; with an RCY of 13% forming 
at 40°C, 23% RCY forming at 70 °C and 34% RCY forming at 100 °C. The RCYs were also 
verified by radioTLC with near matching RCYs of 14% and 24% respectively, as shown in 
Figure 230. Given the volatile nature of [18F]ESF, higher reaction temperatures were not 
trialled which may afford even greater RCYs under pressurised conditions. The radiolabelling 
of PhenNH2 to afford the [
18F]RePhenESF product was far less efficient, however, with only 
253 
 
1-2% RCY determined by radioHPLC (and 3% RCY determined by radioTLC) irrespective of 
the reaction temperature. The integration of the radioTLC results are shown for [18F]PhenESF 
at 40 °C and 70 °C in Figure 231 and Figure 232, respectively, and for [18F]RePhenESF at 
40 °C in Figure 233. 
 
 
Figure 229. RadioHPLC determined non-isolated RCYs plotted as a function of reaction 
temperature for the [18F]ESF conjugation reactions to form [18F]PhenESF (red, 
diamonds) and [18F]RePhenESF (blue, crosses). 
 
254 
 
 
Figure 230. Sampled radioTLC results for the radiosyntheses of [18F]PhenESF (70°C L1, 
40 °C L2) and [18F]RePhenESF (40 °C L3) used to validate RCYs attained by 
non-isolated radioHPLC peak integrations. 
 
 
Figure 231. RadioTLC peak integration for reaction forming [18F]RePhenESF at 40 °C in 
3% RCY (2% by radioHPLC). 
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Figure 232. RadioTLC peak integration for reaction forming [18F]PhenESF at 70 °C in 24% 
RCY (23% by radioHPLC), accompanied by an unknown by-product. 
 
 
Figure 233. RadioTLC peak integration for reaction forming [18F]PhenESF at 40 °C in 14% 
RCY (13% by radioHPLC), accompanied by an unknown by-product. 
256 
 
6.3 Photophysical Properties of the Rhenium-ESF Conjugate 
 
Towards discerning the value of [18F]RePhenESF as a PET-optical agent, photophysical 
analyses were performed on both the non-radioactive RePhenNH2 precursor and RePhenESF 
product to comment on their respective optical properties. The UV-Vis spectra for both 
compounds shown in Figure 234 and Figure 235, exhibit dπ → π* absorption bands to the 
MLCT excited state at 416 nm (ε 2726 L.mol-1.cm-1) and 414 nm (ε 2517 L.mol-1.cm-1) for 
RePhenNH2 and RePhenESF respectively. Higher energy π → π* to LC excited states are 
also notably present at 348, 296, 244 and 194 nm for RePhenNH2, and 347, 297, 243 and 194 
nm for RePhenESF in acetonitrile solution. 
 
 
Figure 234. UV-Vis spectrum of RePhenNH2 (2 mg.mL
-1) in acetonitrile solution showing 
the dπ → π* transition to the MLCT excited state and π → π* transitions to the 
LC excited state. 
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Figure 235. UV-Vis spectrum of RePhenESF (5 mg.mL-1) in acetonitrile solution showing 
the dπ → π* transition to the MLCT excited state and π → π* transitions to the 
LC excited state. 
 
Excitation at 410 nm for both compounds in DMSO solution afforded emission maxima of 612 
nm for RePhenNH2 and RePhenESF for 621 nm as shown in Figure 236. When measured in 
aqueous media, containing only 5% v/v DMSO to aid solubility, RePhenESF exhibited a 
solvatochromic shift of the emission maxima to 606 nm. RePhenNH2 exhibited a relatively 
short excited state lifetime of less than 10 ns, in agreement with previously obtained 
photophysical data for the Re−Cl derivative of the compound in DMSO solution.[112] 
Interestingly, RePhenESF instead exhibited a much longer luminescence lifetime of 138 nm 
with a χ2 value of 0.995 for the fit of monoexponential decay from the MLCT excited state. 
Based on a measured absorbance maximum of 0.412  at 410 nm and an integration of 2.75×106 
counts⋅nm from the emission spectrum, which were substituted into equation (14) alongside 
the previously reported variables for [Ru(BiPy)3Cl], the quantum yield of RePhenESF in 
DMSO solution was determined to be 0.4%, as shown in Table 10. The quantum yields of 
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RePhenESF in 5% v/v DMSO in water solution and RePhenNH2 in DMSO solution were 
both determined to be less than 0.1%. 
 
Figure 236. Summary of photophysical properties in DMSO showing A) the quantum yield 
and lifetime for compounds RePhenNH2 (red) and RePhenESF (blue), B) the 
monoexponential decay profile for RePhenESF and C) the emission spectra of 
both compounds following excitation at 410 nm wavelength. 
 
Table 10. Quantum yield of RePhenESF in DMSO solution as determined by comparison 
with the [Ru(BiPy)3Cl] reference standard and with correction factors applied 
for the refractive index of the solvent, absorbance at the 410 nm excitation 
wavelength and the integration of the emission spectrum, as shown below. 
Analyte Solvent 
Refractive 
Index 
Absorbance 
Emission 
Integration 
(counts⋅nm) 
Quantum 
Yield (%) 
[Ru(BiPy)3]Cl Water 1.333 0.045 4.71×10
6 2.8% 
RePhenESF DMSO 1.479 0.242 2.75×106 0.4% 
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CHAPTER SEVEN 
CONCLUSIONS AND FUTURE WORK 
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7.1 Conclusions on the Fluorine-18 Labelling of Luminescent 
Rhenium Complexes 
 
The original intent of this work was to validate the underlying thesis that a luminescent rhenium 
complex could be radiolabelled with the fluorine-18 radioisotope and would have desirable 
properties for use as a PET-optical agent. Towards verifying this hypothesis, rhenium 
complexes were synthesised from ligands based on 1,10-phenanthroline and 2,2’-bipyridine N-
heterocyclic ligands bearing leaving groups for substitution with [18F]fluoride. Radiosynthesis 
of the 2-[18F]fluoro-1,10-phenanthroline bearing rhenium complex, [18F]Re2FPhen, resulted 
in a reasonable molar activity of 71 MBq.nmol-1. Additionally, the radiolabelled complex was 
not only found to afford considerable RCY at low temperatures (60 – 80% maximum RCYs 
formed between 30 to 50 °C) when compared to the radiolabelled ligand, [18F]2FPhen (40 – 
60% maximum RCYs formed at greater than 170 °C), though was also able to radiofluorinate 
under non-azeotropically dry reaction conditions. Fluorine-18 radiolabelling reactions which 
tolerate aqueous conditions are notably rare in the research literature and offer profound 
benefits for the labelling of drugs or biomolecules which are particularly sensitive to their 
reaction environments. Such labelling efficiencies were also observed in the rhenium 
complexed 2,2’-bipyridine systems which afforded RCYs greater than 80% and 60% for the 
[18F]Re6FBiPy and [18F]Re4FBiPy complexes, respectively. Given these promising 
radiofluorination efficiencies it can be claimed that fluorine-18 labelled rhenium complexes 
certainly have desirable properties for the use in PET tracer development. 
The optical properties of the rhenium complexes were also satisfactory, with quantum yields 
between 0.2% to 1.0% being determined depending on the functionalisation of the ligand and 
whether it was in DMSO or an aqueous environment. Such quantum yields are within the range 
of those reported for PET-optical agents based on cyanine dyes with methine chains, such as 
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the 0.4% quantum yield reported for the fluorine-18 labelled Cy5.5 dye by Priem, et al.,[61] 
though are still notably lower than PET-optical agents based, for instance, BODIPY 
luminescent structures. Satisfactory luminescent lifetimes between 0.014 µs and 0.138 µs were 
also measured and represent one of the few examples in literature that reported this crucial 
parameter for the synthesised PET-optical complexes. Thus, considering these results, it can 
also be claimed that rhenium complexes also have desirable properties for use in PET-optical 
tracer development. Further work towards improving the quantum yield of this new class of 
rhenium(I) based PET-optical agents would be desirable, however, if they are to compete with 
alternative fluorophores. 
  
262 
 
7.2 Significance of the Rhenium Mediated Method Discovered 
to Improve Fluorine-18 Radiotracer Synthesis 
 
Perhaps of greater significance, and certainly serendipitous in its finding, was the discovery 
that thermal decomplexation of the intended PET-optical rhenium complexes could be used to 
produce fluorine-18 labelled ligands which could not formerly be synthesised. This was 
particularly true for the [18F]6FBiPy and [18F]4FBiPy ligands which were discovered to form 
in as great as 51% and 27% RCY using the rhenium thermal decomplexation approach and 
which were unable to be formed from traditional nucleophilic substitution with the ligand 
precursors using azeotropically dried [18F]fluoride. While this method did not improve upon 
the radiosynthesis of the [18F]CABS13 Alzheimer’s disease imaging agent in preliminary tests, 
it did enable the radiosynthesis of another alternative fluorine-18 labelled 8-hydroxyquinoline 
ligand, [18F]5F8HQ,  which was also unable to be synthesised via traditional means. The use 
of such a method, as summarised in Figure 237, may be a valuable tool towards enabling the 
radiosynthesis of novel nuclear medicines and presents an exciting academic opportunity to 
further define the scope of precursors with which it can be applied to. 
 
Figure 237. Summary of the rhenium complexation-dissociation approach. A pyridinyl 
bidentate ligand which would otherwise not substitute for [18F]fluoride can be 
complexed, radiofluorinated and dissociated to afford the desired radioligand. 
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7.3 Future Work in Refining the Radiofluorination Method 
and Rhenium PET-Optical Hybrid Nuclear Medicines 
 
There are certainly many other bidentate ligands which rhenium activation could improve the 
radiofluorination of and, given sufficient lability of the ligand, could afford the fluorine-18 
labelled ligand in greater RCY also. Among these possibilities, testing the radiofluorination of 
monopyridine ligands could perhaps be of the greatest benefit given the widespread use of 
fluorine-18 labelled monopyridine systems in the field; such as [18F]MEL050 used in the 
imaging of melanin in skin cancers, [18F]T807 used to image tau proteins in Alzheimer’s 
disease and [18F]NIDA522131 used for the imaging of acetylcholine receptors, each shown in 
Figure 238.[113-115] This could be achieved by complexing the monopyridine as an ancillary 
ligand to the rhenium centre, alongside a bidentate ligand with electron withdrawing groups to 
aid in the electron withdrawal from the monopyridine π-system, thus improving the 
nucleophilic aromatic addition of [18F]fluoride. As this would be a monodentate ligand, 
dissociation could likely be achieved more efficiently and at lower temperatures given its 
greater lability. This concept could also be applied to the radiofluorination of other such N-
heterocyclic ligands, such as tetrazoles or triazoles. Alternatively, the addition of such 
monodentate pyridine ligands with electron withdrawal ligands could also improve 
radiofluorination on the bidentate ligand, though may be much harder to complex to the 
rhenium centre. The use of two microreactors in series to control the rates of radiofluorination 
and decomplexation, as discussed in Chapter Five, could also greatly enhance the RCYs of the 
fluorine-18 labelled ligands reported herein. Determining the identity of the unidentified by-
product that formed from dissociation of the fluorine-18 labelled 2,2’-bipyridine complexes 
would also greatly help towards designing methods which limit its formation and thus improve 
the RCY of the desired radioproducts. Towards this aim, loss of the radioproduct following 
addition of a silicon-based fluoride scavenger could suggest formation of a Re–18F bond.[116] 
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Figure 238. Examples of fluorine-18 labelled monopyridine radiotracers of varying 
applications with which the rhenium complexation-dissociation approach could 
potentially be applied to improve overall RCYs or means of production. 
 
Furthermore, while the thermal dissociation approach proved to be a highly effective strategy 
for decomplexing the radiolabelled rhenium complexes to achieve the corresponding fluorine-
18 labelled ligands, alternative decomplexation strategies are certainly worth investigating. 
Acid or light induced decomplexation, for instance, may enhance the RCY of the desired 
fluorine-18 labelled ligand while minimising the formation of the radioactive unidentified by-
product. Such alternative approaches may also be useful for dissociating less labile ligands, 
such as 1,10-phenanthroline, thus expanding the scope of radiotracer product with which this 
method could be applied to. Verifying the identity of the unknown by-products would 
furthermore aid in designing improved reaction conditions which circumvent their formation. 
Also, worth considering is the incorporation of other metal centres. If the activation effect can 
be explained largely in terms of electron withdrawal from the metal centre, then other metals 
may perhaps be able to achieve a similar effect with perhaps greater advantages. A manganese 
tricarbonyl centre, for instance, would certainly be worth investigating given that it is a group 
VII transition metal akin to rhenium with purportedly lesser complex stability.[117, 118] Thus, 
decomplexation of such a complex may occur more readily and at lower temperatures to 
liberate more of the fluorine-18 tracer. 
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From the perspective of improving the use of these rhenium complexes as PET-optical agents, 
ancillary ligands bearing conjugated π-systems could significantly improve the quantum yield, 
as seen in literature examples, compared to other PET-optical agents (for instance of the 
BODIPY class). The utility of this new class of complexes as PET-optical agents will 
ultimately rely on their subsequent bioconjugation, the nature of which will depend on the 
application being explored. In contrast to the Michael-donating strategy used to conjugate the 
rhenium complex to [18F]ESF in the synthesis of RePhenESF, such conjugation strategies 
could alternatively exploit the electron withdrawing property of the rhenium centre to improve 
the Michael-acceptor ability of the complex for conjugation to the free amine or thiol groups 
of lysine or cysteine amino acids. Additionally, these reagents could also find potential utility 
as SPECT-optical theranostic agents by incorporating the radioactive rhenium-188 
radioisotope in the complex centre.[119, 120] Overall there remains a bright future for the use of 
rhenium in fluorine-18 labelled PET tracers, both for the addition of an optical emission 
modality and for the improved radiosynthesis of certain ligands, which warrants much greater 
exploration. 
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Abstract: Azeotropic distillation is typically required to
achieve fluorine-18 radiolabeling during the production of
positron emission tomography (PET) imaging agents.
However, this time-consuming process also limits fluorine-
18 incorporation, due to radioactive decay of the isotope
and its adsorption to the drying vessel. In addressing
these limitations, the fluorine-18 radiolabeling of one
model rhenium(I) complex is reported here, which is sig-
nificantly improved under conditions that do not require
azeotropic drying. This work could open a route towards
the investigation of a simplified metal-mediated late-stage
radiofluorination method, which would expand upon the
accessibility of new PET and PET-optical probes.
Positron emission tomography (PET) plays an important clinical
role towards unveiling the underlying biochemistry of diseases
through the administration of positron (b+) emitting radio-
pharmaceuticals. Radiosynthesis of most PET tracers needs to
be performed quickly to obtain a large enough dose for a suc-
cessful PET imaging experiment, owing to the radioactive
decay of the b+ emitting isotope. Therefore, the production of
PET radiotracers is performed using automated synthesis mod-
ules, and many research groups have worked towards integrat-
ing microfluidic technologies to reduce the radiation dose,
miniaturize the workspace, and improve production.[1] Fluo-
rine-18 is the most commonly employed PET radioisotope,
owing to its 97% b+ decay profile, ideal 109.7 min half-life,
and low 0.64 MeV b+ energy.[2] However, one drawback is that
fluorine-18 is generally produced by the cyclotron-mediated
18O(p,n)18F reaction on oxygen-18 enriched water, which af-
fords [18F]fluoride in an aqueous environment, which is typical-
ly unreactive towards nucleophilic substitution; nonetheless,
the interest in employing this unfavorable aqueous environ-
ment has inspired some innovative approaches.[3] Traditionally,
to provide an anhydrous environment, the [18F]fluoride in
water is trapped on an anion-exchange resin (thus also remov-
ing radioactive cationic impurities), eluted with a complexing
agent in aqueous/organic solvent mixture, and azeotropically
dried in a distillation vial. This azeotropic drying is an ineffi-
cient and time-consuming process (>15 mins),[4] during which
period, radioactivity (+10%) is lost due to the radioactive
decay of the fluorine-18 isotope, as well as non-specific ad-
sorption of [18F]fluoride to the surface of the distillation vial,
leading to lower radiochemical yield (RCY) of the PET radiotrac-
er.[3, 5]
Having been inspired by recent efforts to couple PET imag-
ing with an optical tracer to complement disease diagnosis,[6]
and given our experience in the use of phosphorescent
rhenium(I) tricarbonyl diimine systems as optical markers for
live cell imaging and diagnosis of pathologies,[7] we sought to
investigate the fluorine-18 radiolabeling of this class of rheni-
um complexes as potential precursors for the future develop-
ment of PET-optical multimodal markers. Scheme 1 shows the
synthetic route used to synthesize the ligand (3) and complex
(5) precursors, as well as the non-radioactive standards 4 and
6. N-Oxidation of 1,10-phenanthroline allowed for selective
chlorination in the 2-position by the Vilsmeier reagent to
afford 3. Nucleophilic aromatic substitution with azeotropically
dried fluoride, using 18-crown-6 as a phase-transfer catalyst,
then afforded the novel 2-fluoro-1,10-phenanthroline ligand
(4). Ligands 3 and 4 were then chelated to a ReI metal center
to attain complexes 5 and 6, respectively (see the Supporting
Information, sections 1.1–1.5).
The radiosyntheses of [18F]4 and [18F]6, from 3 and 5 precur-
sors, respectively, were automated by means of a flow chemis-
try set-up adapted from our previous work,[8] as shown in
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Figure 1. Within this set-up, aqueous [18F]fluoride was first
passed through an MP1 cartridge and eluted with tetraethy-
lammonium bicarbonate (TEA+HCO3
@) in 90% CH3CN:H2O so-
lution. The resulting [18F]TEA+F@ complex was then either
azeotropically dried (“dry” conditions) or not azeotropically
dried (“wet” conditions), before being loaded into the micro-
reactor alongside the desired precursor solution (3 or 5).
The RCYs obtained for the radiosynthesis of [18F]4 from 3
under varying temperature conditions are illustrated in
Figure 2. These conditions employed the same residence times
(47 s) and precursor amounts (0.08–0.12 mmol) within the mi-
croreactor. Under traditional dry conditions, the RCY of ligand
[18F]4 followed the expected trend, whereupon the yield in-
creases as a function of temperature.[8] In this instance, [18F]4
only formed at temperatures greater than 130 8C, providing
a maximum RCY of 61% at 190 8C. The radiosynthesis of com-
plex [18F]6 from 5 was then attempted under analogous dry
conditions, and the dependence of RCY on temperature is illus-
trated in Figure 3.
Intriguingly, in this case we observed an opposite trend to
the ligand, whereupon the complex [18F]6 only formed at tem-
peratures below 150 8C (in contrast to the ligand [18F]4, which
required higher temperatures to afford a radioproduct). The
RCYs for the complex [18F]6 were also noticeably lower than
that of the ligand [18F]4, with a maximum of 19% RCY obtained
Scheme 1. Synthesis of radiolabeling precursors 3 and 5, and non-radioac-
tive standards 4 and 6. Refer to the Supporting Information, sections 1.1–1.5
for detailed procedures.
Figure 1. Simplified schematic of the flow chemistry configuration assem-
bled for the automated syntheses of compounds [18F]4 and [18F]6.
Figure 2. Temperature dependence of nucleophilic aromatic substitution of
ligand 3 with [18F]fluoride under azeotropically dried (red crosses) and non-
azeotropically dried (blue squares) conditions.
Figure 3. Temperature dependence of nucleophilic aromatic substitution of
complex 5 with [18F]fluoride under azeotropically dried (red crosses, “dry”)
and not azeotropically dried (blue squares, “wet”) conditions.
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at 30 8C; in addition, there was the clearly noticeable appear-
ance of a UV-absorbing degradation product (Figure 4). We
suspected that this byproduct could be due to base-mediated
degradation of 5, and we indeed verified this by analyzing in
HPLC a DMSO solution of 5 spiked with 5 mL of 5n NaOH.
Therefore, we sought to suppress this undesired process by
modifying the basicity of the reaction media. Thus, the radio-
synthesis of [18F]6 was performed under wet conditions,
whereupon azeotropic drying was excluded while preparing
the radiofluorinating solution, which realized a 10% v/v con-
tent of H2O. Such wet conditions have been shown previously
to be influential in the formation of different reaction prod-
ucts[9] or improved RCYs; to our delight, the radiosynthesis of
[18F]6 under wet conditions was successful and we achieved as
large as 78% RCY at a temperature as low as 50 8C. Residence
times and precursor amounts were also optimized to maximize
the RCY (see the Supporting Information, section 3.1), yielding
[18F]6 in as high as 87% RCY when using 0.38 mmol of precur-
sor within a residence time of 47 s. Significantly less of the
degradation product from 5 was observed under these wet
and low temperature conditions, confirming the desired switch
from degradation to improved nucleophilic displacement by
[18F]fluoride in these aqueous conditions. To verify that the ReI
center was influential in facilitating nucleophilic substitution in
the 2-position in such extremely mild conditions, we also per-
formed the radiosynthesis of the ligand [18F]4 under identical
wet conditions, which, as expected, afforded no radioproduct
at all, as shown in Figure 2. It is suspected that the electron-
withdrawing nature of the ReI metal center, due to the p-ac-
ceptance of the CO ligands, may activate the 2-position of
phenanthroline for improved nucleophilic substitution at low
temperatures. Mechanistic studies are currently underway in
our labs to explain why the presence of water favors the radio-
fluorination reaction so greatly.
The direct radiolabeling of the ReI tricarbonyl diimine com-
plex was also compared to a two-step automated radiosyn-
thetic process.[10] Using microfluidic technology, we assembled
a second microreactor in series, alongside a fourth pump to
supply the Re(CO)5Cl precursor, as shown in Figure 5. RCYs as
great as 35% were able to be achieved using +5V stoichio-
metric equivalents of Re(CO)5Cl compared to 3, as shown in
Figure 6, despite the residual basic conditions from the reac-
tion in the first microreactor. Therefore, this unprecedented
two-step microfluidic approach indeed led to the desired final
Figure 4. UV absorbance (254 nm, solid blue) and superimposed radioactive
(dashed red) profiles, for dry and wet analogous conditions (top and
bottom, respectively). UV active degradation byproduct (Rt : 3 min) is re-
duced under wet conditions. Rt : [
18F]F@ (RAD, 1 min), [18F]6 (RAD, 3.7 min) 5
(UV, 6.2 min).
Figure 5. Simplified schematic of the flow chemistry configuration assembled for the automated two-step radiosynthesis of [18F]6.
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product by marginally increasing total process time (4 vs.
10 min), but provided a reduced RCY compared to the direct
milder radiofluorination of 5. A process involving the purifica-
tion of [18F]4 and performance of a separate 2nd step reaction
was not attempted, as it would have involved a much longer
and more complex system resulting in further radioactive
decay.
Before performing the radiolabeling using microfluidic sys-
tems, we were unable to synthesize 6 from 5 using the usual
heated and anhydrous conditions that afforded 4 from 3.
Given the resulting formation of [18F]6 from 5 under wet, low
temperature conditions, we revisited the bulk non-radioactive
synthesis and attempted the reaction of 5 to 6 under analo-
gous conditions. UV reaction monitoring revealed that com-
plex 6 did indeed form under these wet and low temperature
conditions (32% HPLC conversion), thus demonstrating how
fast and efficient microfluidic optimization can be also used to
identify the best reaction conditions for bulk syntheses.
Photophysical properties of 6 were also assessed, to investi-
gate the effect of replacing a chloro for a fluoro substituent in
the 2-position of phenanthroline, given our initial research in-
centives to develop PET-optical probes. We therefore verified
that these ReI complexes afforded similar quantum yields (F=
0.3%), lifetimes (t=27–41 ns), emission maxima (lex=410 nm,
lem=653–654 nm) and monoexponential decay profiles in
DMSO (see the Supporting Information, sections 4.1–4.3).
In summary, the fluorine-18 radiolabeling of a ligand com-
plexed to ReI was found to afford optimal RCYs under remarka-
bly mild conditions, without the need for azeotropic distillation
and with a reduction of >100 8C for the optimal temperature.
Further investigations will clarify the involvement of the ReI
center in the radiofluorination mechanism, and will seek to
apply this radiolabeling strategy toward improving the RCY of
existing PET tracers, as well as toward accessing new PET and
PET-optical probes.
Experimental Section
Aqueous [18F]fluoride was produced on an IBA Cyclone 18 Twin cy-
clotron (ANSTO, Camperdown, Australia) using the 18O(p,n)18F nu-
clear reaction. Microfluidic radiosyntheses were performed in Dis-
covery Mode using a NanoTek LF Microfluidic Synthesis System
(Advion, Ithaca, NY) connected to a standard laptop using the
NanoTek software, V1.4.0 GMP Lite. Microreactors were made of
fused silica tubing (100 mmV2 m), coiled tightly into a brass ring
containing a thermoresistent polymer to hold the tubing in place.
RadioHPLC analyses were carried out using a Shimadzu system
comprised of a CBM-20 controller, LC-20AD pump, SIL-20AHT auto-
injector, SPD-M20A PDA detector (for UV analyses) and a Lablogic
Posi-RAM gamma detector. Analyses were performed using isocrat-
ic conditions consisting of CH3CN/H2O/TFA mobile phases
(7.95:91.95:0.10% v/v for [18F]4 and 64.95:34.95:0.10% v/v for
[18F]6), on a Chromolith RP column (monolith system, Merck, 50V
4.6 mm). RCYs were calculated using the radio-HPLC profiles, inte-
grating the radioproduct peak against all the other radioactive
peaks (inclusive of the unreacted [18F]fluoride), using Laura V4.1.70
SP2 HPLC data analysis software.
The microfluidic experiments were carried out on the scale of 29:
10 MBq, and afforded [18F]6 with a molar activity of 71:
12 MBqnmol@1.
Experimental details concerning the general syntheses, structure
elucidation, radiochemistry, and photophysical characterizations of
the reported compounds can be found in the Supporting Informa-
tion, sections 5.1–5.3.
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Effect of Rhenium(I) Complexation on Aza-Michael
Additions to 5-Amino-1,10-Phenanthroline with [18F]
Ethenesulfonyl Fluoride towards PET Optical Tracer
Development
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Conjugations with the recently developed [18F]ethenesulfonyl fluoride ([18F]ESF) were performed on 5-amino-1,10-
phenanthroline, in its free form and coordinated to a rhenium(I) tricarbonyl complex, as ameans of radiosynthesizing dual-
modal optical and positron emission tomography (PET) tracers. The Michael-donating ability of the aromatic amine was
noticeably perturbed on coordination with the rhenium(I) centre, resulting in decreased radiochemical yields from 34%, in
the case of the free ligand, to 1%. We attribute the decreased nucleophilicity of the amine to metal deactivation from the
electron-withdrawing feature of the rhenium(I) tricarbonyl centre, based on spectroscopic and computational evidence,
thus highlighting this effect as a crucial parameter in designing late-stage metal coordination methods employing related
aza-Michael additions. Photophysical analyses were also performed on the ESF-conjugated rhenium(I) complex,
exhibiting a longer decay lifetime from the triplet metal-to-ligand charge transfer excited state when compared with
the non-conjugated analogue.
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Introduction
Aza-Michael additions are an invaluable tool for forming
molecular linkages as well as bioconjugating peptides and
proteins, typically through the free e-amino groups of lysine
units or alternative N-terminals of end-chain amino acids.[1–3]
The reaction mechanism involves the bonding of free amine
Michael donors to a,b-unsaturated olefin Michael acceptors,
and generally progresses relatively fast compared with other
enolate or thia-Michael additions.[4] Furthermore, aza-Michael
additions can function under physiological temperatures and do
not require deprotonation of the donating group by an external
base,[5,6] thus suppressing the likelihood of denaturing any
biomolecular target. However, limited applicability of aza-
Michael additions has been noted in the conjugation of organ-
ometallic complexes bearing aMichael-donatingmoiety. As the
presence of a metal centre can reduce the nucleophilicity of the
donating group, synthetic routes tend to synthesize conjugated
ligands before late-stage metal complexation.[6–8] Despite this
hindrance, towards our development of positron emission
tomography (PET) optical tracers coupling the fluorine-18
radioisotope (109.7 min half-life) with luminescent rhenium
complexes,[9] it was hypothesized that any loss of radiochemical
yield (RCY) due to metal deactivation effects may in fact be less
detrimental than the loss of RCYdue to radioactive decay during
the metal complexation phase. We compared Michael addition
reactions on 5-amino-1,10-phenanthroline (PhenNH2) as a
stand-alone substrate or coordinated to a rhenium(I) tricarbonyl
centre with our recently developed peptide-labelling prosthetic
group, [18F]ethenesulfonyl fluoride ([18F]ESF).[10] In addition,
we modelled the reaction pathway via density functional theory
(DFT) techniques to gain an improved mechanistic insight on
the influence of rhenium deactivation, and characterized the
photophysical properties of the rhenium complexes for use as
optical probes.
Results and Discussion
Non-Radioactive Syntheses
The synthetic route used to obtain PhenESF, RePhenNH2,
and RePhenESF is shown in Fig. 1 (rt, room temperature). To
bioconjugate the probe for use as a PET optical imaging agent,
the bromo-ancillary ligand of the RePhenESF complex is
envisioned to be easily substituted for a suitable ancillary
monodenate ligand, either bearing or modified with a
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pyridine,[11–13] tetrazole[14] or similar N-heterocyclic func-
tional group,[15] for conjugation to a biological vector. The
synthesis of the non-radioactive RePhenESF standard was
performed by Michael addition of ESF to PhenNH2, which
afforded a reaction yield of 63% in DMF at room temperature.
Subsequent complexation of PhenESF to bromopentacarbo-
nylrhenium(I) afforded the desired product in 79% yield when
refluxed in a 1 : 1 DCM/toluene mixture, from which the tar-
geted complex could be separated with high purity by simple
filtration. Similarly, PhenNH2 was complexed with bromo-
pentacarbonylrhenium(I) in toluene solution, in accordance
with the previously reported synthesis of RePhenNH2,
[16]
affording the complex in 93% yield. NMR and IR spectra can
be viewed in Figs S1–S11 and Figs S1, S2 of the Supplemen-
tary Material respectively.
Direct 18F/19F Exchange of PhenESF and RePhenESF
In a preliminary attempt towards the radiosynthesis of [18F]
PhenESF and [18F]RePhenESF, we tested the 19F/18F
direct exchange of the non-radioactive analogues using
cyclotron-produced [18F]fluoride. The [18F]fluoride was
eluted off a QMA cartridge using tetraethylammonium (TEA)
hydrogen carbonate, azeotropically dried with anhydrous
acetonitrile, and reconstituted in anhydrous DMSO. The
resulting solution afforded 32 7 MBq mL1 of activity. The
[18F]fluoride solution (20 mL) was then added to a volume of
PhenESF (80 mL, 2.5 mg mL1), which afforded a 2% RCY
for [18F]PhenESF and 3% RCY for an unknown product. The
19F/18F direct exchange on RePhenESF (5 mg mL1), how-
ever, did not afford any radioproduct. The direct exchange on
RePhenESF was also attempted in a solution of ethanol under
analogous conditions using 107 22 MBq mL1 of radioac-
tivity, though still exhibited no yield. Thus, [18F]ESF was
instead used to produce the radiotracers via aza-Michael
addition.
Radiolabelling of PhenNH2 and RePhenNH2 with [
18F]ESF
The aza-Michael additions were performed by mixing 80 mL of
1 mg mL1 PhenNH2 and RePhenNH2 solutions in DMSO
with 20 mL of 93 19 MBq mL1 no-carrier added [18F]ESF
aqueous solution. The reaction mixture was analysed by radio-
HPLC, and the radioproduct identity was confirmed via reten-
tion time comparison against the UV absorbance peak of the
non-radioactive standard. As can be seen in Fig. 2, related to the
conjugation of PhenNH2, the radioproduct eluting at 258 s
coincides with the UV absorbing peak of the separately injected
PhenESF non-radioactive standard. Curiously, alongside the
radiolabelled [18F]PhenESF product and unreacted [18F]ESF
(107 s elution), we observed not only degradation to form [18F]
fluoride but also an unknown radio by-product eluting at 231 s.
In Fig. 3, example chromatograms are also shown for the UV
absorbance of the non-radioactive standardRePhenESF and the
elution profile for the radiosynthesis of [18F]RePhenESF from
RePhenNH2. Here, we observed also the consistent degradation
of unreacted [18F]ESF to form [18F]fluoride, accompanied by an
unknown by-product eluting at 210 s. One hypothesis for the
identity of this unknown by-product could involve the direct
interaction of the allyl functional group with the rhenium(I)
centre by displacement of the bromo ligand, for instance through
Z2 coordination. At 414 s, we observe a minute peak for a radio-
product, shown in the zoomed-in region of Fig. 3, which cor-
responds with the UV absorbance peak for [18F]RePhenESF.
The non-isolated RCYs for these radioproducts were then
determined by calculating the ratio of the integrated peak area
for the radioproduct against the integrated area of the entire
radiochromatogram. The determined RCYs for these radi-
olabelled products are shown in Fig. 4 for each of the three tested
temperature conditions. Radiolabelling of the ligand resulting in
[18F]PhenESF improved as a function of higher temperature,
with an RCY of 13% forming at 408C, 23% RCY forming at
708C, and an improved RCY of 34% forming at 1008C. The
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Fig. 1. Conditions used to synthesize the novel compounds PhenESF via
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alongside unreacted [18F]ESF and degraded [18F]fluoride.
Rhenium Complexation on Aza-Michael Additions 289
RCYs at 408C and 708Cwere also further verified by radio-TLC
with closely matching yields of 14 and 24% respectively, as
shown in Fig. S3.1–S3.4 of the Supplementary Material. Higher
temperature conditions were not trialled given the volatile
nature of ESF within our experimental set-up. The radiolabel-
ling of RePhenNH2 to afford [
18F]RePhenESF was not as
efficient, however, forming only 1–2% RCY by radio-HPLC
(3% by radio-TLC) irrespective of the reaction temperature
(Fig. 4).
Mechanism of ESF aza-Michael Additions with PhenNH2
and RePhenNH2 by DFT Analyses
To investigate the difference in these radiolabelling efficiencies,
we studied the mechanisms of the two reactions by DFT, using
crystal structures previously obtained by S´witlicka-Olszewska
et al.[17] In both cases, the first molecular event occurs via
nucleophilic addition (‘attack’) by the lone electron pair of the
amino group at the b-carbon of ESF, thus forming the first
transition state (TSattack). The attack is directed by a hydrogen
bond existing between the amino group and the oxygen atom of
ESF and leads to an intermediate species (Int) with charge
separation. The negative charge is present on the a-carbon and
the positive charge is present on either the nitrogen (uncoordi-
nated phenanthroline) or shared between the sulfur and the
oxygen atoms (coordinated phenanthroline). Successively, one
proton shifts from the nitrogen to the a-carbon, affording the
final product (Fig. 5). In agreement with experimental results,
the activation free energy of all the steps is higher in the presence
of the metal centre (40.8 instead of 36.8 kcal mol1
(1 kcal mol1¼ 4.186 kJ mol1) for the rate-determining step),
indicating that the amine group on the phenanthroline is less
reactive when coordinated to the rhenium. When also compar-
ing the electronic and geometrical properties of PhenNH2 and
RePhenNH2, the C–NH2 bond is noticeably longer for the
complexed ligand than in the free ligand (1.394 and 1.389 A˚
respectively), and the lone pair of the nitrogen atom is also more
occupied in the uncoordinated ligand than in the coordinated
analogue (natural orbital occupancy of 1.79 and 1.75 e respec-
tively), in accordance with the natural bond order (NBO) anal-
ysis (refer to Fig. S4 of the Supplementary Material for more
detail). This information suggests that greater electron density
resides in the C=N p-bond when coordinated to rhenium(I) and
therefore is less available for nucleophilic attack by the amine,
in agreement with the experimental data. The natural orbital for
chemical valance–charge displacement (NOCV-CD) analysis of
RePhenNH2 reveals that the rhenium–PhenNH2 bond can be
decomposed into four main contributions, two of which are
related to PhenESF - Re s-donation and the other two
describe the Re- PhenESF p-backbonding donation. In all of
these contributions, the ligand is polarized, with a depauperation
of the ligand electronic density (depicted in Fig. S4.1–S4.2 in the
Supplementary Material). This hypothesis is further backed by
the downfield shift in proton signals displayed in the compara-
tive NMR spectra between PhenESF and RePhenESF, shown
in Fig. 6, which is consistent with a loss of electron density
evident from the diminished effect of magnetic shielding. Also
in this case, the NOCV-CD analysis on RePhenESF denotes a
depauperation of the ligand electronic density qualitatively
similar to that forRePhenNH2 in agreementwith theNMRdata.
Photophysical Characterization Following Michael
Addition of PhenNH2 with ESF
In accordance with our intentions to further develop the probe
for PET optical imaging, we assessed the photophysical prop-
erties of RePhenNH2 in comparison with its Michael addition
product RePhenESF. The UV-vis spectra for both compounds,
shown in Fig. S6.1–S6.2 of the Supplementary Material, exhibit
dp-p* absorption bands to the metal-to-ligand charge transfer
(MLCT) excited state at 416 nm (extinction coefficient e
2726 L mol1 cm1) and 414 nm (e 1835 L mol1 cm1) for
RePhenNH2 and RePhenESF respectively. Higher-energy
p-p* bands are also present at shorter wavelengths, 348, 296,
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244, and 194 nm for RePhenNH2, and 347, 297, 243, and
194 nm for RePhenESF. Following excitation at 410 nm for
both compounds in DMSO solution, emission maxima of
612 nm for RePhenNH2 and 621 nm for RePhenESF were
obtained, as shown in Fig. S7.2 of the Supplementary Material.
Whereas RePhenNH2 exhibited a relatively short excited state
decay lifetime of less than 10 ns, in agreement with previously
obtained photophysical data for the Re–Cl derivative in
DMSO,[18]RePhenESF instead exhibited a longer luminescent
lifetime of 138 ns with a x2 value of 0.995 for the fit of mono-
exponential decay from the MLCT excited state. The photo-
physical properties of RePhenESF were also assessed in
aqueous media, containing 5% DMSO to aid solubility, which
resulted in a solvatochromic shift of the emission maxima to
606 nm.
Conclusion
Rhenium(I) deactivation was evident in both the obtained NMR
spectra and difference in Gibbs free energy calculated along the
reaction coordinate of our mechanistic studies by DFT analysis.
Despite our underlying hypothesis that a loss of RCY could be
minimized by circumventing multistep radiosynthesis via
aza-Michael addition of [18F]ESF to an already rhenium(I)
deactivated complex, the RCYs attained for this radiolabelled
complex were negligible compared with the ligand under all
temperature conditions. Photophysical studies of the conjugated
complex affirm the typical longer decay lifetime from the
MLCT excited state exhibited by rhenium(I) tracers and mark
potential for development of the compound as an optical probe
coupled with PET imaging modality.
Experimental and Computational Methods
Chemical Reagents
All chemical reagents, including the 5-amino-1,10-phenan-
throline, bromopentacarbonylrhenium(I), and ESF reactants,
were purchased from Sigma–Aldrich. All solvents were pur-
chased fromMerck.Water was purified using aMerckMillipore
Milli-Q integral water purification system.
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Instruments Used in Non-Radioactive Characterization
Quality control HPLC analyses were performed on a Waters
HPLC system equipped with a Waters 626 pump, inline
degasser AF unit, 717-plus autosampler, 2996 photodiode array
(PDA) detector, 2424 evaporative light scattering (ELS)
detector, and 600S controller. A Waters Bridge Columns
XBridge (C18, 3.5 mm pore size, 4.6 mm internal diameter (ID),
50 mm length) column was employed. An isocratic method was
applied using 10% acetonitrile in water containing 0.1% TFA
modifier with a 1.5 mL min1 flow rate. Low resolution mass
spectrometry (LRMS) was performed using a Waters micro-
mass ZQ, equipped with an electrospray ionization (ESI (þ))
source with the following conditions: voltages: 3 kV capillary
voltage, 25 V cone voltage for PhenESF and 70 V cone voltage
for RePhenNH2 and RePhenESF (higher cone voltage was
required to dissociate Re–Br bonds), 5V extractor voltage, 0.2V
radiofrequency (RF) lens voltage; temperatures: 458C source
temperature, 3008C desolvation temperature; gas flows:
350 L h1 desolvation N2 gas flow, 90 L h
1 cone N2 gas flow.
Samples for high-resolution mass spectrometry (HRMS) anal-
yses were sent to the Mass Spectrometry User Resource and
Research Facility (MSURRF) at the University of Wollongong.
Melting point analyses were performed using a Stanford
Research Systems Optimelt automated melting point system
with digital imaging processing technology. IR analyses were
performed using a Brucker ALPHA-p IR spectrometer. UV-vis
analyses were performed using an Agilent technologies Cary
100 UV-vis spectrometer. NMR analyses were performed using
a Bruker Spectrospin 400MHz UltraShield NMR spectrometer.
TMS was used as the internal standard for 1H and 13C mea-
surements, and para-difluorobenzene (p-DFB) as the internal
standard for 19F measurements. Samples for elemental analyses
were sent to the Campbell Microanalytical Laboratory at the
University of Otago in New Zealand for C, H, N, and Br
analyses.
Equipment Used for Radiosynthesis
Aqueous [18F]fluoride was produced on an IBA Cyclone
18 Twin cyclotron (ANSTO, Sydney, NSW, Australia) using
the 18O(p,n)18F nuclear reaction. Analyses were performed
using gradient conditions consisting of 0.1% v/v TFA in
both acetonitrile (A) and water (B) mobile phases on a
Chromolith column (Merck, 50 4.6 mm). The method
duration was 12 min with 5% A held for 1 min, %A increased
to 95% over 7 min, %A held at 95% for 2 min, %A reduced
to 5% over 30 s, and then held at 5% for the remaining 1 min
30 s for equilibration. RCYs were calculated using the radio-
HPLC profiles, integrating the radioproduct peak against all
the other radioactive peaks (including the unreacted [18F]
fluoride), using Laura V4.1.70 SP2 HPLC data analysis
software.
Radiochemical Production of [18F]ESF
No-carrier added [18F]ESF was formed from a 2,4,6-tri-
chlorophenylethenesulfonate (TCPE) precursor in DMSO
solvent under microfluidic conditions.[10] The TCPE in DMSO
solution was radiofluorinated from non-azeotropically dried
TEA [18F]fluoride complex in acetonitrile, both of which were
pumped from storage loops into a fused silica microreactor
(2 m 100 mm, 15.6 mL) heated to 1008C, at an overall flow
rate of 40 mLmin1 (24 s residence time). The reaction mixture
underwent distillation, following conditions reported in the
literature,[10] and the pure product was trapped in a Silica Plus
cartridge and eluted with purified water. Such conditions
provided an optimal non-isolated 86 10% RCY solution of
[18F]ESF with 31.8 6.4 MBq mL1 of activity. Refer to
Fig. S5.1 and S5.2 of the Supplementary Material for sche-
matics of the microfluidic set-up.
Equipment Used for Photophysical Characterization
Photophysical measurements were performed using an
Edinburgh FLS980 spectrometer. Light from a 450W xenon arc
lamp source was passed through excitation and emission
monochromators to acquire the corresponding spectra. Emission
lifetimes were determined using the time correlated single-
photon counting (TCSPC) technique with a pulsed picosecond
light-emitting diode (LED, 377 nm).[19,20] The goodness-of-fit
was assessed by minimizing the reduced x2 function and by
visual inspection of the weighted residuals.
Computational Details and Methods
The geometry optimizations and bond analyses were computed
using ORCA software[21] at the DFT level using def2-TZVP
basis sets, B97 functional[22] corrected using the Grimme D3
correction with Becke–Johnson damping to the DFT energy.[23]
The resolution of identity (RI) approximation[24] and the
Effective Core potential LANL2DZwere also applied.[25–27] All
of the structures were confirmed to be local energy minima (no
imaginary frequencies) except the transition states (one imagi-
nary frequency). Thermodynamic properties were computed at
the def2-TZVP/B97-D3 level of theory and calculated at 298 K.
Zero-point energy corrections are included. NBO analyses were
performed using the NBO6 suite of programs.[28] Charge dis-
placement function analysis is based on Eqn 1[29,30] wherein Dr
(x, y, z) is the difference between the electron density of a
complex and that of its non-interacting fragments placed in the
same position as they occupy in the complex. These fragments
are [PhenNHR] (R¼HorCH2CH2SO2F) and [Re(CO)3Cl]. The
function Dq(z) defines, at each point z along a chosen axis, the
amount of electronic charge that, on formation of the bond
between the fragments, moves across a plane perpendicular to
the axis through the point z. A negative value corresponds to
electron density flowing in the direction of increasing z. Charge
accumulates where the slope of Dq is positive and decreases
where it is negative.
Dq z0ð Þ ¼
Zþ1
1
dx
Zþ1
1
dy
Zz0
1
dzDr x; y; zð Þ ð1Þ
In the natural orbital for chemical valence theory
(NOCV),[31] Dr is built from the occupied orbitals of A and
B, suitably orthogonalized to each other and renormalized
(promolecule), using the valence operator in Eqn 2.[32–34]
V^ ¼
X
i
cðABÞi

E
cðABÞi
D  c0i
  c0i
  ð2Þ
Here, ci
0 is the set of the occupied Kohn–Sham orbitals of
fragments A and B, mutually orthonormalized, and ci
(AB) is the
set of occupied orbitals of the adduct. The NOCVs can be
grouped in pairs of complementary orbitals (jk, j2k) corre-
sponding to eigenvalues with same absolute value but opposite
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sign (Eqn 3). Herein the term nk represents the fraction of
electrons transferred from the j2k to the jk orbital.
V^jk ¼ nkjkðnk40Þ ð3Þ
whereby k numbers the NOCV pairs (k¼ 0 for the largest value
of |nk|). In this framework, Dr0 can be defined as per Eqn 4.
Dr0 ¼
X
k
nk jkj j2 jkj j2
 
¼
X
k
Dr0k ð4Þ
The different Dr0k can then be separately integrated
using Eqn 1.[35,36] The boundary between the two fragments
was defined as the point on the z axis at which equal-
valued isodensity surfaces of the isolated fragments are
tangential. The NOCV orbital cubes weremanipulated through
the software Gabedit,[37] whereas the electronic density
matrices were manipulated through the suite of toolsCubes.[38]
NBO analysis was performed using the NBO6 suite of
software.[39]
Synthesis of Bromotricarbonyl(5-amino-1,10-
phenanthroline) Rhenium(I) (RePhenNH2)
The synthesis of RePhenNH2 was adapted from a literature
method described by Bessette et al.[16] 5-Amino-1,10-
phenanthroline (0.49 g, 2.501 mmol, 1.0 equiv.) was dissolved
in toluene (30 mL) and heated to reflux. Bromopentacarbo-
nylrhenium(I) (1.00 g, 2.462 mmol, 1.0 equiv.) was then added
to the reaction mixture, whereupon the solution turned from
yellow to orange. The reaction mixture was stirred under reflux
under a constant supply of nitrogen gas for 1 h. The solution was
then cooled to room temperature and filtered via vacuum fil-
tration, whereafter the precipitate was washed with n-hexane
and dried to afford an orange powder (1.27 g, 93%); mp 318–
3198C (dec.). dH (400MHz, [D6]DMSO) 9.40 (dd, J
d 5.12, 1.20,
1HAr), 9.11 (dd, J
d 8.52, 1.20, 1HAr), 8.95 (dd, J
d 5.00, 1.28,
1HAr), 7.24 (dd, J
d 8.44, 1.20, 1HAr), 8.05 (dd, J
d 8.52, 5.12,
1HAr), 7.79 (dd, J
d 8.36, 5.0, 1HAr), 7.07 (s, 1HAr), 6.90 (s, br,
1HNH2). dC (100 MHz, [D6]DMSO) 197.50, 197.39, 189.59,
153.35, 148.04, 146.68, 144.89, 139.65, 135.54, 134.29, 132.68,
126.19, 125.00, 123.56, 101.18. nmax/cm
1 (attenuated total
reflectance (ATR) corrected) 3491.45 (w, asym N–H str),
338.00 (w, sym N–H str), 3235.51 (w, sp2 C–H str), 2012.36
(s, sh, A0(1) CO str), 1921.25 (s, A0(2) CO str), 1894.37
(s, A00 CO str). m/z (LRMS ESIþ, cone 60 V) 466.17
[M – Br]þ; calc. 466.02; 546.05 and 457.05 [MþH]þ; calc.
545.95 and 547.94. m/z (HRMS ESIþ) 466.01988 [M–Br]þ;
calc. 466.01959 (D 0.61 ppm). lmax/nm (e/M
1 cm1) (CH3CN)
416 (2726), 348 (10142), 296 (24429), 244 (36534), 194
(58783). Anal. Calc. for ReC15H9O3N3Br: C 33.04, N 7.71, H
1.66, Br 14.65; found C 33.06, N 7.64, H 1.80, Br 14.39%.
Synthesis of 5-N-(2-Aminoethylsulfonylfluoride)-1,10-
phenanthroline (PhenESF)
5-Amino-1,10-phenanthroline (1.000 g, 5.128 mol, 1.0 equiv.)
and ESF (847.0 mg, 7.7 mol, 1.5 equiv.) were dissolved in DMF
(10 mL) and stirred at room temperature (24 h). The resulting
orange solution was then poured into water (300 mL), causing a
yellow solid to precipitate. The precipitate was isolated via
vacuum filtration and washed with water to remove residual
DMF. Further purification was achieved by dissolving the crude
material in a minimum of DMSO and eluting through a 40-g C18
column using a gradient mobile phase of 0.1%TFA inwater and
acetonitrile (5 to 100% over 8 column volumes). The eluents
containing the product were then combined, evaporated under
reduced pressure, and dried by lyophilization to obtain a yellow
powder (1.125 g, 63%); mp 200–2058C (dec.). dH (400 MHz,
CDCl3) 9.21 (dd, J
d 4.32, 1.56, 1HAr), 8.96 (dd, J
d 4.32, 1.64,
1HAr), 8.26 (dd, J
d 8.44, 1.52, 1HAr), 8.04 (dd, J
d 8.12, 1.64,
1 HAr), 7.65 (dd, J
d 8.40, 4.32, 1HAr), 7.53 (dd, J
d 8.08, 4.32,
1HAr), 7.53 (dd, J
d 8.08, 4.32, 1HAr), 6.71 (s, 1HAr), 5.03 (t, J
t
6.08, 1HNH), 4.08 (app. q, J
q 12.16, 6.08, 2HCH2–SO2F), 3.89 (td,
Jq 6.16, 4.48, 2HCH2). dC (100 MHz, CDCl3) 150.43, 147.44,
146.91, 142.31, 138.96, 129.59, 128.51, 123.27. 122.58, 122.02,
101.11, 49.66 (J 15.08 Hz), 38.08. dF (376 MHz, CDCl3) 70.67
(t, Jt 4.63). nmax/cm
1 3402.28 (w, br, N–H str), 2933.34 (m, sp2
C–H str), 2872.24 (m, sp3 C–H str), 1595.69 (s, sh, asym S=O
str), 1384.34 (s, sh, sym S=O str), 818.10 (m, S–F str). m/z
(LRMS ESIþ) 306.23 [MþH]þ; calc. 306.07. m/z (HRMS
ESIþ) 306.07093 [MþH]þ; calc. 306.07070 (D 0.74 ppm).
lmax/nm (e/M
1 cm1) (CH3CN) 331 (9098.68), 279
(28578.41), 259 (21861.26), 221 (41646.31), 194 (22288.72).
Anal. Calc. for C14H12O2N3SF: C 55.07, N 13.76, H 3.96; found
C 54.54, N 13.64, H 3.63%.
Synthesis of Bromotricarbonyl(5-N-(2-
Aminoethylsulfonylfluoride)-1,10-phenanthroline)
Rhenium(I) (RePhenESF)
5-N-(Aminoethylsulfonylfluoride)-1,10-phenanthroline
(65.4 mg, 0.214 mmol, 1.0 equiv.) was dissolved in a solution of
50% DCM in toluene (15 mL), to which pentacarbonylrhenium
(I) bromide (79.1 mg, 0.195 mmol, 1.1 equiv.) was added. The
solution was then stirred and heated at reflux (2 h). The solution
was left to cool to room temperature and the DCM evaporated,
after which the resulting precipitate was filtered via vacuum
filtration, washed with diethyl ether, and dried under vacuum to
afford a yellow powder (110.4mg, 79%); mp 295–3018C (dec.).
dH (400 MHz, [D6]DMSO) 9.28 (d, J
d 5.04, 1HAr), 9.10 (d, J
d
7.88, 1HAr), 9.03 (dd, J
d 5.00, 1.12, 1HAr), 8.53 (dd, J
d 8.36,
1.12 Hz), 8.11 (dd, Jd 8.82, 5.08, 1HAr), 7.87 (dd, J
d 8.36, 5.00,
1HAr), 7.57 (t, J
t 5.76, 1HNH), 7.16 (s, 1HAr), 4.41 (app. q, J
q
11.88, 5.88, 2HCH2–SO2F), 3.96 (app. q, J
q 11.56, 5.76, 2HCH2).
dC (100 MHz, [D6]DMSO) 197.42, 197.33, 189.51, 153.48,
148.82, 146.68, 142.12, 140.37, 136.31, 133.52, 132.52, 126.47,
125.45, 124.00, 99.41 (d, Jd 26), 48.67 (d, Jd 12), 37.62. dF
(376 MHz, [D6]DMSO) 70.67 (t, Jt 4.63). nmax/cm
1 3347.38
(w, sh, N–H str), 3051.21 (w, sp2 C–H str), 3003.10 (w, sp3 C–H
str), 2025.18 (s, sh, A0(1) CO str), 1919.09 (s, sh, A0(2) CO
str), 1898.11 (s, sh, A00 CO str).m/z (LRMS ESIþ) 576.15 [M–
Br]þ; calc. 576.00. m/z (HRMS ESIþ) 576.00387 [M–Br]þ;
calc. 576.00337 (D 0.86 ppm). lmax/nm (e/M
1 cm1) (CH3CN)
414 (1835.32), 347 (7341.28), 297 (16255.69), 243 (25956.66),
194 (39590.46). Anal. Calc. for ReC17H12O5N3SFBr: C 31.15,
N 6.41, H 1.85, S 4.89, Br 12.19; found C 30.61, N 6.36, H 1.85,
S 4.91, Br 12.05%.
Supplementary Material
The NMR and FTIR spectra for each of the compounds syn-
thesized, the radioTLC results used for RCYverification, amore
detailed analysis of the DFT computed mechanism, details for
the microfluidic set-up used in the production of [18F]ESF, as
well as the UV-Vis spectra and photophysical characterization
data for the synthesized rhenium complexes are available on the
Journal’s website.
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Rhenium Complexation-Dissociation Strategy for Synthesizing 
Fluorine-18 Labeled Pyridine Bidentate Radiotracers 
Mitchell A. Klenner,[a,b] Giancarlo Pascali,*[a,c] Bo Zhang,[a,d] Gianluca Ciancaleoni,[e] James Howard,[a] 
Helen E. Maynard-Casely,[a] Jack Clegg,[f] Massimiliano Massi,[b] Benjamin H. Fraser.*[a]
Abstract: A novel fluorine-18 labelling method referred to as pyridine 
fluorination activated by rhenium (PYFLARE) is described herein. The 
PYFLARE method was found to afford high to moderate 
radiochemical yields of labelled rhenium complexes. More 
significantly, by exploiting thermal dissociation, the PYFLARE method 
enabled the radiosynthesis of fluorine-18 labelled bipyridine 
structures which could not be radiofluorinated by traditional means. 
The PYFLARE method was further applied to the radiosynthesis of 
[18F]CABS13, an Alzheimer’s disease imaging agent, alongside other 
phenanthroline and 8-hydroxyquinoline radiotracers. Computational 
modelling was also performed to elucidate the reaction mechanism. 
This data suggests that the efficiency of the PYFLARE method may 
be attributed to both an electron withdrawal effect by the rhenium and 
the formation of an acylfluoride intermediate which may ‘anchor’ the 
fluoride subsequent to nucleophilic addition. 
Radiotracers are commonly used to investigate biochemical 
systems in living organisms and are routinely employed as 
nuclear medicines to diagnose cancers and other disease 
pathologies.[1] The discovery of new radiolabeling methods is 
critical to the improved synthesis of new radiotracers needed to 
diagnose currently untreated disease states. Positron emission 
tomography (PET) is the most sensitive of all nuclear imaging 
techniques and fluorine-18 is the most widely utilized radioisotope 
in existing PET medicines.[2,3] Given the difficulties associated 
with fluorine-18 labeling pyridine-containing bidentate structures, 
it was hypothesized that a rhenium activation approach could be 
a powerful tool towards expanding the scope of such 
radiotracers.[4] To test this hypothesis, we selected three common 
bidentate structures throughout our investigation; 1,10-
phenanthroline, 2,2’-bipyridine and 8-hydroxyquinoline. In each of 
these studies we systematically tested the nucleophilic 
substitution of chloro, bromo and/or nitro leaving groups for 
[18F]fluoride on different positions of the molecule to establish the 
advantages and limitations of a thermally mediated rhenium 
complexation-dissociation strategy, following a method herein 
referred to as pyridine fluorination activated by rhenium 
(PYFLARE). Additionally, the PYFLARE method fits within a 
limited scope of fluorine-18 labelling methods which can 
substitute under aqueous conditions, inclusive of AlF,[4-7] boron-
dipyrromethene (BODIPY)[8-10] and ethenesulfonyl fluoride (ESF) 
agents.[11,12] This discovery lead us to compare reaction 
conditions employing azeotropically distilled (‘dry’) and non-
distilled (‘wet’) fluorine-18 sources, the latter of which typically 
suppresses radiochemical yield (RCY) due to the decreased 
nucleophilicity of the [18F]fluoride in aqueous media.[3] 
Each precursor was reacted under microfluidic conditions using 
an automated synthesis module assembled as per the schematic 
in Figure 1. Herein cyclotron generated [18F]fluoride was trapped 
on an ion-exchange cartridge and eluted to an azeotropic 
distillation vial using a solution of tetraethylammonium (TEA) 
bicarbonate in 9:1 acetonitrile: water solution. Dry reaction 
conditions were then achieved by azeotropically drying the 
[18F]fluoride complex via the heated dropwise addition of 
acetonitrile followed by reconstitution in anhydrous DMSO to 
enhance the nucleophilicity of the fluoride. Whereas wet reaction 
conditions omitted this distillation step and thus consisted of a 5% 
[a] Mr. M. A. Klenner, Dr. G. Pascali, Mr. B. Zhang, Dr. J. Howard, Dr. 
H. Maynard-Casely, Dr. B. H. Fraser.  
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[c] Dr. G. Pascali. 
Brain and Mind Centre 
University of Sydney  
Camperdown, NSW, Australia. 2050. 
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Figure 1. Automated synthesis module assembled from microfluidic 
components for the azeotropic drying of cyclotron generated 
[18F]fluoride and subsequent PYFLARE radiolabeling reactions with a 
precursor molecule in a microreactor of varying temperature. 
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v/v content of water and acetonitrile. Both the [18F]fluoride (29±10 
MBq) and precursor solution (0.08 μmol) in DMSO were then 
dispensed concurrently from pumps 2 and 3 (P2, P3) respectively 
through a heated microreactor at a rate of 20 μL.min-1 (47 s 
reaction time). Reaction temperatures between 50 and 190 °C 
were trialed for each experiment in 20 °C increments. The solution 
was then dispensed into a final product vial where the solution 
was subsequently analysed by radioHPLC and/or radioTLC to 
determine the non-isolated RCYs of the radioproducts. 
A list of each of the tested precursors and fluorinated standards 
are provided in figure 2. Initial PYFLARE reactions employing the 
Re2ClPhen precursor provided the fluorine-18 labelled 
[18F]Re2FPhen in a considerable 90% RCY at 90 °C under dry 
conditions and exhibited some minor thermal dissociation to form 
the [18F]2FPhen ligand in 13% RCY at 170 °C. Curiously, the 
same reaction under wet conditions afforded [18F]Re2FPhen in 
59% RCY at a much lower temperature of 50 °C though exhibited 
no dissociation to form [18F]2FPhen at all. Radiofluorination of 
Re2BrPhen under dry conditions via PYFLARE demonstrated a 
similar trend whereupon [18F]Re2FPhen formed in a maximum 
73% RCY at 70 °C and afforded a small 8% RCY of [18F]2FPhen 
via thermal dissociation at 170 °C. To widen the scope of available 
fluorine-18 labelled rhenium complexes we then trialed 
radiolabeling reactions in the 5-position using PYFLARE. 
Fluorine-18 labeling of Re5ClPhen afforded [18F]Re2FPhen in 
33% RCY under dry conditions, though only 2% of 
[18F]Re2FPhen under wet conditions, with neither reaction 
thermally decomplexing to form the [18F]5FPhen ligand. Thus, 
PYFLARE reactions were attempted with Re5NO2Phen bearing 
the more electron withdrawing nitro group which we hypothesized 
would improve nucleophilic substitution for [18F]fluoride. Indeed 
under dry conditions using Re5NO2Phen we not only observed 
[18F]Re2FPhen radiolabeling in 39% RCY at 110 °C though also 
observed some very minor ligand dissociation forming 
[18F]5FPhen in 2% RCY. Worth mentioning is that each of these 
reactions appeared to also form another unknown (‘mystery’) 
radio by-product for which we did not have a non-radioactive 
standard to confirm the identity of. Plots illustrating the RCY of the 
fluorine-18 labelled complex, ligand and mystery compounds as 
a function of increasing reaction temperature can be found in S.3 
of the SI. 
 
Based on these results we opted to trial a dissociation strategy 
using similarly complexed 2,2’-byridine ligands. Intriguingly, 
Re2ClBiPy did not only radiolabel to form [18F]Re2FBiPy in 82% 
RCY at 130°C under dry conditions, though also readily 
dissociated with increasing temperature to form the desired 
[18F]2FBiPy ligand in 64% RCY at 190°C. To our surprise the 
[18F]2FBiPy radioproduct would not form from the 2ClBiPy 
precursor under analogous conditions and hence could only be 
synthesised using the PYFLARE method. Radiolabeling reactions 
using the Re2BrBiPy precursor similarly formed [18F]Re2FBiPy 
in a maximum of 72% RCY at 110°C under dry conditions and 
dissociated to form [18F]2FBiPy in 51% at 190°C. Substituting for 
[18F]fluoride in the para instead of ortho position using the 
Re4ClBiPy precursor provided [18F]Re4FBiPy in 68% RCY and 
dissociated to form [18F]4FBiPy in 31% RCY at 190°C, which 
likewise could not be synthesized from the 4ClBiPy ligand 
precursor under analogous conditions. Using PYFLARE to 
synthesize [18F]Re5FBiPy from Re5ClBiPy afforded less than 
1% RCY of the radiolabeled complex, however, which proved too 
little of an amount to dissociate any of the [18F]5FBiPy ligand. A 
summary of the RCYs formed per temperature for each of the 
bipyridines successfully radiolabeled under dry conditions using 
PYFLARE is shown in figure 3. Example chromatograms in this 
figure also show the dissociation of the complex to form the 
Figure 2. List of rhenium complex and ligand structures based on 1,10-
phenanthroline (1), 2,2’-bipyridine (2) and 8-hydroxyquinoline (3) N-
heterocycles used as precursors or standards in this study. *Note that 
[18F]2F8HQ is also known as the [18F]CABS13 Alzheimer’s disease PET 
diagnostic radiotracer. 
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radiolabeled ligand at two differing temperatures, alongside the 
appearance of the mystery by-product. Reactions under wet 
conditions also demonstrated lower yielding yet similar trends 
with [18F]Re6FBiPy forming from Re6ClBiPy and Re6BrBiPy in 
29% RCY at 130 °C and 9% RCY at 150 °C respectively, and 
dissociating to form [18F]6FBiPy in 24% RCY at 190 °C and 10% 
RCY at 190 °C respectively. RCY vs. temperature plots for these 
wet reactions can be found in S.3 of the SI. One hypothesis as to 
why the 2,2’-bipyridine complexes thermally dissociate with 
greater efficiency than the 1,10-phenanthroline rhenium 
complexes, and thus form their respective fluorine-18 labeled 
ligands in greater RCY, may be due to the lesser rigidity exhibited 
by bipyridine molecules in comparison to phenanthroline ring 
systems. [13] 
 
After establishing the efficiency of the PYFLARE method, and its 
subsequent thermal dissociation of fluorine-18 labelled 2,2’-
bipyrine ligands, we were interested in translating the method to 
8-hydroxyquinoline structures. Notably because of the 
documented use of these structures as markers of amyloid-β (Aβ) 
plaques characterized by Alzheimer’s disease.[14-18] Though also 
because complexation of the hydroxyl group to rhenium was 
hypothesized to circumvent multiple step radiosynthesis, which is 
usually required to protect the alcohol, during which time 
radioactivity is lost due to decay. The first of these precursor 
structures to be radiolabeled was Re2Cl8HQ in the hopes of 
radiosynthesising [18F]CABS13 (i.e. [18F]2F8HQ), a radiotracer 
which provided efficient PET imaging of Aβ plaques in transgenic 
mouse models of Alzheimer’s disease,[19] though which failed 
when translating to a non-human primate due to low brain uptake 
and rapid metabolism.[20] Radiolabeling of Re2Cl8HQ afforded 
only 2% RCY of both [18F]ReCABS13 (i.e. [18F]Re2F8HQ) and 
[18F]CABS13 at 190°C under dry conditions, thus prompting us to 
increase the molar amount of precursor used. Using ten-fold the 
mass of Re2Cl8HQ (0.8 μmol) resulted in a remarkable increase 
to 18% RCY of [18F]ReCABS13 and 5% RCY of the dissociated 
[18F]CABS13 PET radiotracer at 190°C. This RCY of 
[18F]CABS13 obtained using PYFLARE is still below the 19±5% 
RCY achieved by Liang and coworkers using multi-step 
radiosynthesis,[20] however these results suggest that further 
optimizations could be made for all analyses by increasing the 
molar amount of the precursor. More interestingly, the 
[18F]5F8HQ radiotracer which was hypothesized to be more 
efficient at disaggregating Aβ plaques,[21] though which was 
unable to be synthesized by traditional means, was able to be 
formed from both Re5Cl8HQ and Re5NO28HQ precursors in 1% 
and 2% RCY respectively, with the radiolabeled complex 
[18F]Re5F8HQ also forming in 3% and 6% RCY respectively, 
under dry conditions. Under wet conditions [18F]ReCABS13 and 
[18F]Re5F8HQ could both be formed from their respective 
precursors, albeit in lower RCY. Only Re5NO28HQ was able to 
undergo ligand dissociation to afford [18F]5F8HQ under such wet 
conditions, however. RCY plots for the rhenium complexed and 
dissociated 8-hydroxyquilone tracers as a function of reaction 
temperature can be viewed in S.3 of the SI. A list of the RCYs 
obtained for each of the fluorine-18 labelled rhenium complexes  
Figure 3. RCY plotted as a function of reaction temperature alongside 
radiochromatograms for Re6ClBiPy (top), Re6BrBiPy (middle) and 
Re4ClBiPy (bottom) precursors. These trends show the formation of  a 
fluorine-18 labelled complex and subsequent dissociation of the 
formerly unobtainable fluorine-18 labelled ligand at higher temperatures. 
Figure 4. Radiochromatogram obtained for the [18F]ReCABS13 tracer 
(5.7 min) forming in 18% RCY and thermally dissociating to form the 
[18F]CABS13 Alzheimer’s PET radiotracer (4.6 min) in 5% RCY. 
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and dissociated ligands under comparable conditions is provided 
in Table 1. 
 
Towards understanding the mechanism by which PYFLARE 
improves fluorination of a pyridine bidentate structure, we opted 
to model the reaction via DFT calculations at the B97-D3/def2-
TZVP level of theory. The input coordinates were acquired from 
the XRD data of crystals of the rhenium complexes grown from 
slow evaporation in DMSO solution. First, the coordination on the 
rhenium center leads to a depletion of electron density on the 
ligand, a phenomenon also realised by the downfield chemical 
shifts observed in NMR spectra of the rhenium complexes. This 
depletion can be quantified by the Natural Orbitals for Chemical 
Valence-Charge Displacement (NOCV-CD),[22] according to 
which the L → M σ-donation is 0.266 e and the L ← M π back-
donation is 0.116 e in the case of Re6FBiPy. Such electronic 
depletion favours nucleophilic addition of the fluoride on the 
carbon bound to the chlorine atom. The DFT-computed activation 
energies are 6.3 and 34 kcal.mol-1 in the presence and absence 
of the metal fragment, respectively. Notably the fluoride primarily 
bonds to the carbonyl in the cis position relative to the diimine 
ligand, forming an acylfluoride intermediate as shown in figure 5. 
This intermediate is unstable, however, and quickly detaches 
from the carbonyl anchor to undergo nucleophilic aromatic 
substitution for the chlorine atom. From the experimental data is 
was observed that Re6FBiPy formed in a greater fluorination yield 
than Re4FBiPy, whereas the Re5FBiPy complex formed in 
almost no appreciable yield at all. This trend can be explained by 
calculating the atomic charges by Natural Population Analysis, 
whereupon it was shown that the carbon atoms bound to the 
chlorine consisted of partial charges equal to 0.29, -0.01 and 0.04 
e for the Re6ClBiPy, Re5ClBiPy and Re4ClBiPy precursors 
respectively. Clearly a positive partial charge facilitates 
fluorination and a negative partial charge inhibits nucleophilic 
addition of the fluoride. 
 
In a former study we also verified the photophysical properties of 
the Re2ClPhen and Re2FPhen complexes for potential use of 
the latter as a PET-optical multimodal imaging agent.[4] Given the 
reasonable RCYs which were likewise obtained for the rhenium 
bipyridine complexes in this study, we further determined 
quantum yields of 5.8 ×10-3, 1.1×10-2, 4.7×10-3 and 6.1×10-3 for 
Re4ClBiPy, Re5ClBiPy, Re6ClBiPy and Re6FBiPy complexes 
in DMSO solution respectively. 
 
In conclusion, we report the novel PYFLARE method for 
radiolabeling rhenium tricarbonyl complexes with the fluorine-18 
radioisotope. The rhenium center improves radiofluorination via 
an electron withdrawal effect and, in accordance with our 
computational models, may facilitate radiofluorination reactions 
via formation of an acylfluoride intermediate with a carbonyl ligand. 
Through a series of radiosyntheses under microfluidic conditions 
we verified that high to moderate RCYs could be obtained by 
substituting [18F]fluoride in the rhenium-activated ortho and para 
positions of bidentate pyridine ligands, as well as in the 5-position 
of a phenanthroline ligand. Radiolabeling in the meta position, 
however, proved challenging and lies outside the scope of the 
PYFLARE method. In addition to providing reasonable RCYs of 
Table 1. Optimum RCYs obtained for varying temperatures when reacting 
TEA [18F]fluoride with each of the rhenium precursors under the same dry 
experimental conditions (solvent: DMSO, reaction time: 47 s, precursor 
amount: 0.08 μmol, radioactivity: 29 ± 10 MBq). Save for these exceptions: 
*Reaction time of 188 s used. **Ten-fold mass (0.8  μmol) of precursor used. 
Radiotracer Precursor Temperature (°C) RCY (%) 
[18F]Re2FPhen Re2ClPhen 90 91 
 Re2BrPhen 110 69 
[18F]Re5FPhen Re5ClPhen 170 33 
 Re5NO2Phen 110 39 
[18F]Re6FBiPy Re6ClBiPy 130 82 
 Re6BrBiPy 110 72 
[18F]Re4FBiPy Re4ClBiPy 130 68 
[18F]Re2F8HQ** Re2Cl8HQ 190 18 
[18F]Re5F8HQ Re5Cl8HQ 130 3 
 Re5NO28HQ 170 6 
[18F]2FPhen Re2ClPhen 170 13 
 Re2BrPhen 170 8 
[18F]5FPhen Re5ClPhen - 0 
 Re5NO2Phen 130 2 
[18F]6FBiPy Re6ClBiPy 190 64 
 Re6BrBiPy 190 51 
[18F]4FBiPy* Re4ClBiPy 190 37 
[18F]2F8HQ** Re2Cl8HQ 190 5 
[18F]5F8HQ Re5Cl8HQ 190 1 
 Re5NO28HQ 190 2 
Figure 5. DFT modelling of the reaction mechanism forming Re6FBiPy 
from Re6ClBiPy. The optimized geometries of the intermediate species  
(Int) and the rate-determining transition state (TS) are shown. 
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many radiolabeled complexes, which may find applications in the 
development of PET-optical multimodal tracers, a thermal 
decomplexation approach has also been shown to dissociate 
more labile bidentate ligands. This rhenium complexation-
dissociation approach was particularly useful for synthesizing 
fluorine-18 labelled bipyridine compounds in considerable RCYs, 
which were unable to be synthesised under analogous conditions 
without using PYFLARE. Such a method may thus expand the 
scope of new PET radiotracers which can be developed. 
Furthermore, the PYFLARE method also joins the limited suite of 
radiofluorinating methods which can afford radiotracers under 
aqueous conditions. This discovery may expand the scope for 
PYFLARE to be used at low temperatures following subsequent 
bioconjugation for further PET-optical development. Future work 
towards alternative decomplexation methods (e.g. 
photodissociation or acid dissociation), as well as attempts to 
fluorine-18 label monodentate pyridine ligands complexed to the 
rhenium center, may further expand the scope of radiotracer 
syntheses which PYFLARE could be applied to. 
Experimental Section 
Synthesis of rhenium complexes 
Complex diveratives of ReXPhen and ReXBiPy were prepared by 
refluxing rhenium(I) pentacarbonyl chloride (300 mg, 830 µmol, 1.0 eq.) 
and the appropriately substituted chloro, bromo or nitro 2,2-bipyridine or 
1,10-phenanthroline (1.1 eq.)  in a solution of anhydrous toluene (10 mL) 
for 4 hours in an inert nitrogen environment, resulting in a colour change 
from blue or colourless to yellow or orange. The solid precipitate was 
isolated by vacuum filtration and washed with diethyl ether. The crude 
material was then dissolved in a minimum of DCM and eluted over neutral 
alumina Brockmann grade II using a DCM/MeOH gradient mobile phase. 
The eluents containing the product were subsequently combined and 
evaporated down under reduced pressure to afford the yellow or orange 
powder. 
 
Complex derivatives of ReX8HQ were prepared by first refluxing 
rhenium(I) pentacarbonyl chloride (100 mg, 275 µmol, 1.0 eq.) in 
anhydrous acetonitrile (10 mL) for 4 hours in an inert nitrogen environment 
(purged by vacuum for 3 cycles) in order to make the rhenium(I) 
diacetonitrilo tricarbonyl chloride intermediate, which can be monitored by 
HPLC or IR spectroscopy. Simultaneously, the appropriate chloro or nitro 
substituted 8-hydroxyquinoline (1.0 eq.) was deprotonated with sodium 
hydride (60% wt/wt in mineral oil washed with hexanes) in anhydrous 
acetonitrile (2 mL) at room temperature under an inert nitrogen 
environment, resulting in a vibrant green solution. The green solution was 
then filtered (0.2 µm PTFE) and added drop wise to the solution containing 
rhenium. This solution was then left to stir for 12 hours at room temperature 
eventually forming an orange solution. The orange solution was then 
added to a volume of aqueous triflic acid (0.1 M, 10 mL) and evaporated 
under reduced pressure to remove the acetonitrile, thus precipitating out a 
a yellow or orange solid in aqueous suspension. The crude material was 
then isolated by vacuum filtration, dissolved in acetonitrile and eluted over 
neutral alumina Brockmann grade II using an isocratic acetonitrile mobile 
phase. The eluents containing the product were subsequently combined 
and evaporated down under reduced pressure to afford the yellow or 
orange powder. 
 
Radiolabeling protocol 
 
Aqueous [18F]fluoride was produced on an IBA Cyclone 18 Twin cyclotron 
via the 18O(p,n)18F nuclear reaction. The [18F]fluoride was trapped by a 
QMA catridge and eluted off with tetraethylammonium bicarbonate in 10% 
v/v water/acetonitrile for wet conditions, and azeotropically dried using 
anhydrous DMSO for dry conditions. Microfluidic radiosyntheses were 
performed in in Doscovery Mode using a NanoTek LF Microfluidic 
Synthesis System (Advion) connected to a standard laptop using NanoTek 
software v1.4.0 GMP Lite. Microreactors were made of fused silica tubing 
(100 µm × 2 m, 15.6 μL) coiled tightly into a brass ring and held by a 
thermoresistent polymer. RadioHPLC analyses were carried out using a 
Shimadzu system comprised of a CBM-20 controller, LC-20AD pump, SIL-
20AHT autoinjector, SPD-M20A PDA detector and a Lablogic Posi-RAM 
gamma detector. Analyses were  performed using gradient conditions over 
15 minutes, consisting of 95:5 water: acetonitrile for the first 3 minutes 
followed by a a linear transposition to 5:95 water:acetonitrile over the 
remaining 12 minutes using a 2 mL.min-1 flow rate. A Chromolith RP 
column (monolith system, Merck 50 × 4.6 mm), demonstrated to have 
>92% [18F]fluoride retention in low pH ranges,[23] was employed as the 
stationary phase. RadioHPLC derived non-isolated RCYs were calculated 
via the integrated peak area ratio between the radioproduct and other 
radioactive species present, inclusive of any unreacted [18F]fluoride, using 
Laura V4.1.70 SP2 HPLC data analysis software. 
 
Computational, photophysical and characterisation data 
 
Further information on the characterisation data, computational details and 
photophysical experiments can be found in sections S.1-S.2, S.4 and S.5 
of the SI respectively. 
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